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General introduction 
1. Introduction 
The skin is a very attractive organ for the application of pharmaceutically active substances due 
to its considerable size and easy accessibility. The aim of the drug administration via the skin can 
be either the local therapy of dermatological diseases or the transdermal delivery of drugs to the 
underlying tissues or the systemic circulation. 
The transdermal delivery of drugs as alternative to oral dosage forms has been the subject of 
research for many decades. Due to the considerable advantages of the transdermal application 
route for some drugs different dosage forms have been developed for the drug delivery through 
the skin: polymeric patches and semisolids. Currently, the patches still represent the majority of 
preparations for this application route, but the semisolids (and among them especially the 
alcoholic hydrogels) have gained more and more acceptance in recent years. Although the 
number of transdermally applied drugs is limited the existing dosage forms are quite successfully 
marketed for various indications (the annual market volume for transdermal patches alone in the 
United States of America was approximately 3 billion USD in 2004 [1]). However, each of the 
dosage forms is associated with certain drawbacks that can negatively influence the patient 
compliance or limit the usage of the dosage form (for details see section 4.2.3). Hence the search 
for alternatives to the conventional transdermal dosage forms is reasonable to further improve 
the transdermal drug application for the patient.  
2. Objectives of this work 
The scope of the present work is to develop and investigate a novel delivery system for the skin 
as alternative to the existing transdermal dosage forms. The approach chosen for the new dosage 
form is a film forming polymeric solution. On the skin surface the solution solidifies into a film 
which is able to deliver the active moiety to the body. In a first step desirable properties of the 
novel delivery systems are to be defined and an evaluation system based on these properties is to 
be established to perform a formulation screening process. With the help of the developed 
evaluation system various polymeric materials and formulation parameters will be investigated 
in terms of suitability to provide the technological basis for the dosage form. The film forming 
formulations resulting from this process will be characterized concerning their mechanical and 
occlusive properties. The relevance of the utilized evaluation and characterization methods for 
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the film forming systems will be assessed. To evaluate their potential as drug delivery systems 
film forming solutions loaded with drugs of different lipophilicity are to be studied concerning 
their drug release and drug permeation behaviour. Crucial parameters will be investigated to 
control and improve the drug permeation from the potential delivery systems. The drug 
permeation from drug loaded film forming solutions will also be compared to registered 
transdermal patches in vitro and possibly in vivo to gain a realistic assessment of their drug 
delivering capability. Finally, the possibilities and limitations of the novel film forming systems 
and their advantages and disadvantages in comparison to the conventional dosage forms are to be 
discussed. 
3. Anatomy of the skin 
The skin is the largest organ of the human body with a surface area of approximately  
1.5 – 2.0 m2 [2] and an average thickness of 0.5 mm (ranging from 0.05 mm to 2 mm) [3]. As 
interface between the body and the outside world the skin fulfils important protective as well as 
sensory functions. It contains a variety of receptors to receive different impulses such as 
pressure, touch, temperature and pain for the communication between the body and the 
environment. Through its capillary system and the subcutaneous fatty tissue the body 
temperature is regulated. The mechanical strength of the skin protects the body against 
mechanical stress. Its low permeability for a broad range of substances shields the body against 
chemical and microbiological noxes and prevents the dehydration of the body by limiting the 
transepidermal water loss. Melanocytes in the skin serve as protection against harmful ultraviolet 
radiation. Apart from this, the skin performs endocrine functions such as the synthesis of 
Vitamin D and the production of pheromones. 
 
Basically the skin can be divided into three layers: the epidermis, the dermis and the hypodermis. 
The different structures are displayed in Fig. 1 and will be described more detailed in the 
following. 
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Fig. 1: Schematic cross-section of the skin (adapted from Thews [4]) 
 
 
3.1. The epidermis 
The epidermis is the uppermost layer of the skin with an average thickness of 0.1 – 0.15 mm [5]. 
As it is a non-vascularized tissue, it receives its nutrition by diffusion from the capillary system 
of the dermis. Apart from the keratinocytes, which represent the majority of the cells in the 
epidermis, other cell types like melanocytes, Langerhans cells and Merkel cells are located in 
this skin layer. Furthermore, a number of catabolic enzymes such as esterases, phosphatases or 
lipases are present throughout this tissue [3]. The epidermis can be further subdivided into a 
viable part, consisting of the stratum basale, the stratum spinosum, the stratum granulosum and 
(only in certain anatomical regions) the stratum lucidum, and a non-viable part, the stratum 
corneum.  
hair follicle muscle
hair root sweat gland
capillary
fat cells
sweat gland
excretory duct
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3.1.1. The viable epidermis 
The viable part of the epidermis consists mainly of three, in certain anatomical regions of four 
different layers. The lowest layer, the stratum basale represents the border of the epidermis to the 
dermis. Above the stratum basale the stratum spinosum is located, followed by the stratum 
granulosum. The stratum granulosum borders on the non-viable tissue of the stratum corneum, 
which is the outermost layer of the skin. In the skin of the soles of the feet and the inner sides of 
the hands a fourth layer is found, the stratum lucidum, which is located between the stratum 
corneum and the stratum granulosum. The average thickness of all layers of the viable tissue is 
approximately 100 µm [6].  
 
The stratum basale consists of a single layer of actively dividing cells (the only ones in the 
epidermis). These are connected to the basal membrane and the dermis via hemidesmosomes. 
Adjacent and overlying cells in the cell layer are connected via desmosomes. The main function 
of the stratum basale is the regeneration of the epidermal tissue. The cells that result from the 
mitotic activity of these epidermal stem cells, the keratinocytes, migrate in the direction of the 
stratum corneum where they are finally shed after approximately 30 days [7]. During the 
migration the keratinocytes undergo a differentiation process (loss of phospholipids, increase in 
sphingolipid and cholesterol content, loss of cell organelles) at the end of which they have 
become the dead, completely cornified corneocytes that represent the main body of the stratum 
corneum. Apart from the keratinocytes melanocytes and Merkel cells (pressure receptors) are 
also located in the stratum basale. The melanocytes, which are responsible for the protection of 
the basal layer against UV radiation, can also be located in the lower layers of the stratum 
spinosum. 
 
The stratum spinosum, which is located next to the stratum basale, consists of 4 - 8 cell layers. 
The high number of desmosomes that connect adjacent cells accounts for the spiny appearance 
of these cells in histological sections. In this layer an increased synthesis of proteins and lipids 
takes place in the cells including the production of the Odland bodies. These lipid-enriched 
lamellar bodies are secreted by the keratinocytes later in the migration process at the border of 
the stratum granulosum to the stratum corneum and form the intercellular lipid matrix in the 
stratum corneum [5]. A first aggregation of the keratinous filaments in the keratinocytes is 
observed in the stratum spinosum. In the upper layers a re-orientation of the cell bodies takes 
place as the keratinocytes become horizontally oriented in relation to the cells in the stratum 
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basale. In addition to the keratinocytes the stratum spinosum contains immunologically active 
Langerhans cells. 
 
The layer above the stratum spinosum, the stratum granulosom, contains only 2 – 5 layers of 
flattened cells with keratohyalin granules. These granules contain various proteins such as 
keratins, profillagrin or loricrin [5]. The profillagrin is converted into fillagrin that serves to 
aggregate and align the keratin filaments in the further cornification process. The stratum 
granulosum is also the location for the formation of the cornified envelope. This structure, 
consisting predominantly of the cross linked protein loricrin, is a protein layer on the inner side 
of the cell membrane that serves to mechanically stabilize the keratinocytes. During the 
migration of the keratinocyte through the stratum granulosum the transition from granular to 
cornified cell takes place with the cytoplasmatic degradation of the cellular organelles performed 
by various proteases. 
3.1.2. The stratum corneum 
The stratum corneum, the uppermost layer of the epidermis, consists typically of 18 - 21 cell 
layers and has a thickness of 10 – 20 µm [3]. On the external side it is covered by a liquid, 
weakly acidic film (pH 5 – 6) for antimicrobial protection. The cells in this layer are corneocytes 
(terminally differentiated keratinocytes) that are embedded in a lipid matrix consisting of the 
secreted contents of the lamellar Odland bodies. This structure has been characterized by Elias as 
brick-and-mortar-organization [8] where the protein rich corneocytes represent the bricks and the 
hydrophobic lipids organized in lamellar structures the connecting mortar. Corneodesmosomes 
improve the cohesiveness of this cell layer [9]. The corneocytes contain between 10% and 30% 
of water [5]. Their degree of hydration is related to the presence of the degradation products of 
fillagrin, a blend of amino acids, uric acid and further compounds termed as natural moisturizing 
factor [10]. 
The intercellular lipid matrix consists mainly of ceramides, cholesterol and fatty acids besides 
small amounts of triglycerides, glycosphingolipids and cholesterol sulphate [11]. Ceramides 
(approximately 50% of the total lipid mass) are responsible for the lipid organization, cholesterol 
(approx. 25%) improves the mixing of the different lipid compounds. The free fatty acids 
(approx. 10%) are mainly of the saturated type with a chain length of 20 carbon atoms or more, 
with additional smaller fractions of oleic and linoleic acids. Contrary to other biological lipid 
membranes polar phospholipids are not present in the lipid mixture. The intercellular lipids are 
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basically organized in multilamellar bilayers, containing crystalline, liquid crystalline and 
possibly also gel phases [5]. The presence of additional liquid phases has also been suggested 
[12]. 
3.2. The dermis 
The dermis is a highly elastic tissue made of a network of protein fibres (different types of 
collagen and elastin) which is embedded in an amorphous ground substance consisting of 
glycosaminoglycan [3]. Apart from the protein network the dermis contains nerve endings and 
blood vessels as well as lymphatic vessels. Additionally, fibroblasts, macrophages, mast cells 
and leukocytes are found in this skin layer. The dermis is subdivided into the stratum papillare, 
that borders on the epidermis, and the stratum reticulare, which is located near the hypodermis. 
Both tissues differ in the strength of the collagenic fibers which are rather fine in the stratum 
papillare and fairly strong in the stratum reticulare.  
3.3. The hypodermis 
The hypodermis is located below the dermis and displays a high content of fatty tissue. Due to 
this the main functions that can be attributed to the hypodermis are the protection of the body 
against cold and the provision of energy resources. 
3.4. Skin appendages 
Throughout the skin different skin appendages can be found such as nails, hairs, sebaceous 
glands and sweat glands. Hair follicles as well as sebaceous and sweat glands can be found in the 
hypodermis as well as in the dermis and traverse through the epidermis to the surface. Sebaceous 
glands are often connected to hair follicles. For nutrition purposes the hair follicles are connected 
to the capillary system of the dermis. 
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4. Transdermal drug delivery 
4.1. Delivery routes through the skin 
Due to its size the skin is an attractive organ for the application of pharmaceutically active 
substances. However, the drug delivery via the skin is challenging due to its very efficient barrier 
properties. In order to reach the capillary or lymphatic system in the dermis and finally the 
systemic circulation a drug has to permeate several layers of the skin with different chemical 
properties. After the release from the formulation the drug has to partition into the uppermost 
layer of the skin, the stratum corneum. After diffusion through this first layer with its highly 
lipophilic intercellular matrix the drug has to partition from the stratum corneum into the 
hydrophilic viable epidermis. From the viable epidermis it diffuses into the dermis to be taken up 
into the local capillary network of the dermis. Once the drug has entered the capillary system 
perfect sink conditions and therefore a maximum concentration gradient for the drug diffusion 
are achieved. In this permeation process the uppermost layer of the skin, the stratum corneum, 
with its protein rich corneocytes and the intercellular lipid structure has been acknowledged as 
main barrier for many years [13]. 
For the permeation of substances through this first and principal barrier several different routes 
are discussed (Fig. 2): the intercellular route, the transcellular route and appendageal pathway 
[14]. Traditionally, it was postulated that hydrophilic drugs prefer to diffuse through the stratum 
corneum on the transcellular route, that is along the keratinous fibers through the corneocytes, 
while lipophilic drugs tend to diffuse through the lamellar lipid structures between the cells [6]. 
The transcellular route, however, requires the drug to pass not only the hydrophilic corneocytes 
but also the lipid intercellular matrix between adjacent corneocytes. This circumstance 
complicates the drug passage on this permeation route. Therefore the intercellular route is 
presently considered the major pathway for lipophilic and hydrophilic drugs, assuming that the 
hydrophilic compounds preferably diffuse along the polar head-groups of the bilayers while 
lipophilic drugs choose the non-polar tail-groups [15]. Apart from the transcellular and the
intercellular passage way another possible route is the drug diffusion along hair follicles, 
sebaceous glands or sweat glands, the so-called shunt pathways. Scheuplein has proposed this 
diffusion route as opportunity predominantly for ionic drugs and large molecules to pass not only
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Fig. 2: Possible permeation routes through the skin according to Barry [16] 
 
the stratum corneum but the complete epidermis [6]. Barry has shown with the help of a skin 
sandwich technique that hydrophilic permeants might possibly use this diffusion route contrary 
to lipophilic drugs [17]. As the appendages cover only 0.1% of the surface area of the skin their 
importance for drug absorption is limited. However, the appendageal pathway might be of 
relevance for the uptake of special delivery systems such as liposomes or nanoparticles [18, 19]. 
The existence of an additional aqueous polar pathway in the stratum corneum for hydrophilic 
permeants is discussed controversially in the literature [20, 21]. 
Mitragotri has recently suggested four permeation pathways that are used by permeants in 
relation to their lipophilicity and molecular size [22]. He postulated that hydrophobic molecules 
(log Poct > 1) with low molecular weight (Mr < 400 Da) diffuse through the stratum corneum by 
free-volume diffusion while larger hydrophobic solutes rather use lateral diffusion in the lipid 
layers. He proposed that the free-volume pathway is also preferred by low molecular weight, 
moderately hydrophilic molecules (0.01 < log Poct < 1) while small and excessively hydrophilic 
solutes (log Poct < 0.01) use a porous pathway generated by imperfections in the lipid structures. 
Large hydrophilic molecules, finally, are supposed to diffuse through the shunt pathway. The 
different pathways suggested by Mitragotri in dependence of the size and lipophilicity of the 
molecule are illustrated in Fig. 3. The model Mitragotri proposed on the basis of these 
assumptions was well supported by experimental data. 
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Fig. 3: Relative role of diffusion pathways in dependence of the permeant size and lipophilicity adapted from 
Mitragotri [22].The regions correspond to a set of parameters where the named pathway determines more 
than 50% of the overall skin permeability. 
 
 
All described permeation options are passive diffusion processes, no active transport has been 
identified yet [23].  
 
With respect to the different lipophilic and hydrophilic structures of the skin it is obvious that 
drugs with different chemical properties encounter different problems concerning their passage 
through the skin. Hydrophilic drugs for example typically show low permeabilities in the stratum 
corneum as they do not partition to a great extent into the lipophilic domains of the intercellular 
pathway. Highly lipophilic drugs on the other hand can readily partition into the stratum 
corneum, but cannot diffuse easily into the hydrophilic viable epidermis. This circumstance can 
slow down the diffusion process and can lead to an enrichment of the drug at the interface 
stratum corneum – stratum granulosum [24]. Drug with hydrophilic and lipophilic moieties are 
less problematic as they can partition into hydrophilic as well as into lipophilic domains. This is 
the reason for the recommendation to choose drugs for a transdermal application with a log Poct 
between 1 and 3. Other properties that are beneficial for the transdermal absorption are a low 
molecular weight (< 500 Da), the absence of charges in the molecule, a low melting point and a 
low number of hydrogen-bonding groups [25, 26]. 
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Due to the generally low permeability of human skin it is still a challenge to achieve sufficient 
delivery levels in the human body for most drugs. Therefore much research has been done to find 
ways to improve the drug delivery and to open the transdermal application route for a larger 
group of drugs, especially for larger drugs such as proteins or peptides. Examples for different 
approaches to overcome the skin barrier are described in various review articles [15, 27, 28] and 
are summarized in Table 1. 
 
It has to be kept in mind that the transdermal absorption of a drug is not only influenced by the 
chemical properties of the drug and the functionalities of the vehicle but that it also underlies 
various inter- and intraindividual variations with respect to the application site on the body, the 
condition of the skin (healthy or diseased) and other factors such as age or race [29, 30]. 
 
Table 1: Examples for penetration enhancement techniques  
 
Chemical enhancement Physical enhancement 
• Pro-drugs • Complexes • Iontophoresis • Magnetophoresis 
• Ion pairs • Vesicles • Electroporation • Heat assisted delivery 
• Chemical 
enhancers  • Microneedles 
• Needle-free 
injection 
• Supersaturation  • Acoustical methods 
• Chemical skin 
abrasion 
• Eutectic 
systems    
  
- Liposomes 
- Transfersomes 
- Niosomes 
- Ethosomes 
- Solid lipid 
nanoparticles 
- Ultrasound 
- Short-duration 
shock waves 
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4.2. Delivery systems 
Although the transdermal delivery of drugs has been the subject of research for more than 
100 years [27] the active development of transdermal products began to gain pace only in the last 
40 years. The first transdermal product that was approved by the FDA in the United States of 
America was a scopolamine patch against motion sickness in 1979. Since then various 
transdermal products have entered the market. The number of drugs that are administered 
transdermally, however, remains small due to the abovementioned difficulties that are associated 
with this application route. 
The predominant dosage form for the systemic administration of drugs via the skin is the 
transdermal patch. However, in recent yeast the conventional patches have been joined by 
various semisolid formulations that aim to use the advantages of the transdermal application 
route while avoiding some of the disadvantages of the patches.  
4.2.1. Transdermal patches 
The group of transdermal patches can be divided into two subgroups, the matrix-type patches 
and the reservoir type patches. 
 
In matrix type patches the drug is either dissolved or suspended in a hydrophilic or lipophilic 
polymeric matrix. This matrix either has good adhesive properties itself (drug-in-adhesive type) 
or is covered completely or partly with an additional adhesive layer to provide a reliable 
adhesion to the skin. The outside part of the drug containing matrix is covered with an 
impermeable, often occlusive backing layer to protect the delivery system and to prevent 
diffusion of the drug to the outer surface of the patch. The opposite side of the patch, which will 
be brought in contact with the skin, is covered with a thin, inert release liner which can be 
removed easily and without residue before the application of the patch. The structure of a matrix 
type transdermal patch is illustrated in Fig. 4. 
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Impermeable backing
Drug-adhesive matrix
Release liner
 
 
 
 
Fig. 4: Structure of a matrix, drug-in-adhesive type transdermal patch (not in original scale) 
 
In reservoir type patches the drug is incorporated into a liquid or semisolid reservoir (for 
example in a hydrogel) that is located below an impermeable backing layer. The drug release 
from this reservoir is controlled by a non-porous or microporous membrane. If the membrane is 
non-adhesive an additional adhesive layer ensures a close contact between the patch system and 
the skin. Fig. 5 shows the structure of a reservoir-type patch. 
 
The polymers that are used for the manufacturing of the transdermal patches are selected 
according to their function in the different patch layers. The backing layer can consist of natural 
or synthetic polymers (for example cotton tissue, polyester or polyethylene) and can contain an 
aluminium layer if a strong occlusive effect is desired. 
The release liner can be manufactured from a thin, inert polyester foil, often covered with an 
additional layer (for example made of silicone) to allow a residue free removal of the 
transdermal system from the protective liner. 
For the rate-controlling membrane in the reservoir-type systems materials such as 
poly(ethylenvinylacetate) or polyethylene are used [31]. 
The adhesive layer of the patch is a very crucial part as it is responsible for an undisturbed drug 
release by maintaining close contact of the drug loaded system to the skin. In case of the drug-in-
adhesive systems it is also the main body of the patch and controls the drug release from the 
patch. The three polymer groups that are predominantly used for the manufacturing of this 
Impermeable backing
Drug reservoir
Rate controlling membrane
Adhesive layer
Release liner
 
 
 
 
 
 
Fig. 5: Structure of a reservoir type transdermal patch (not in original scale) 
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layer (‘pressure sensitive adhesives’) are polyisobutylenes, polysiloxanes (silicones) and 
polyacrylate polymers [32]. The basic structures of these polymer groups are illustrated in Fig. 6. 
In addition to these basically hydrophobic polymers the usage of hydrophilic polymers such as 
polyvinylpyrrolidone/polyethylene glycol, aminoalkylmethacrylate copolymers or polyurethanes 
has been discussed [32]. 
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Fig. 6: Basic polymer structures of pressure sensitive adhesives according to Tan [32] 
 
Apart from the polymers for the different patch layers further excipients can be incorporated into 
the patch for various purposes (for example to improve the drug solubility in the formulation, the 
drug permeation, the chemical or physical stability of the drug during storage or the adhesive 
properties of the adhesive layers). 
 
Currently transdermal patches, either of the reservoir- or of the matrix type, are marketed only 
for a small number of drugs such as buprenorphine, clonidine, fentanyl, lidocaine, nicotine, 
nitroglycerine, estradiol, oxybutinin, scopolamine or testosterone [33, 34]. Recently patches with 
methylphenidate, selegiline or rotigotine have entered the market indicating that research 
continues to make use of this special application route. For the indications hormone replacement 
and contraception there are also patches available that supply a combination of two drugs such as 
ethinylestradiol/norelgestromin (EVRA®, Janssen-Cilag GmbH, Germany) or 
estradiol/levonorgestrel (Fem7® Combi, Solvay Arzneimittel GmbH, Germany). Table 2 shows 
some examples for commercially available transdermal patches.  
 
Special attention in research is paid to the transdermal delivery of proteins or peptides with the 
help of novel enhancement techniques. Examples for drugs from this group are human growth 
hormone (microneedles, phase I), insulin or parathyroid hormone (thermal enhancement, 
phase I) [26]. 
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Table 2: Examples for commercially available transdermal patches [33, 34] 
 
Active ingredient Trade name System type Wearing time Clinical indication 
Patch size 
(cm2) 
Buprenorphin Transtec® PRO Matrix 3 days Analgesia 25 - 50 
Clonidine Catapres-TTS® Reservoir 7 days Hypertension 20 
Estradiol Estraderm® Reservoir 3 - 4 days HRT1 5 - 20 
 Estradot® Matrix 3 - 4 days HRT1 2.5 - 10 
 Fem7® Matrix 7 days HRT1 15 – 22.5 
Fentanyl Durogesic® Reservoir 3 days Analgesia 10.5 - 42 
Lidocaine Lidoderm® Matrix 12 hours Post-herpetic neuralgia 140 
Methylphenidate Daytrana® Matrix 9 hours ADHD2 12.5 – 37.5 
Nicotine Nicorette® Matrix 1 day (16 hours) Smoking cessation 10 - 30 
 Nicotinell® Reservoir 1 day Smoking cessation 10 - 30 
Nitroglycerin Nitro-Dur® Matrix 12 – 14 hours Angina 5 - 40 
Oxybutinin KENTERATM Matrix 3 - 4 days Overactive bladder 39 
Rotigotine Neupro® Matrix 1 day Parkinsons disease 10 - 40 
Selegiline EMSAM® Matrix 1 day Depression 20 - 40 
Scopolamin Scopoderm® TTS Matrix 3 days Motion sickness 2.5 
Testosterone Androderm® Reservoir 1 day Hypogonadism 37 - 44 
      
Estradiol + 
Norethindrone 
Acetate 
Estragest TTS® Reservoir 3 - 4 days HRT1 10 
Estradiol + 
Levonorgestrel Fem7
® Combi Matrix 7 days HRT1 15 
Ethinylestradiol + 
Norelgestromin EVRA
® Matrix 7 days Contraception 20 
 
1 HRT = Hormone Replacement Therapy 
2 ADHD = Attention Deficit Hyperactivity Disorder 
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4.2.2. Transdermal semisolids 
Traditionally, semisolid formulations were only used for the therapy of dermal diseases where 
the target of the drug was the skin itself and not the systemic circulation. However, due to the 
fact that semisolid formulations show certain advantages compared to transdermal patches and 
have proved that they can equally well deliver sufficient amounts of drug to the systemic 
circulation [29, 35, 36] these systems have been developed as an alternative to the traditional 
polymeric patches. Especially alcoholic hydrogels have gained acceptance in this field. 
The materials used for these formulations depend on the formulation type (gels or cream). They 
range from different kinds of solvents (for example water, alcohols, glycols) over hydrophilic or 
hydrophobic polymers (acrylates, cellulose derivatives) and emulsifiers to fatty compounds 
(paraffins, oils, waxes). 
Although considerable research is done in this field the number of commercially available 
products is limited. Transdermal semisolids are for example marketed with steroidal hormones 
for the indications hypogonadism (for example Testogel®, Jenapharm GmbH & Co. KG, 
Germany) or postmenopausal symptoms (Estreva® gel, Solvay Arzneimittel GmbH, Germany, or 
Cordes® Estriol Creme, APS GmbH, Germany). 
4.2.3. Advantages and disadvantages of current systems 
The transdermal administration of a sufficient dose is challenging and only feasible for a small 
number of drugs. Still the advantages of the transdermal application route in general are 
numerous [23, 25, 26]: with a transdermal application the gastrointestinal tract is avoided 
altogether. This is especially advantageous for drugs that are sensitive to degradation due to the 
pH conditions or enzymatic activity in the gastrointestinal tract. There is no impact on the 
reliability of the medication of the gastrointestinal activity such as gastric emptying or disorders 
(vomiting, diarrhoea). Mucosal irritation that can be caused by the drug or an excipient is also 
avoided. Moreover, the hepatic first-pass effect is omitted. In consequence the administered drug 
dose can be reduced and less metabolic degradation products occur in the systemic circulation 
which reduces the risk of side effects. The plasma levels achieved by the controlled delivery of 
the transdermal systems are fairly steady. Plasma level peaks or troughs, that are often observed 
after oral application, are minimized which also reduces the appearance of side effects. The 
assistance of the patient (consciousness, ability to swallow) is not necessarily required for the 
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application. Contrary to oral dosage forms the medication can be instantly removed in case of an 
emergency. Depending on the drug, however, a possible reservoir formation in the upper skin 
layers has to be kept in mind that might prolong the effect of the drug beyond the time of 
removal. Finally, the administration of the transdermal system is non-invasive, painless and 
convenient for the patient. These application conditions together with the often considerably 
reduced dosing frequency (up to once weekly) especially for drugs with a short half-life can 
positively influence the patient compliance. 
 
Besides these positive aspects there are also limitations to this delivery route [25, 26]. Apart 
from the already discussed problem to overcome the efficient skin barrier the drugs can also 
suffer from degradation on their way to the systemic circulation due to the presence of metabolic 
enzymes in the skin. In addition to this, an inter- and intraindividual variability of the drug 
resorption has been described with respect to the location of the application site (differing 
thickness of the stratum corneum and skin hydration), the skin type (varying lipid compositions), 
enzymatic activity, age or health condition of the skin (healthy or diseased). Due to the relatively 
slow onset of the drug action the transdermal delivery is not suitable for indications where a 
rapid, bolus-type drug input is required. Finally, skin irritation and skin sensitisation are often 
responsible for the discontinuation of the treatment, although this problem occurs predominantly 
with transdermal patches and not with semisolids. 
 
Except for the last point the abovementioned general advantages and disadvantages of the 
application route account for all transdermal delivery systems independent of their design. In 
addition to these, however, a few special pros and cons have to be mentioned that are associated 
with the different dosage forms. 
 
Transdermal patches for example reach a high precision as to the dosing of the drug, but the 
dosing flexibility is usually limited for manufacturing reasons [23]. The often occlusive climate 
below the patches can be an advantage as it can promote the permeation of some drugs [37, 38]. 
On the other hand, it can also be a disadvantage as occlusion can be the source for skin irritation 
[39, 40]. For some drugs the low dosing and the considerable reservoir size of the polymeric 
patch can allow longer application intervals up to one week which can positively influence the 
patient compliance. However, a sufficient adhesion to the skin is not always provided by the 
contact layer of the patch. Cases of adhesion failure occur especially for the weekly patches [41]. 
The usage of strong adhesives, on the other hand, reduces this risk but can be problematic 
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with respect to skin irritation and residues on the skin that are difficult to remove by the patient 
and aesthetically unattractive. Although much work has been done to improve the appearance of 
the patches some are still criticized by patients for their high visibility and the resulting lack of 
discreetness [29]. An example for a highly visible patch is shown in Fig. 7. Finally it has to be 
pointed out that the production of polymeric patches requires specialized production equipment 
and generates considerable manufacturing costs. 
 
 
 
 
 
 
 
 
Fig. 7: Ortho-EVRA/EVRA® patch as shown on the internet [42] 
 
 
In contrast to this the typical semisolid formulations can be manufactured with a fairly simple 
equipment. They offer a high dosing flexibility, which is an advantage in comparison to the 
patches, but they lack the dosing accuracy. The latter results from the fact that a correct dosing of 
the drug relies on the patients ability to distribute the fixed amount of formulation on a skin area 
of appropriate size. The application sites for the semisolids that are required to produce adequate 
dosing levels are considerable larger than the sizes of the transdermal patches (the Testim® gel 
(5 g) for example is distributed on one shoulder and arm [43]). Similar to the patch application 
the administration of the semisolids is simple for the patients. However, due to the fact that the 
administered semisolid is usually not completely absorbed a sticky or greasy residue can remain 
on the skin directly after application which can negatively influence the patient compliance. The 
incomplete absorption carries also the risk of environmental contamination [44]. Part of the drug 
that remains on the skin surface after application can be transferred to other persons or can 
contaminate the patients clothes which can raise safety concerns especially for highly potent 
drugs. The lack of permanence on the skin is also the reason why a sustained release is difficult 
to achieve with semisolid formulations in contrast to the patches. 
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5. Film forming pharmaceutical preparations 
For this work film forming preparations are defined as non-solid dosage forms that produce a 
substantial film in situ after application on the skin or any other body surface. Such compositions 
can either be liquids or semisolids with a film forming polymer as basic material for the matrix. 
The formed film is sufficiently substantial to provide a sustained drug release to the skin. 
 
In the past film forming preparations have been known predominantly from the field of surgery 
or wound care. Film forming solutions or gels have been used for example as tissue glues for the 
sealing of operative wounds [45]. The film formers mainly used in this area are fibrin as natural 
material and cyanoacrylates (octyl- and butylcyanoacrylate) as synthetic polymers [46-48]. 
Cyanoacrylates or recently acrylate polymers have also been used for the closure of superficial 
wounds as liquid bandages [49, 50]. Examples for commercially available products of this type 
are given in Table 3. While most film formers are incorporated into the formulations as already 
polymerised material the cyanoacrylates are often applied as monomers. The polymerisation of 
the monomers takes place in situ and is catalysed for example by the presence of water on the 
skin. The velocity of the polymerisation process has to be controlled thoroughly to avoid 
inconveniences for the patient as the process is exothermic [51, 52]. 
Wound care preparations can either be drug free or combined with antimicrobial drugs to reduce 
the risk of infections in the wounds [53-55]. 
 
Apart from the wound care film forming preparations are also administered in ostomy care to 
protect the skin surrounding the ostomy wound from the aggressive bodily fluids [56]. 
 
For dermal therapy a few liquid film forming products are approved, mainly for the therapy of 
warts and calluses. Examples are Verrumal® (Hermal oHG, Germany) or Clabin® Plus (Chefaro, 
Germany). Furthermore some film forming products for the therapy of nail mycoses are 
registered such as Loceryl® (Galderma GmbH, Germany) or Penlac® (Dermik Laboratories, 
USA). 
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Table 3: Examples for film forming wound care products 
 
Trade name Manufacturer Film forming polymer 
Dermabond® Ethicon GmbH, Germany Octylcyanoacrylate 
EPIGLU® Gewebekleber Meyer-Haake GmbH, Germany Ethylcyanoacrylate, Poly(methylmethacrylate) 
Flint® Sprühverband Togal, Germany Poly(butylmethacrylate, methylmethacrylate) 
Band Aid® Sprühpflaster Ethicon GmbH, Germany Cellulose Acetate Butanoate 
Opsite® Spray Smith&Nephew GmbH, Austria Poly(methylacrylate) 
 
 
The film forming systems that have been described so far are used in the pharmaceutical field 
but are not designed for the transdermal administration of pharmaceutically active substances. 
Only very few preparations that aim at a sustained delivery over a longer period of time have 
been described in the literature. 
Misra et al. have investigated a film forming solution with a mixture of polyvinyl pyrrolidone 
and polyvinyl alcohol as film former in isopropanol for the transdermal delivery of testosterone 
[57, 58]. The group reported that the film forming solution provided a sustained release of the 
steroidal hormone with a biphasic pharmacokinetic profile. So far, no liquid film forming 
preparation has been approved for transdermal drug delivery. 
 
Bryan et al. reported on a film forming composition in the form of a cream for the local delivery 
of a eutectic mixture of Lidocaine and Tetracain for pre-surgical anaesthesia [59]. The cream 
was left to dry on the skin for at least 20 minutes, after which it was removed by peeling. During 
this time the formulation had delivered a sufficient amount of the local anaesthetics through the 
skin to provide a significant pain reduction for the patient during the following laser treatment. 
The product has recently been approved by the FDA (S-CaineTM Peel, Zars Inc., Salt Lake City, 
USA). 
 
Another film forming semisolid preparation was described by An et al. [60]. This group 
investigated a transdermal hydrogel on the basis of polyvinyl alcohol and polyisobutylene that 
solidified into a substantial film in situ on the skin. The formed film was able to provide a 
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sustained release of testosterone over 24 hours. Due to its cohesive structure the formed film was 
removable by peeling.  
The fact that the preparation investigated by An et al. produced a substantial and robust film on 
the skin, which is the prerequisite for a sustained drug release, distinguishes it from other 
transdermal gels. In these gels the main purpose of the gelling agents, that can be film forming 
polymers as well, is not to form films but to increase the viscosity by establishing a gel structure 
in the preparation. Due to this the gelling agents are not selected for their film forming ability 
and are often used in low concentrations so that the resulting films (if formed at all) are rather 
weak and show little persistence on the skin. Therefore most transdermal gels cannot provide a 
sustained release to the skin and can thus not be considered film forming preparations in the 
sense of this work. 
 
Apart from the preparations that form a polymeric film on the skin for the transdermal drug 
delivery there are also other, mostly liquid formulations that are worth mentioning in this 
context. These are solutions of drugs, with or without enhancers, in volatile solvents that are 
typically sprayed onto the skin where they form liquid films. Due to the fact that the 
formulations do not contain a film forming polymer these films vanish shortly after application 
with the evaporation of the solvent, leaving a drug loaded residue or re-crystallized drug behind. 
Examples for solutions of this type have been investigated for example by Leichtnam et al. with 
testosterone [61, 62], Tucker et al. with lidocaine [63] or Morgan et al. with steroidal hormones 
[64-66]. Based on the findings of Morgan et al. products with a metered dose transdermal 
technology are being developed by Acrux Ltd., Melbourne, Australia, for several indication with 
the drugs estradiol, testosterone, Nestorone®, fentanyl and buspirone [67]. 
 22
General introduction 
6. References 
[1] R. Langer, Transdermal drug delivery: past progress, current status and future prospects, 
Adv. Drug Delivery. Rev. 56 (2004) 557-558. 
[2] Psyrembel, Klinisches Wörterbuch, de Gruyter, Berlin, New York (2004). 
[3] M. Foldvari, Non-invasive administration of drugs through the skin: challenges in 
delivery system design, Pharm. Sci. Technol. To. 3 (2000) 417-425. 
[4] G. Thews, E. Mutschler, P. Vaupel, Haut, in: Anatomie, Physiologie, Pathophysiologie 
des Menschen, 5th Ed., Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart (1999)  
[5] G.K. Menon, New insights into skin structure: scratching the surface, Adv. Drug 
Delivery. Rev. 54 (2002) S3-S17. 
[6] R.J. Scheuplein, Permeability of the skin: a review of major concepts, Curr. Probl. 
Dermatol. 7 (1978) 172-86. 
[7] M.S. Roberts, K.A. Walters, The relationship between structure and barrier function of 
skin, in:, M. S. Roberts, K.A. Walters (Eds.), Drugs and the pharmaceutical sciences. 
Dermal Absorption and Toxicity Assessment, Vol. 91, Marcel Dekker, New York (1998) 
1-42. 
[8] P.M. Elias, Epidermal lipids, barrier function, and desquamation, J. Investig. Dermatol. 
80 (1983) 44-49. 
[9] P. Corcuff, F. Fiat, A.-M. Minondo, Ultrastructure of the human stratum corneum, Skin 
Pharmacol. Appl. Skin Physiol. 14 (2001) 4-9. 
[10] A.V. Rawlings, I.R. Scott, C.R. Harding, P.A. Bowser, Stratum corneum moisturization 
at the molecular level, J. Investig. Dermatol. 103 (1994) 731-740. 
[11] P.N. Wertz, D.L. Downing, Epidermal lipids, in: L. A. Goldsmith (Ed.), Physiology, 
Biochemistry and Molecular Biology of the Skin, Vol., Oxford University Press, New 
York (1991) 205-236. 
[12] J. Bouwstra, G. Pilgram, G. Gooris, H. Koerten, M. Ponec, New aspects of the skin 
barrier organization, Skin Pharmacol. Appl. Skin Physiol. 14 (2001) 52-62. 
[13] R.J. Scheuplein and I.H. Blank, Permeability of the skin, Physiol. Rev. 51 (1971) 702-47. 
[14] R.J. Scheuplein, Properties of the skin as a membrane, Adv Biol Skin 12 (1972) 125-52. 
[15] H.A. Benson, Transdermal drug delivery: penetration enhancement techniques, Current 
Drug Delivery 2 (2005) 23-33. 
[16] B.W. Barry, Lipid-Protein-Partitioning theory of skin penetration enhancement, J. 
Control. Release 15 (1991) 237-248. 
[17] B.W. Barry, Drug delivery routes in skin: a novel approach, Adv. Drug Delivery. Rev. 54 
(2002) S31-S40. 
[18] J. Lademann, H. Richter, U.F. Schaefer, U. Blume-Peytavi, A. Teichmann, N. Otberg, W. 
Sterry Hair follicles - a long-term reservoir for drug delivery, Skin Pharmacology and 
Physiology 19 (2006) 232-236. 
 23
General introduction 
[19] S. Jung, N. Otberg, G. Thiede, H. Richter, W. Sterry, S. Panzner, J. Lademann, 
Innovative liposomes as a transfollicular drug delivery system: penetration into porcine 
hair follicles, J. Invest. Dermatol. 126 (2006) 1728-1732. 
[20] K.D. Peck, A.H. Ghanem, W.I. Higuchi, Hindered diffusion of polar molecules through 
and effective pore radii estimates of intact and ethanol treated human epidermal 
membrane, Pharm. Res. 11 (1994) 1306-1314. 
[21] R.O. Potts, R.H. Guy, Predicting skin permeability, Pharm. Res. 9 (1992) 663-669. 
[22] S. Mitragotri, Modeling skin permeability to hydrophilic and hydrophobic solutes based 
on four permeation pathways, J. Control. Release 86 (2003) 69-92. 
[23] M.B. Brown, G.P. Martin, S.A. Jones, F.K. Akomeah, Dermal and transdermal drug 
delivery systems: current and future prospects, Drug Delivery 13 (2006) 175-187. 
[24] J.W. Wiechers, The barrier function of the skin in relation to percutaneous absorption of 
drugs, Pharm. Weekbl. Sc. 11 (1989) 185-198. 
[25] A. Naik, Y.N. Kalia, R.H. Guy, Transdermal drug delivery: overcoming the skin´s barrier 
function, Pharm. Sci. Technol. To. 3 (2000) 318-326. 
[26] B.J. Thomas, B.C. Finnin, The transdermal revolution, Drug Discov. Today 9 (2004) 
697-703. 
[27] M.R. Prausnitz, S. Mitragotri, R. Langer, Current status and future potential of 
transdermal drug delivery, Nature Reviews. Drug Discovery. 3 (2004) 115-124. 
[28] A. Nanda, S. Nanda, N.M. Khan Ghilzai, Current developments using emerging 
trandermal technologies in physical enhancement methods, Current Drug Delivery 3 
(2006) 233-242. 
[29] G. Samsioe, Transdermal hormone therapy: gels and patches, Climacteric 7 (2004) 347-
356. 
[30] D. Southwell, B.W. Barry, R. Woodford, Variations in permeability of human skin within 
and between species, Int. J. Pharm. 18 (1984) 299-309. 
[31] C. Valenta, B.G. Auner, The use of polymers for dermal and transdermal delivery, Eur. J. 
Pharm. Biopharm. 58 (2004) 279-289. 
[32] H.S. Tan, W.R. Pfister, Pressure-sensitive adhesives for transdermal drug delivery 
systems, Pharm. Sci. Technol. To. 2 (1999) 60-69. 
[33] Physicians Desk Reference [online], available: http://www.pdr.net [accessed 25.09.06] 
[34] Rote Liste [online], available: http://www.rote-liste.de/Online [accessed 26.09.2006] 
[35] L.J. Gooren, M.C. Bunck, Transdermal testosterone delivery: testosterone patch and gel, 
World J. Urol. 21 (2003) 316-319. 
[36] I. Alberti, A. Grenier, H. Kraus, D.N. Carrara, Pharmaceutical development and clinical 
effectiveness of a novel gel technology for transdermal drug delivery, Expert Opinion on 
Drug Delivery 2 (2005) 935-950. 
[37] D.A. Bucks, J.R. McMaster, H.I. Maibach, R.H. Guy, Bioavailability of topically 
administered steroids: a " mass balance" technique, J. Investig. Dermatol. 91 (1988)  
29-33. 
 24
General introduction 
[38] P. Treffel, P. Muret, P. Muret-D'Aniello, S. Coumes-Marquet, P. Agache, Effect of 
occlusion on in vitro percutaneous absorption of two compounds with different 
physicochemical properties, Skin Pharmacol. 5 (1992) 108-113. 
[39] H. Zhai, H. Maibach, Effects on skin occlusion on percutaneous absorption: an overview, 
Skin Pharmacol. Appl. Skin Physiol. 14 (2001) 1-10. 
[40] H. Matsumura, K. Oka, K. Umekage, H. Akita, J. Kawai, Y. Kitazawa, S. Suda, K. 
Tsubota, Y. Ninomiya, H. Hirai, et al., Effect of occlusion on human skin, Contact 
Dermatitis 33 (1995) 231-235. 
[41] J.A. Erianne, L. Winter jr., Comparison of the local tolerability and adhesion of a new 
matrix system (Menorest) for estradiol delivery with an established transdermal 
membrane system (Estraderm TTS), Maturitas 26 (1997) 95-101. 
[42] The Ortho Evra/Evra Transdermal Contraceptive System [online], (29.01.2002), 
available: http://www.contraceptiononline.org/slides/slide01.cfm?tk=5&dpg=3 [accessed 
28.09.2006] 
[43] Ipsen Pharma GmbH, Fachinformation Testim 50mg Gel, (2004), 1. 
[44] N. Mazer, D. Fischer, J. Fischer, M. Cosgrove, D. Bell, B. Eilers, Transfer of 
transdermally applied testosterone to clothing: a comparison of a testosterone patch 
versus a testosterone gel, Journal of Sexual Medicine 2 (2005) 227-234. 
[45] M. Donkerwolcke, F. Burny, D. Muster, Tissues and bone adhesives - historical aspects, 
Biomaterials 19 (1998) 1461-1466. 
[46] C.J. Dunn, K.L. Goa, Fibrin sealant: a review of its use in surgery and endoscopy, Drugs 
58 (1999) 863-886. 
[47] A.J. Singer, H.C. Thode, A review of the literature on octylcyanoacrylate tissue adhesive, 
The American Journal of Surgery 187 (2003) 238-248. 
[48] L.T. Hall, J.E. Bailes, Using Dermabond for wound closure in lumbar and cervical 
neurosurgical procedures, Neurosurgery 56 (2005) 147-150. 
[49] D.C. Ritterband, S.W. Meskin, D.E. Shapiro, J. Kusmierczyk, J.A. Seedor, R.S. Koplin, 
Laboratory model of tissue adhesive (2-octyl cyanoacrylate) in sealing clear corneal 
cataract wounds, Am. J. Ophthalmol. 140 (2005) 1039-1043. 
[50] W.H. Eaglstein, T.P. Sullivan, P.A. Giordano, B.M. Miskin, A liquid adhesive bandage 
for the treatment of minor cuts and abrasions, Dermatol. Surg. 28 (2002) 263-267. 
[51] S.C. Woodward, J.B. Herrmann, J.L. Cameron, G. Brandes, E.J. Pulaski, F. Leonard, 
Histotoxicity of cyanoacrylate tissue adhesive in the rat, Annals of Surgery 162 (1965) 
113-122. 
[52] A.J. Singer, P. Giordano, J.L. Fitch, J. Gulla, D. Ryker, S. Chale, Evaluation of a new 
high-viscosity octylcyanoacrylate tissue adhesive for laceration repair: a randomized, 
clinical trial., Academic Emergency Medicine 10 (2003) 1134-1137. 
[53] S.M. Foroutan, H.A. Ettehadi, H.R. Torabi, Formulation and in vitro evaluation of silver 
sulfadiazine spray, Iran. J. Pharm. Res. 1 (2002) 47-49. 
[54] D.K. Jeng, A new, water-resistant, film-forming, 30-second, one-step application 
iodophor preoperative skin preparation, Am. J. Infect. Control 29 (2001) 370-376. 
[55] S. Garg, S.N. Sharma, Development of medicated aerosol dressings of chlorhexidine 
acetate with hemostatics, Pharmazie 47 (1992) 924-926. 
 25
General introduction 
[56] K. Campbell, M.G. Woodbury, H. Whittle, T. Labate, A. Hoskin, A clinical evaluation of 
3M No Sting Barrier Film, Ostomy Wound Manage. 46 (2000) 24-30. 
[57] A. Misra, R.S. Raghuvanshi, S. Ganga, M. Diwan, G.P. Talwar, O. Singh, Formulation of 
a transdermal system for biphasic delivery of testosterone, J. Control. Release 39 (1996) 
1-7. 
[58] A. Misra, R. Pal, S.S. Majumdar, G.P. Talwar, O. Singh, Biphasic testosterone delivery 
profile observed with two different transdermal formulations, Pharm. Res. 14 (1997) 
1264-1268. 
[59] H.A. Bryan, T.S. Alster, The S-Caine Peel: a novel topical anestetic for cutaneous laser 
surgery, Dermatol. Surg. 28 (2002) 999-1003. 
[60] N.M. An, D.D. Kim, Y.H. Shin, C.H. Lee, Development of a novel soft hydrogel for the 
transdermal delivery of testosterone, Drug Dev. Ind. Pharm. 29 (2003) 99-105. 
[61] M.L. Leichtnam, H. Rolland, P. Wüthrich, R.H. Guy, Formulation and evaluation of a 
testosterone transdermal spray, J. Pharm. Sci. 95 (2006) 1693-1702. 
[62] M.L. Leichtnam, H. Rolland, P. Wüthrich, R.H. Guy, Identification of penetration 
enhancers for testosterone transdermal delivery from spray formulations, J. Control. 
Release 113 (2006) 57-62. 
[63] A.T. Tucker, Z. Chik, L. Michaels, K. Kirby, M.P. Seed, A. Johnston, C.A.S. Alam, 
Study of a combined percutaneous local anaesthetic and the TDS system for 
venepuncture, Anaesthesia 61 (2006) 123-126. 
[64] T.M. Morgan, R.A. Parr, B.L. Reed, B.C. Finnin, Enhanced transdermal delivery of sex 
hormones in swine with a novel topical aerosol, J. Pharm. Sci. 87 (1998) 1219-1225. 
[65] T.M. Morgan, B.L. Reed, B.C. Finnin, Enhanced skin permeation of sex hormones with 
novel topical spray vehicles, J. Pharm. Sci. 87 (1998) 1213-1218. 
[66] T.M. Morgan, H.M. O´Sullivan, B.L. Reed, B.C. Finnin, Transdermal delivery of 
Estradiol in postmenopausal women with a novel topical aerosol, J. Pharm. Sci. 87 
(1998) 1226-1228. 
[67] Acrux Limited, Products [online], available: 
http://www.acrux.com.au/IRM/content/products/default_frame.html [accessed 
22.09.2006] 
 
 
 
 26
  
 
 
 
 
 
CHAPTER 2 
Development and characterization of film forming polymeric 
solutions for skin drug delivery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27
  
 
 28
Development and characterization 
1. Abstract 
Film forming polymeric solutions as a novel approach for skin drug delivery were developed and 
characterized concerning their mechanical properties and water vapor permeability. They were 
developed by varying type and content of the film forming polymer as well as nature and content 
of the plasticizer. The resulting formulations were evaluated according to five criteria: drying 
time, cosmetic attractiveness, outward stickiness, integrity on skin (after 18 hours) and viscosity. 
Among the 14 tested polymers ten film formers yielded formulations with a positive evaluation 
in all five test criteria. Selected formulations were then investigated for tensile strength and 
elongation at break in vitro and for water vapor permeability in vitro (WVP) and in vivo 
(TEWL). Their mechanical properties determined in vitro were found to be not predictive for the 
flexibility and abrasion resistance observed on living skin. Similar to this, the results derived 
from the WVP and the TEWL methods were not in accordance with each other. Obviously, the 
investigated in vitro methods do not characterize the properties of the thin films on living skin 
satisfactorily. Nevertheless, the identified film forming solutions are a promising approach and 
will provide the basis for the further development of this novel dosage form. 
 
Keywords:  
Film forming polymeric solution; Mechanical Properties; Water Vapor Permeability; Transepidermal Water Loss 
 
 
 
 
 
 
 
 
 
 
Part of this chapter has been published as: 
I. Zurdo Schroeder, P. Franke, U.F. Schaefer, C.-M. Lehr, Development and characterization of film forming 
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Reprinted with permission from Elsevier. 
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2. Introduction 
The skin is a very important route for the dermal or transdermal delivery of pharmaceutically 
active substances. Film forming polymeric solutions are a novel approach in this area that might 
present an alternative to the conventional dosage forms used on the skin, such as ointments, 
creams, gels or patches. The polymeric solution is applied to the skin as a liquid and forms an 
almost invisible film in situ by solvent evaporation. 
 
So far only very few authors have described the use of film forming systems for the delivery of 
drugs to the skin. Misra et al. [1, 2] reported on a liquid film forming solution for the biphasic 
delivery of testosterone but investigated only one formulation containing a mixture of 
polyvinylpyrrolidone and polyvinyl alcohol in isopropanol as film forming matrix without 
performing a polymer screening. Also, Misra did not investigate the mechanical or cosmetic 
properties of the formed film but focused mainly on the drug permeation from this system in 
vitro as well as in vivo. Other film forming systems described in the literature are not applied as 
liquids but as transdermal gels [3, 4] or cream [5]. Similar to the works of Misra these groups 
investigated only one individual formulation without testing a broader range of film formers and 
focused also mainly on the drug delivery from the film forming system [3, 4] or the clinical 
efficacy of the formulation [5]. 
 
Due to the fact that film forming solutions can provide many advantages over patches (higher 
dosing flexibility, higher patient compliance due to improved cosmetic appearance) or semisolid 
preparations (rub off resistance) the aim of this study was to test a wider range of materials, to 
select suitable excipients and to characterize the properties of the resulting formulations to 
provide a broader technological basis for the development of this novel dosage form. 
In a first step formulation experiments were performed with 14 polymers from different chemical 
classes. Basically the compositions contained a film forming polymer dissolved in a volatile 
solvent. Further excipients such as plasticizers or crosslinkers were added if necessary. Mainly 
polymer content, type of plasticizer and plasticizer content were varied to find the best 
composition for the desired purpose. 
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Since no suitable evaluation method for these new application systems was available from the 
literature a simple score system had to be developed in order to identify suitable formulations for 
the intended application. The testing of the formulations was performed in vivo as pre-
experiments had shown that the special properties of the skin (surface structure and movement) 
were very important for the differentiation between the formulation variants. The evaluation 
system was based on five criteria: viscosity, drying time, outward stickiness, cosmetic 
attractiveness and integrity after a certain wearing time (18 hours). These properties were 
considered key features for the practical application of the novel dosage form especially from the 
patients’ point of view: The viscosity of the film forming solution is required to be low to enable 
an application of the dosage form as spray, which would ensure an accurate, but at the same time 
flexible dosing and would be most convenient for the patient. In order to avoid long waiting 
times for the patient the novel dosage form is supposed to dry quickly on the skin. The formed 
film is required to be non-sticky to avoid adhesion to the clothes of the patient. Considering the 
fact that many patients complain about the high visibility of transdermal patches which is 
considered cosmetically unattractive the formed film is supposed to be almost invisible. In 
addition to this, the delivery system is required to show a certain permanence on the skin in order 
to be able to provide a continuous drug supply over a prolonged period of time. 
 
Following the polymer screening selected formulations with polymers from different chemical 
groups were characterized concerning their water vapour permeability and mechanical 
properties. Based on the observation that the developed formulations had displayed similar 
mechanical properties, that is flexibility and abrasion resistance, during the in vivo evaluation the 
assumption was that they would also show similar mechanical properties in the in vitro test 
method. If this was the case the in vitro method could serve as a useful instrument in further 
polymer screening experiments for a more objective evaluation of the developed formulations. 
The mechanical properties (tensile strength and elongation at break) were determined according 
to a standard test method [6] that has been frequently used in the literature for the 
characterisation of strength and flexibility of free polymeric films [7-11]. In addition to the 
mechanical properties, the water vapor permeability of the same four formulations was 
investigated in vitro according to a method from the British Pharmacopoeia [12] and in vivo by 
measuring the impairment of the transepidermal water loss to assess the occlusive properties of 
the formed films. Finally, characterization methods for the film forming solutions and important 
parameters for the development of this novel dosage form are discussed. 
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3. Materials and Methods 
3.1. Materials 
All polymers (Table 4, Appendix 1) were kindly provided by the manufacturers: 
Eudragit® RL PO, Eudragit® E 100, Eudragit® S 100 and Eudragit® NE 40D (Roehm Pharma 
Polymers, Darmstadt, Germany), Avalure® AC 118 (Noveon Inc., Cleveland, USA), SGM 36 
and Dow Corning® Q7-9180 (Dow Corning S.A., Seneffe, Belgium), DynamX® and 
Dermacryl® 79 (National Starch and Chemical Company, Bridgewater, USA), Oppanol® B 100, 
Oppanol® 10SFN, Kollidon® 12 PF and Kollidon® VA 64 (BASF, Ludwigshafen, Germany), 
Hydagen® HCMF (Cognis, Düsseldorf, Germany), EC® NF1 and Klucel® LF (Hercules Inc., 
Wilmington, USA). Polyethylene imine 1800 was a gift from Alfa Aesar GmbH&Co KG, 
Karlsruhe, Germany. Polyvinyl alcohol 72000, ethanol (96 %), butyl acetate, isopropanol, 
aceton, polyethylene glycol 400, triethyl citrate, dibutyl phthalate, triacetin, succinic acid, lactic 
acid, glycerol and polysorbat 80 were purchased from Merck, Darmstadt, Germany. 
3.2. Preparation of the polymeric solutions 
Film forming solutions were prepared by adding the polymer to the solvent and stirring the 
solution overnight to ensure complete dissolution of the polymer. The solvent used was Ethanol 
(96 %) for all preparations except the silicone formulation. For the silicone formulation the 
silicon gum (SGM 36) was dissolved in a volatile silicone (Dow Corning® Q7-9180, 
hexamethyldisiloxane/octamethyltrisiloxane). Having obtained a clear polymeric solution other 
optional excipients such as crosslinker or plasticizer were added. After addition of all excipients 
the solution was stirred for another 24 hours before use. The formulations were stored in glass 
vials sealed tightly with a siliconized rubber plug and an aluminium cap. 
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Table 4: Polymers used in the formulation experiments 
Trade name Polymer 
Avalure® AC 118 Acrylates copolymer 
Dermacryl® 79 Acrylate/octylacrylamide copolymer 
DynamX® Polyurethane-14 and AMP-acrylates copolymer 
Eudragit® E 100 Poly(butyl methacrylate, (2-dimethylaminoethyl)methacrylate, methyl methacrylate) 1:2:1 
Eudragit® NE 40D Poly(ethyl acrylate, methyl methacrylate) 2:1 
Eudragit® RL PO Poly(ethyl acrylate, (2-trimethylaminoethyl)methacrylate, methyl methacrylate) 1:0.2:2 chloride 
Eudragit® S 100 Poly(methacrylic acid, methyl methacrylate) 1:2 
Hydagen® HCMF Chitosan 
Kollidon® 12 PF Polyvinylpyrrolidone 
Kollidon® VA 64 Polyvinylpyrrolidone-vinyl acetate copolymer 
Klucel® LF  Hydroxypropylcellulose 
Oppanol® B100 / 10SFN Polyisobutylene 
PVA 7200 Polyvinyl alcohol  
SGM 36 Silicon gum 
EC® NF1 (ethylcellulose) and polyethylene imine 1800 are not listed here as they were not used as main film 
forming compounds in the formulations. 
3.3. Evaluation of the formulations 
For a first assessment of the suitability of film forming solutions, the obtained formulations were 
evaluated according to a rating system for five characteristics: viscosity, drying time, stickiness 
of the outer surface, cosmetic attractiveness and integrity on the skin after 18 hours (Table 5). 
 
The viscosity of the solution was evaluated visually and rated as low (water-like), medium 
(glycerol-like) or high (syrup-like). 
 
Table 5: Rating system for the evaluation of the film forming polymeric solutions 
Rating score 1 2 3 
Viscosity low medium high 
Drying time < 5 min 5-7 min > 7 min 
Outward stickiness low medium high 
Cosmetic attractiveness high medium low 
Integrity on skin  
(after 18 hours) 
complete film,  
no cracks, no flaking 
complete film with cracks
or sporadic flaking 
film partly or 
completely missing 
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For the assessment of the drying time the formulation was applied to the inner sides of the 
forearm of a volunteer, who participated in the study on informed consent basis, with the help of 
a steel positioning device and a pipette. The applied volume was 10 µl/cm2 as a pre-experiment 
had shown that this amount was small enough to be applicable without flowing away from the 
application site. A dosing range from 5 – 10 µl/cm2 is also recommended by the OECD for the 
conduct of skin absorption studies [13]. After 5 minutes a glass slide was placed on the film 
without pressure. If no remains of liquid were visible on the glass slide after removal, the film 
was considered dry. If remains of liquid were visible on the glass slide the experiment was 
repeated with a drying time of 7 minutes instead of 5 minutes. 
 
The stickiness of the outer surface was tested by pressing cotton wool on the dry film under low 
pressure. Depending on the quantity of cotton fibers that were retained by the film the stickiness 
was rated high (dense accumulation of fibers on the film), medium (thin fiber layer on the film) 
or low (occasional or no adherence of fibers). 
 
The cosmetic attractiveness of the films was assessed by visual examination of the dry films. 
Transparent films with a low skin fixation had a high attractiveness as they were almost 
invisible. Opaque films and films with a medium skin fixation were considered less attractive as 
they exhibited an increased visibility and a slight wrinkling of the skin. Whitish films and films 
causing heavy wrinkling of the skin due to strong skin fixation displayed only a low 
attractiveness. 
 
To test the integrity on skin the formulation was applied to the forearm of a volunteer as 
described for the assessment of the drying time. The dry film was then worn overnight by the test 
subject. After 18 hours the test area was examined visually with the help of a magnifying glass 
(magnification 10x) for completeness of the film, appearance of cracks or flaking. 
 
Three rating scores were assigned to each criterion with 1 representing the most positive 
evaluation (meaning that the film characteristic closely matched the target) and 3 the most 
negative result. Formulations were considered successful when all five criteria were rated 1. 
These formulations showed a low viscosity, short drying time, low outward stickiness, high 
cosmetic attractiveness and stayed intact on the skin for a prolonged time. For these successful 
formulations the evaluation on skin was repeated on two further volunteers to support the 
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positive findings. Formulations with one or more criteria rated 2 were considered acceptable 
with limitations, formulations with one or more criteria rated 3 were not acceptable. 
3.4. Determination of the mechanical properties 
For the determination of the mechanical properties polymeric films were produced by solvent 
evaporation in a teflon mould (6 cm x 10 cm). Into this mould 15 ml of the polymeric solution 
were cast and left to dry at room temperature for 72 hours (24 hours ventilated in the open air for 
the evaporation of Ethanol, then in an exsiccator containing orange gel as desiccant). The dry 
films were cut into rectangular samples of 10 mm x 40 mm with the help of a scalpel. Film 
thickness was measured at 10 places with a digital micrometer (Mitutuyo, Kawasaki, Japan). The 
mechanical properties of the films were determined with a tensile tester (UPM Z010, 
Zwick/Roell, Ulm, Germany) based on the ASTM D882-02 [6] with a modification of the 
sample size. The testing device was equipped with a 20N load sensor. The films were carefully 
placed between the two vertical grips of the tester that were covered with a silicon gum to 
prevent slippage of the films during the test. The movable grip was then driven upward with a 
speed of 500 mm/min until the rupture of the film. From the recorded load-time profiles tensile 
strength (σ) and percent elongation at break (ε) were calculated representing abrasion resistance 
and flexibility, respectively. The tensile strength (σ) was calculated as 
A
Fmax=σ      ⎥⎦
⎤⎢⎣
⎡
2m
N      (Eq. 1) 
where Fmax [N] is the maximum force and A [m2] is the crossectional area. The values for percent 
elongation at break were calculated with the following equation: 
100*
0L
LR=ε      [ ]%      (Eq. 2) 
where LR [m] is the extension of the sample in the moment of rupture and L0 [m] is the original 
sample length. Each experiment was repeated five times. 
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3.5. Investigation of the water vapor permeability 
The water vapor permeability (WVP) was investigated according to a method modified from the 
British Pharmacopoeia [12]. Films were produced with a solvent evaporation technique by 
pouring 3 ml of the preparations (50 µl/cm2) into a teflon mould (6 cm x 10 cm) on a 
polycarbonate filter (IsoporeTM Membrane Filters, Millipore, Billerica, USA filter; pore size 
0.2 µm, thickness 11 µm,) as supporting membrane. The films were left to dry for 72 hours at 
room temperature (three hours ventilated in the open air to allow the evaporation of Ethanol, 
afterwards in an exsiccator containing orange gel as desiccant). Circular samples with a diameter 
of 2.0 cm were cut from the dry film sheets with the help of a scalpel. For the sample preparation 
10 ml glass vials with an opening of 1.2 cm diameter (A = 1.13 cm2) were filled with 
approximately 8 g of distilled water, covered with the circular film samples and a silicone ring 
and sealed tightly with an aluminium vial cap. To start the experiment, the top of the vial cap 
was opened and the weight of the vial was determined with an analytical scale (Sartorius, type 
MC BA 100, Göttingen, Germany). The vials (six replicates per formulation) were then placed 
into an exsiccator containing either a desiccant to create a climate of low relative humidity 
(approximately 0%) or a saturated solution of sodium bromide (Merck, Darmstadt, Germany) 
creating an atmosphere of 58% relative humidity [14, 15]. They were kept at a determined 
temperature (25°C, 32°C or 37°C) for 72 hours and weighted after predetermined intervals after 
having adjusted to room temperature for one hour. From the weight loss of the vials W [g] the 
WVP was calculated as the amount of water that had permeated through the film in relation to 
the surface area A [cm2] and the time t [24 hours]: 
tA
WWVP
*
=     ⎥⎦
⎤⎢⎣
⎡
hcm
g
24*2
     (Eq. 3) 
The WVP ratio shows the relation of the WVP of the vials covered by the tested film to the WVP 
of the vials with unlimited permeability (filter only samples): 
( )
( )filterWVP
filmpolymericfilterWVPratioWVP +=     (Eq. 4) 
For each formulation the mean value and the standard deviation were calculated. Controls for 
this experiment were vials with the supporting filter without polymeric film (representing 100 % 
WVP) and vials covered with aluminium discs (thickness 20 µm) to verify the tightness of the 
seal. 
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3.6. Transepidermal water loss measurement 
Twelve healthy volunteers (seven males, five females) participated in the study on informed 
consent basis. The subjects were aged between 25 – 39 with a mean age of 29.7 years. None of 
the subjects had any dermatological diseases in their history. Before the experiment the subjects 
were asked not to use any skin care products for at least 12 hours before the test. Temperature 
and humidity in the laboratory were monitored throughout the experiment and showed little 
variation (temperature 21.3°C ± 0.5°C, relative humidity 54.3 % ± 4.3%). 
For the determination of the TEWL the ventral sides of both forearms were chosen as test 
locations as they provide a fairly even surface with only little hair-growth, which might 
otherwise disturb the measurements, especially on male volunteers. On each arm two test areas 
(2 cm x 2 cm, minimum distance between the test fields 2 cm) were limited by applying a silicon 
paste (windowcolor, simplicol, Brauns-Heitmann GmbH&CoKG, Warburg, Germany) to the 
borders. The silicon paste was left to dry for 15 minutes. The area between the two test areas on 
each arm remained uncovered and served as a reference value for the TEWL measured on the 
test sites. The test subjects were allowed to acclimatize and calm down for 30 minutes before the 
start of the experiment. A volume of 200 µl of each formulation (50 µl/cm2, corresponding to the 
amount applied for the in vitro experiment) were applied to one of the test fields. This amount 
was higher than the amount applied for the formulation screening experiments under the 
assumption that the differences in the TEWL impairment caused by the different films would be 
more pronounced with thicker films and therefore better detectable in spite of the considerable 
variations associated with this test method. The formulations were left to dry ventilated in the 
open air at room temperature for two hours. 
The TEWL was measured according to published guidelines [16] with a Tewameter 
(Tewameter 300, Courage + Khazaka, Cologne, Germany) on the test sites and on the reference 
sites located close to the test sites. The TEWL ratio was calculated from the TEWL on the test 
sites after two hours drying time in relation to the TEWL measured on the uncovered reference 
sites: 
filmwithoutTEWL
filmdryonTEWLratioTEWL =      (Eq. 5) 
From the ratios for each individual subject the overall average ratio, standard deviation and 
confidence intervals (P<0,05, two sided) were calculated. 
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4. Results 
4.1. Formulation experiments 
A selection of 14 polymers from different chemical groups, all described by their manufacturer 
or in the literature as good film formers were tested in the formulation experiments. With these 
polymers over 150 formulations were manufactured containing basically one of the polymers, a 
plasticizer and a volatile solvent. Mainly polymer content, type of plasticizer and plasticizer 
content were varied for every one of the chosen polymers to determine the composition with the 
highest scores in the evaluation system. The evaluation of these features was performed in vivo 
as casting the formulations on an artificial surface such as a glass slide did not offer the 
possibility for a realistic assessment of the film properties. The stress exerted on the formed film 
by the movement of the skin is one of the key challenges for the flexibility and the adhesive 
properties of the film and is difficult to imitate on artificial substrates. Also the cosmetic 
attractiveness can be judged more realistically on skin as an increased skin fixation and 
wrinkling often becomes more apparent with the movement of the skin. Table 6 shows the 
formulations that produced the best scores in the rating system as they were rated 1 in all 
categories. 
 
Table 6: Composition of the positively evaluated formulations; concentrations in % [w/w] 
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  10.0 7.0 10.0 10.0 7.0 20.0 5.0 10.0 5.0 10.0 
Plasticizer Triethyl citrate   1.0 1.0  6.0 1.6  1.0  
 Triacetin  2.1         
 Dibutyl phthalate        4.0   
Solvent Ethanol 75.0 90.9 72.2 88.1 82.5 74.0 93.4 86.0 94.0  
 Water 15.0  16.8  10.5      
 Q7-9180          90.0 
Other 
Ingredients Succinic acid    0.9       
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One of the positively evaluated films applied on the skin of a human forearm is shown in Fig. 8. 
All formulations could either be removed by ethanol wipe or could be washed off with water and 
gentle rubbing. 
The detailed results for all tested formulations are given in Appendix 2. 
 
 
 
 
 
 
 
 
 
Fig. 8: Polymeric film on human forearm (Formulation F, 10mg/cm2) 
 
4.2. Mechanical properties 
Mechanical properties such as tensile strength and percent elongation at break are determined to 
characterize polymeric films for their abrasion resistance and flexibility, respectively. Deducted 
from these two values polymeric films can be classified as shown in Table 7. This classification, 
however, is not based on absolute values for the two parameters tensile strength and elongation 
but has to be seen as a relative comparison between different polymeric films. Hard and tough 
films have properties suited best for the intended application as drug delivery systems for the 
skin: they are flexible enough to follow the movements of the skin without breaking but at the 
same time they show an increased strength to prevent abrasion of the film caused for example by 
contact with clothing. 
 
Table 7: Classification of polymeric films according to Aulton et al. [17] 
 
Tensile strength Elongation at break Film description 
Low Low Soft and weak 
Low High Soft and tough 
High Low Hard and brittle 
High High Hard and tough 
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To investigate if these features can be determined by an in vitro method three of the positively 
evaluated formulations (C, F and I, Table 6) with the polymers Eudragit® RL PO, DynamX®, 
Klucel® LF were tested for their mechanical properties. The SGM 36 formulation could not be 
tested as it does not form cohesive films. All these formulations had scored the highest rating in 
the evaluation criterion “integrity on the skin (after 18 hours)” indicating that they contained 
sufficient strength and flexibility not to crack or to be rubbed off during the wearing period. 
Based on this observation it was expected that all three formulations formed films with similar 
mechanical properties, most probably films classifiable as hard and tough. 
 
Table 8: Mechanical properties of different polymeric films; mean values ± standard deviation   
evaluation criterion:  integrity on skin after 18 hours  
rating 1:   complete film, no cracks, no flaking  
rating 2-3:   film partly or completely missing, cracks, flaking 
 
Tensile strength Elongation at break Formulation Polymer [N/mm2] [%] 
Films with sufficient strength and flexibility in vivo (rating 1) 
C DynamX® 12,2 (± 1,0) 323,4 (± 42,1) 
F Eudragit® RL PO 1,0 (± 0,1) 798,4 (± 93,9) 
I Klucel® LF 5,0 (± 0,3) 131,4 (± 5,8) 
Films with non-sufficient strength and flexibility in vivo (rating 2-3) 
F (var1) 
(F with less plasticizer) Eudragit
® RL PO 1,3 (± 0,1) 662,0 (± 83,7) 
F (var2) 
(F with different plasticizer) Eudragit
® RL PO 1,3 (± 0,1) 515,2 (± 19,8) 
I (var1) 
(I without plasticizer) Klucel
® LF 10,7 (± 0,8) 107,2 (± 1,2) 
 
 
The upper half of Table 8 shows the results for tensile strength and percent elongation at break 
for the three tested films (C, F and I). Surprisingly, the results for the three films revealed 
considerable differences. While the Eudragit® RL PO film showed a high elongation with a low 
tensile strength (rather soft and tough), the Klucel® LF film displayed a low elongation with 
medium tensile strength (fairly soft and weak in comparison to the Eudragit® RL PO film). Only 
the third film, the DynamX® formulation, could be classified as hard due to its comparatively 
high tensile strength. Concerning the elongation this film was weaker than the Eudragit® RL PO 
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film but tougher than the Klucel® LF film. The similar strength and flexibility of these three 
films observed on living skin was apparently not reflected in the results of the in vitro 
experiments. 
 
For a better interpretation of these results the mechanical properties of three additional films 
were determined. The formulations F (var1), F (var2) and I (var1) were variations of the 
positively evaluated films F and I with changes in the plasticizer type or content. Contrary to the 
previously tested formulations these films had not displayed a sufficient strength or flexibility on 
the skin as they had cracked or flaked off during the integrity test (rating 2 or 3). The change in 
the plasticizer type or content resulted in harder and less flexible films as indicated by an 
increase in tensile strength and a decrease in the elongation values in comparison to the formerly 
tested films F and I with the same polymers (the results are shown in the lower half of Table 8). 
This might explain why F (var1), F (var2) and I (var1) had cracked up while the original 
formulations F and I had not displayed any cracks during the wearing period. Unexpectedly, 
however, the non-successful formulations F (var1) and F (var2) with the polymer 
Eudragit® RL PO displayed higher elongation values than the successful formulations I and C 
with other polymers. This implies that even though the elongation value is an indicator for the 
flexibility of a polymeric film it cannot serve to predict if a formulation will show the desired 
film properties in vivo when formulations with different polymers are concerned. 
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4.3. Water vapor permeability 
The human body is constantly losing water to the environment by evaporation through the skin. 
This transepidermal water loss (TEWL) is a passive diffusion process and very important for 
skin functions such as body temperature control. Occlusion – meaning impairment of the 
TEWL – influences several properties of the skin such as hydration of the stratum corneum, skin 
temperature and blood flow and can therewith increase the percutaneous absorption of certain 
drug substances depending on the anatomic site and the drug vehicle [18-21]. Various skin 
parameters such as pH and bacterial flora are also influenced by an occlusive treatment resulting 
in an increased risk of infection and skin irritation [22, 23]. Accordingly, the degree of occlusion 
is an important feature of a drug delivery system that is supposed to be worn on the skin for a 
prolonged period of time. 
 
Fig. 9 shows the absolute water vapor permeability (WVP) of the four tested films and the WVP 
for the control representing unhindered water vapor permeation. According to the British 
Pharmacopoeia a material can be considered permeable to water vapor when the WVP exceeds 
0,05 g*cm-2*24h-1 [12]. Although the four films displayed different WVP values all of them 
showed a permeability above the limit set in the Pharmacopoeia and can therefore be considered 
non-occlusive. 
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Fig. 9 WVP of the formulations F (polymer: Eudragit® RL PO), C (DynamX®), I (Klucel® LF), J (SGM 36) and  
control (without polymeric film); test conditions: 37°C, 0% r.h.; mean values ± standard deviation; n = 6 
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These in vitro results, however, could not be compared directly to the results of the TEWL 
measurements with the same films in vivo as the test conditions (37°C, 0% r.h.) differed from the 
conditions in the in vivo experiment. The skin temperature for example is considerably lower 
than 37°C. In the literature the skin surface temperature is reported to be between 28°C and 32°C 
[16], a range that our own measurements supported. As the temperature severely influences not 
only the TEWL measurements [24, 25] but also the WVP properties of polymeric films [26] the 
test conditions for the in vitro test were modified, investigating the WVP at different test 
temperatures. Fig. 10 shows the WVP for the four tested films at 25°C, 32°C and 37°C in a 
climate of low relative humidity (approximately 0% r.h.). The absolute WVP values increased 
with rising temperatures for all tested films. This was expected as higher temperatures increase 
evaporation and lead to a higher water vapor pressure driving more water through the films. 
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Fig. 10: WVP of the formulations F (polymer: Eudragit®RL PO), C (DynamX®), I (Klucel® LF), J (SGM 36) and  
control (without polymeric film); test conditions: 25°C, 32°C or 37°C, 0% r.h.; mean values ± standard 
deviation; n = 6 
 
 
The second condition to be modified to match the test conditions of the TEWL measurements 
more closely was the humidity gradient. During the TEWL experiment the climatic conditions in 
the test chamber were measured and the relative humidity was found to be 54,3% ± 4,3%. 
Assuming a relative humidity of 100% on the other side of the tested film (that is inside the body 
of the test subject) the resulting water vapor gradient is much lower than the gradient used for the 
in vitro test (100% r.h. inside the vials and approximately 0% r.h. on the outside). Therefore the 
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in vitro experiment was repeated under modified humidity conditions by using a saturated 
solution of Sodium bromide instead of the desiccant to create a climate of approximately 
58% relative humidity. Fig. 11 shows the WVP values for the four tested films and the control 
for both tested humidity degrees at 37°C. As expected the WVP values dropped with a higher 
ambient humidity as the humidity gradient is the strongest driving factor for water vapor 
permeation [27]. 
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Fig. 11: WVP of the formulations F (polymer: Eudragit® RL PO), C (DynamX®), I (Klucel® LF), J (SGM 36) and  
control (without polymeric film); test conditions: 37°C, 0% r.h. or 58% r.h.; mean value ± standard 
deviation; n = 6 
 
 
To compare the WVP values determined in vitro with the TEWL values in vivo the results from 
an experiment performed at 32°C and 58% r.h. were chosen as these test conditions came closest 
to the test conditions of the TEWL experiment. 
4.4. Transepidermal water loss 
TEWL measurements are a well-established method for characterizing the influence of chemical 
substances on the barrier function of the skin. An increase in TEWL usually indicates the 
disturbance of this protective barrier either by physical trauma, chemical treatment or occlusion 
which often results in skin irritation. Therefore TEWL measurements are often conducted to 
characterize the occlusive properties of pharmaceutical preparations such as transdermal patches 
[28]. 
 44
Development and characterization 
To investigate if the WVP values determined in vitro are predictive for the occlusivity of the 
polymeric films in vivo the impairment of the natural TEWL by the films was measured. From 
literature many factors are known that can influence TEWL measurements. These factors are 
either instrument-related, environmental-related or individual-related [16]. Among these factors 
the high inter-individual variations seen in TEWL values on untreated skin play an important 
role [29]. Due to these high inter-individual variations comparisons between absolute TEWL 
values measured on different test subjects are highly problematic. Therefore we decided to 
compare TEWL ratios instead of absolute values and to compare them with the in vitro WVP 
results also calculated as WVP ratios (Eq. 4).  
 
Fig. 12 shows the ratios of the in vitro (WVP) and the in vivo (TEWL) experiments. Clearly a 
close correlation between the results from the different methods could not be established. While 
both values for the Klucel® LF formulation correlated closely and the ratios for the SGM 36 
formulation were fairly similar, the results for the Eudragit® RL PO and the DynamX® 
formulations differed widely. Nevertheless the in vivo results support the finding that all tested 
films are non-occlusive on the skin. This can be concluded from the high TEWL ratios (> 0,7) 
for all films indicating that more than 70% of the water vapor given off by the skin can permeate 
through the films. 
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Fig. 12: Comparison of WVP ratio (open symbols) and TEWL ratio (closed symbols) of the formulations  
F (polymer: Eudragit® RL PO), C (DynamX®), I (Klucel® LF) and J (SGM 36); mean values with 
confidence intervals (P<0,05); n = 6 (WVP), n = 12 (TEWL) 
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5. Discussion 
5.1. Important formulation parameters for film forming polymeric solutions 
For the formulation experiments preparations were manufactured with 14 different polymers 
varying polymer content as well as nature and content of the plasticizer for every one of the 
chosen polymers. All these parameters have an impact on the properties of the resulting film and 
should therefore be considered with care. The first and most important parameter for the 
development of a film forming polymeric solution is the choice of polymer. Suitable excipients 
are polymers that form clear, flexible films at moderate temperatures. This is required as the 
polymeric film is formed in situ on the skin which has a surface temperature of approximately 
28°C to 32°C. Furthermore the polymer has to be soluble in a skin-tolerant, highly volatile 
solvent such as ethanol, isopropanol or ethyl acetate. Film forming polymers requiring a high 
percentage of water in the solvent are not suitable for the formulation of film forming solutions 
due to the comparatively low volatility of water that results in prolonged drying times. 
 
Besides the type of film former the polymer content is another crucial point in the formulation 
process. While the loading capacity for drug substances increases with rising polymer content in 
the solution due to the increasing thickness of the formed films the cosmetic attractiveness of the 
films deteriorates. Thicker films are less “invisible” and often show a stronger skin fixation than 
thinner films. Since solutions of different polymers with the same polymer concentration do not 
result in films of the same thickness and the same properties the appropriate polymer content has 
to be determined individually for each polymer and has to be a compromise between drug 
loading capacity and cosmetic attractiveness. Another limiting factor for the polymer content is 
the increase of viscosity of the solution caused by the polymer. To permit an application of the 
formulation by spraying (which would be most convenient for the patient and most exact as to 
dosing accuracy) a low viscosity of the polymeric solution is required. Therefore the fact that 
different polymers may lead to different viscosities when dissolved in a given solvent has to be 
taken into account as well when determining the appropriate polymer content for the 
formulation. 
 
Apart from polymer and solvent other excipients such as plasticizers or crosslinkers can be 
incorporated into the formulation. As a general observation derived from the formulation 
experiments with over 150 different preparations, especially the plasticizer exerts a strong 
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influence on the properties of the formed film. In polymeric films plasticizer interact with the 
polymer chains reducing the number of active centers available for rigid polymer – polymer 
contacts [17]. These interactions result on the one hand in a decrease in glass transition 
temperature and a higher flexibility of the films, on the other hand in a changed permeability for 
drug substances and water vapor [30]. The plasticizer content is also decisive for the adhesive 
properties of the film. Films with a low plasticizer concentration in the formulation did not 
display a sufficient adhesion to the skin. Films with a high plasticizer concentration showed 
sufficient adhesion but became sticky on the outer surface. Therefore determining the right 
amount of plasticizer is essential for a successful formulation of this dosage form. It is important 
to note that the adequate plasticizer concentration is individual for every plasticizer – polymer 
combination as the efficiency of a plasticizer is polymer dependant. 
 
During the formulation experiments 10 of the 14 tested polymers yielded film forming polymeric 
solutions with the required characteristics. Experiments with the other four polymers, however, 
did not result in satisfactory preparations for various reasons: For Oppanol® no skin-tolerant 
solvent could be found contrary to the manufacturer’s specifications. Hydagen® HCMF required 
a high water content in the solvent resulting in unacceptably long drying times. Additionally, 
Hydagen® HCMF showed a strong increase of viscosity already at low polymer concentrations. 
PVA 72000 displayed poor skin adhesion even with high plasticizer contents and developed a 
profound increase of viscosity during storage. Kollidon® 12 PF produced sticky films with 
insufficient integrity on skin after a longer wearing period. 
 
Taking all this into account it can be stated that a careful composition of the film forming 
solution with a suitable polymer in an adequate concentration and an individually adjusted 
plasticizer content is essential to achieve a formulation with the required properties concerning 
viscosity, drying time, outward stickiness, cosmetic attractiveness and integrity on skin after a 
longer wearing period. Minor variations might be acceptable but major changes in the 
composition should be avoided as they would have an unfavorable impact on the properties of 
the film forming system and lead to a deterioration of the mechanical or cosmetic performance of 
the system on the skin. 
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5.2. Characterisation methods for film forming polymeric solutions 
The finding of suitable methods for the characterization and evaluation of film forming 
polymeric solutions posed a considerable problem during the development process. No screening 
process for film forming polymeric solutions and therefore no evaluation method of the 
macroscopic properties of this dosage form was available from the literature. Beneficial 
macroscopic properties such as a short drying time or a good cosmetic appearance, however, are 
prerequisites for the acceptance of a new dosage form by the patients. Therefore the development 
of a simple evaluation method covering several important macroscopic properties of the 
formulation (viscosity, drying time, outward stickiness, cosmetic attractiveness, integrity on skin 
after a longer wearing time) was necessary. The evaluation was performed on living skin as this 
allowed the assessment of the performance of the formed film under actual wearing conditions. 
Casting the formulations on artificial substrates such as glass slides did not provide the 
opportunity to distinguish between different formulations (almost all formulations yielded 
smooth, transparent films) and was therefore no adequate testing method. 
 
Although the developed evaluation method was fairly simple and to a certain extent subjective it 
surprisingly turned out to be an efficient method for the differentiation between the various 
formulations. Especially the criterion “integrity on skin (after 18 hours)” provided valuable 
information during the screening process to eliminate those formulations that formed attractive 
films on the skin but that were not suitable for the practical application due to their lack of 
persistence on the skin. 
 
The results of the screening process indicated that the flexibility of the film is a very important 
parameter for the successful formulation of this dosage form as considerable mechanical stress is 
exerted on the formed film by the movement of the skin. However, the attempt to replace the 
visual inspection concerning the appearance of cracks by an established in vitro method for the 
determination of the film flexibility was not successful. Although the tested formulations had 
displayed a similar flexibility on skin in vivo the in vitro results differed widely. In Table 8 it is 
shown that the non-successful formulations F (var1) and F (var2) yielded higher elongation 
values than the successful formulations I and C with other polymers. Even though the elongation 
value is a measure for the flexibility of a polymeric film it does apparently not indicate if a 
formulation will also show the required flexibility in vivo when formulations with different 
polymers are regarded. This is surprising as the formed films are supposed to display the same 
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properties, that is to remain intact and free of cracks during the wearing time, independent of the 
polymer that is used for the formulation. Apparently it is not possible to define a polymer-
independent limit value for the elongation at break that has to be reached by a formulation in 
order to yield a film of sufficient flexibility on the skin. Therefore the in vitro determination of 
the mechanical properties cannot serve as a suitable method for a further polymer screening for 
this novel dosage form and cannot replace the described visual assessment of the formed films in 
vivo at this point. 
 
Similar to the observations for the mechanical properties the in vitro and in vivo values for the 
water vapor permeability were not in good accordance either as demonstrated in Fig. 12. Based 
on these results we speculate that the film and its properties are considerably influenced by the 
contact with the skin. It is possible that a part of the plasticizer is absorbed by the skin [31]. This 
would lead to a plasticizer depletion in the film, resulting in harder and more brittle film. On the 
other hand it is also possible that the films absorb water that is evaporating from the skin [32] 
and that the water serves as additional plasticizer in the film [33, 34], resulting in softer and more 
flexible films. While these complex diffusion processes between skin and film might not lead to 
a noticeable change in commonly used transdermal patches they might alter the properties of the 
film forming system to a considerable extent due to the extreme thinness of the formed films 
(approximately 5 –  25 µm). Such changes in the film properties, however, that are related to the 
contact of the film with the skin cannot be mirrored sufficiently under the artificial conditions of 
an in vitro experiment. We presume that this might be one possible explanation for the different 
results seen in vitro and in vivo. However, due to the fact that a suitable in vitro method could 
not be established for an objective evaluation of developed polymeric film forming solutions an 
in vivo evaluation similar to the one we used in our investigations seems to be inevitable at this 
point if further polymers or further formulations are to be screened. 
6. Conclusion 
Film forming solutions were successfully formulated with polymers from different chemical 
groups such as acrylates (Eudragit® RL PO, Eudragit® S 100, Eudragit® NE 40D, 
Eudragit® E 100, Dermacryl® 79, Avalure® AC 118), polyurethane-acrylates (Dynamx®), 
cellulose derivatives (Klucel® LF), polyvinylpyrrolidones (Kollidon® VA 64) and silicones 
(SGM 36). These formulations contained one of the polymers, a volatile solvent and other 
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optional excipients such as plasticizers and were fixed compositions concerning the 
concentrations of all excipients involved. The developed rating system, even though based on 
simple test methods, provided a good basis for the evaluation of the developed formulations 
concerning the five key criteria viscosity, drying time, outward stickiness, cosmetic 
attractiveness or integrity on the skin (after a defined wearing time). The in vitro testing methods 
for the determination of the water vapor permeability and the mechanical properties of the films 
did not adequately describe the film properties observed in vivo. Further research will be 
necessary to develop adequate in vitro testing methods for this new dosage form. At this point, 
however, an evaluation on living skin seems inevitable if further polymers or formulation 
variations are to be tested. Independent of this, the positively evaluated preparations resulting 
from the formulation experiments provide the basis for the development of film forming 
polymeric solutions as a novel dosage form for the skin. This development will be pursued 
further with the incorporation of drug substances into the formulations and the investigation of 
drug release from the polymeric films to evaluate the actual potential of these formulations as 
dermal or transdermal drug delivery systems. 
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CHAPTER 3 
First release and permeation experiments with drug loaded film 
forming polymeric solutions 
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1. Abstract 
Drug loaded film forming polymeric solutions with polymers from different chemical groups 
were investigated concerning their potential as drug delivery systems for the skin. The 
formulations were tested in terms of drug release through an artificial membrane and drug 
permeation through heat separated human epidermis with caffeine and ethinylestradiol as drug 
substances. The influences of the drug loading and the solvent on the drug permeation were also 
investigated with ethinylestradiol as therapeutically relevant drug. A distinction between the 
different formulations was possible in the release as well as in the permeation experiments. The 
results of the two methods, however, were not in accordance with each other as different rank 
orders between the formulations were observed. In the permeation experiments with human 
epidermis the polyurethane-acrylate formulation with DynamX® as film former displayed the 
highest permeation results for both drugs. The results indicate a permeation enhancing effect of 
the polymeric formulation in comparison to the ethanolic reference solutions of the drugs. The 
ethinylestradiol permeation rose proportionately to the drug loading of the tested formulation. Of 
the investigated solvents only the mixture of ethyl acetate with ethanol (1:1) achieved an 
increase of the ethinylestradiol permeation in comparison to the formulation with neat ethanol, 
but the improvement was not substantial. The results of the permeation experiments support the 
idea of film forming solutions as dosage form for the skin and provide the basis for further 
research with this novel approach to transdermal drug delivery. 
 
Keywords:  
Film forming polymeric solution, Drug release, Drug permeation, Skin 
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2. Introduction 
Film forming polymeric solutions are a novel approach for the application of drugs via the skin. 
In a previous study several drug free polymeric compositions had been screened to identify 
suitable formulations for the intended application. The identified formulations showed the 
required properties in terms of drying time, outward stickiness, cosmetic appearance and stability 
on the skin during wearing (chapter 2). The formulations were fixed compositions concerning 
polymer content as well as nature and concentration of the plasticizer since these parameters 
define the macroscopic properties of the formed films. Four of these formulations with polymers 
from different chemical groups (acrylates, polyurethane-acrylates, cellulose derivatives, 
silicones) were then selected to investigate drug loaded film forming solutions. 
 
The aim of the current study was to test the drug release and permeation properties of the 
different drug loaded film forming systems in order to gain a first impression of their drug 
delivering potential. The drugs that were incorporated into the film forming solutions were firstly 
caffeine (Mr = 194.2, log Poct ≈ - 0,07) and secondly ethinylestradiol, (Mr = 296.4, log Poct ≈ 3,7). 
Caffeine is a frequently used hydrophilic model drug for percutaneous absorption experiments 
and OECD standard compound [1-4]. Ethinylestradiol is a therapeutically relevant, highly 
lipophilic estrogenic compound used mainly in oral or transdermal contraceptive systems [5, 6]. 
The structures of the drugs are illustrated in Fig. 13. The initial drug loading in the formulations 
was intended to be 1% (w/w) in the solution but had to be reduced to 0.2% in the case of caffeine 
due to the low solubility of the drug in the main solvent ethanol.  
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Fig. 13:  Chemical structures of the incorporated drugs 
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For the release experiments a simple silicone membrane served as inert physical barrier between 
donor and receptor compartment [7, 8]. For the permeation experiments heat separated human 
epidermis was used as biologically relevant barrier membrane [9]. 
Following the comparison of the different polymeric compositions in the release and permeation 
experiments the formulation with the best permeation performance for the therapeutically 
relevant ethinylestradiol was selected. It was then modified concerning drug loading and nature 
of the solvent to evaluate if these parameters could be utilized to control and improve the drug 
delivery from this novel dosage form for the skin. 
3. Materials and Methods 
3.1. Materials 
Ethinylestradiol was kindly supplied by Schering AG, Berlin, Germany. Caffeine was purchased 
from Caesar & Loretz GmbH, Hilden, Germany. The polymers used were provided by Roehm 
Pharma Polymers, Darmstadt, Germany (ammonio methacrylate copolymer type A, 
Eudragit® RL PO), National Starch and Chemical Company, Bridgewater, USA (polyurethane-
14 and AMP-acrylates copolymer, DynamX®), Hercules Inc., Wilmington, USA 
(hydroxypropylcellulose, Klucel® LF) and Dow Corning S.A., Seneffe, Belgium (Silicon gum, 
SGM 36). Ethanol (96%) and triethyl citrate were purchased from Merck, Darmstadt, Germany. 
Dow Corning® Q7-9180 (hexamethyldisiloxane/octamethyltrisiloxane) and Dow Corning®  
193 Fluid (PEG-12 dimethicone) were gifts from Dow Corning Corning S.A., Seneffe, Belgium. 
All chemicals used for the phosphate buffered saline were of analytical grade and purchased 
from Merck, Darmstadt, Germany. γ-Cyclodextrins were kindly provided by Wacker, Eddyville, 
USA. 
3.2. Tested formulations 
For the preparation of the solutions the drug substance was dissolved in ethanol. In case of 
caffeine moderate heat (50°C for 10 minutes) was applied to facilitate the dissolution of the drug. 
Having obtained a clear solution the polymer was added and the preparation was stirred 
overnight for complete dissolution of the polymer. Finally the plasticizer was added and the 
solution was stirred for another 24 hours before use. An exception to this was the preparation of 
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the silicone formulation. Since neither of the drugs dissolved in the volatile silicone that is 
necessary for the dissolution of the silicone gum, an emulsion was formulated. This emulsion 
consisted of the polymer, the volatile silicone, a silicone emulsifier (193 Fluid) and the smallest 
amount of ethanol (in case of ethinylestradiol) or water (in case of caffeine) necessary to dissolve 
the drug. All formulations were stored in glass vials sealed tightly with a siliconized rubber plug 
and an aluminium vial cap. The composition of the tested formulations are given in Table 9 and 
Table 10. 
For the comparison of the different film forming compositions the polymeric formulations were 
tested together with reference solutions. These references were polymer free ethanolic solutions 
of the drugs with the same drug concentrations as in the polymeric formulations (0.2% for 
caffeine and 1.0% for ethinylestradiol). 
 
Table 9: Composition of the tested film forming solutions and the reference with caffeine 
 
Formulation EUD DYN KLU SIL REF 
Polymer Eudragit®RL PO DynamX® Klucel®LF SGM 36 - 
Polymer content [%] 20.0 10.0 5.0 10.0 - 
Triethyl citrate [%] 6.0 1.0 1.0 - - 
Ethanol [%] 73.8 72.0 93.8 - 99.8 
Water [%] - 16.8 - 15.0 - 
Q7-9180 [%] - - - 69.8 - 
193 Fluid [%] - - - 5.0 - 
Caffeine [%] 0.2 0.2 0.2 0.2 0.2 
 
Table 10: Composition of the tested film forming solutions and the reference with ethinylestradiol 
 
Formulation EUD DYN KLU SIL REF 
Polymer Eudragit®RL PO DynamX® Klucel®LF SGM 36 - 
Polymer content [%] 20.0 10.0 5.0 10.0 - 
Triethyl citrate [%] 6.0 1.0 1.0 - - 
Ethanol [%] 73.0 71.2 93.0 5.0 99.0 
Water [%] - 16.8 - - - 
Q7-9180 [%] - - - 82.0 - 
193 Fluid [%] - - - 2.0 - 
Ethinylestradiol [%] 1.0 1.0 1.0 1.0 1.0 
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3.3. Release experiments through a silicone membrane 
For the release experiments a silicone membrane (Perthese® silicone sheeting, non reinforced, 
thickness 125 µm, obtained from Perouse Plastie, Bornel, France) was clamped into vertical all 
glass `Franz` type diffusion cells (Fig. 14) with an exposed surface area of 1.76 cm2 and a 
receptor volume of 12 ml. The receptor phase was phosphate buffered saline. For the 
experiments with the lipophilic hormone ethinylestradiol (EE) a solubilizer was added to the 
receptor solution as ethinylestradiol is practically insoluble in water. γ-Cyclodextrins in a 
concentration of 0.5% (w/v) were selected for this purpose as they solubilize lipophilic 
substances such as steroid hormones without changing the barrier function of the skin [10]. The 
receptor compartment was kept at 32°C and stirred continuously with a magnetic stirrer. 
The experiment was started after the application of 300 mg of the polymeric solution to the 
membrane with the help of a pipette. This amount proved to be necessary to achieve full and 
even coverage of the membrane surface. The release experiments (four replicates per 
formulation) were conducted over a 24 hours period. During this period samples (200 µl) were 
drawn at predetermined intervals and replaced by aliquots of the receptor fluid. The 
concentration of the drugs in the receptor compartment was below 10% of the saturation 
concentration cs of the drugs in the respective receptor fluids throughout the experiments 
(cs caffeine = 18,3 mg/ml, cs ethinylestradiol = 557 µg/ml). 
3.4. Permeation experiments through heat separated human epidermis 
The skin used for the preparation of the epidermal membrane was obtained from abdominal 
plastic surgery. After removing the subcutaneous fatty tissue the skin was kept frozen until 
further use within six months [11, 12]. For the sample preparation adequate pieces of the frozen 
skin were punched out, cleaned with Ringer solution and immersed in water of 60°C for 
90 seconds. After this treatment the epidermis was carefully removed from the underlying tissue 
with the help of forceps [13]. The epidermis was soaked in the receptor fluid for 30 minutes. 
After this time the epidermis was placed on a supporting membrane (regenerated cellulose, 
MC 10000, thickness 44 µm, Medicell, London, UK, soaked in demineralised water overnight) 
with the stratum corneum side facing the donor compartment. Based on the results of preliminary 
experiments with ethanolic solutions of the drugs (data not shown) the supporting membrane was 
considered non-rate limiting for the drug diffusion. Both membranes were clamped   
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Fig. 14: Experimental setup for the permeation experiments with heat separated human epidermis 
 
 
carefully into the same diffusion cells `Franz` type described for the release experiments. The 
experimental conditions (receptor phase, temperature, stirring velocity) were the same as in the 
release experiments. In contrast to the release experiment, however, only 100 mg of the 
formulations was applied to the epidermal membrane. This amount was sufficient for a complete 
coverage of the membrane due to the different surface properties of the skin and and was closer 
to the amount that can be applied to a patient under realistic conditions (approximately 
10 mg/cm2). The permeation experiments (four replicates per formulation) were conducted over 
a 24 hours period. At predetermined intervals samples of 200 µl were drawn and replaced by 
aliquots of the receptor fluid. Sink conditions were maintained throughout the experiment. 
3.5. Chromatographic analysis 
The samples were analysed for caffeine or ethinylestradiol by HPLC (autosampler model 
717plus, pump model 600, all Waters, Milford, USA). No sample pre-treatment was required. 
The solid phase used for both drugs was a reversed phase column (Lichrospher 100 RP 18, 
125 x 4mm, 5 µm) at ambient temperature. The mobile phase for the caffeine assay was 
acetonitril/phosphate buffered saline pH 2.6 (1:9). With a flow rate of 1.2 ml/min the retention 
time for caffeine was approximately 4.8 minutes. Caffeine was detected with an UV-Vis detector 
model 468 (Waters, Milford, USA) at 262 nm. For the ethinylestradiol assay the mobile phase 
was acetonitril/water (1:1) at a flow rate of 1.5 ml/min. Ethinylestradiol was detected with a 
fluorescence detector (SFM25, Kontron, Zurich, Switzerland) using a wavelength of 280 nm for 
excitation and 310 nm for emission [14]. The retention time for ethinylestradiol was 
approximately 2.7 minutes. The chromatography software was Millennium® (Waters, Milford, 
USA). Both methods provided good precision and linearity in the required concentration range 
(caffeine: 0.2 – 100 µg/ml, R2 = 0.9999, ethinylestradiol: 0.1 – 25 µg/ml, R2 = 0.9999). 
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4. Results 
4.1. Comparison of film forming solutions with different polymers 
4.1.1. Caffeine release through a silicone membrane 
The caffeine release from the film forming preparations with different polymers is displayed in 
Fig. 15. After 24 hours the SIL and the KLU formulations had released considerably more 
caffeine than the reference REF, whereas the other two formulations had released a similar 
amount (DYN) or less (EUD). The caffeine flux from all formulations decreased during the 
course of the experiment. 
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Fig. 15: Caffeine release from different polymeric solutions/films and an ethanolic reference solution through a 
silicone membrane; 0.2% (w/w) caffeine in the solution; mean values ± standard deviation; n=4 
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4.1.2. Caffeine permeation through heat separated epidermis 
Fig. 16 shows the permeation of caffeine from the polymeric systems through heat separated 
human epidermis. Two of the formulations, DYN and SIL, delivered more caffeine through the 
epidermis in 24 hours than the polymer-free ethanolic reference solution (REF). EUD and KLU, 
on the other hand, showed permeation values that were below those of the reference, although 
the values for KLU were only slightly lower than those of the ethanolic caffeine solution. All 
formulations displayed a fairly steady caffeine permeation except for SIL. The silicone 
formulation showed a high drug permeation in the early stages of the experiment, but the drug 
flux started to decreased after the first four hours of the experiment. 
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Fig. 16: Caffeine permeation from different polymeric solutions/films and an ethanolic reference solution through 
human epidermis; 0.2% (w/w) caffeine in the solution; mean values ± standard deviation; n=4 
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4.1.3. Ethinylestradiol release 
The release of ethinylestradiol from the different formulations is displayed in Fig. 17. Similar to 
the results for caffeine the highest ethinylestradiol release was achieved by the silicone 
preparation SIL, followed by the cellulose formulation KLU. The DYN formulation with the 
polyurethane-acrylate DynamX® as film former released slightly less, the preparation with the 
acrylate Eudragit® RL (EUD) considerably less ethinylestradiol than the polymer-free ethanolic 
reference solution (REF). Contrary to the release experiment with caffeine all formulations 
except SIL displayed a continuous flux over 24 hours. The silicone formulation SIL showed a 
high immediate release followed by a decrease in flux during the later stages of the experiment. 
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Fig 17: Ethinylestradiol release from different polymeric solutions/films and an ethanolic reference solution 
through a silicone membrane; 1.0% (w/w) EE in the solution; mean values ± standard deviation; n=4 
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4.1.4. Ethinylestradiol permeation 
Only two of the preparations, DYN and KLU, showed higher permeation values in comparison 
to the ethanolic solution (REF) as demonstrated in Fig. 18. Among these two formulations DYN 
displayed not only the highest absolute values but showed also the strongest increase in flux 
during the early stages of the experiment. Similar to the caffeine experiment the acrylate 
formulation EUD delivered less drug substance through the membrane than the polymer-free 
reference. The formulation with silicon gum as film former, finally, did not have a strong impact 
on the EE permeation in either direction as it delivered a similar, only marginally lower amount 
of drug through the epidermis than the reference. Neither of the formulations showed a 
considerable decrease in flux over 24 hours.  
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Fig. 18: Ethinylestradiol permeation from different polymeric solutions/films and an ethanolic reference solution 
through human epidermis; 1.0% (w/w) EE in the solution; mean values ± standard deviation; n=4 
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4.2. Impact of selected formulation parameters on the EE permeation 
4.2.1. Drug concentration 
Fig. 19 presents the relative drug permeation (percentage of the applied drug that had permeated 
through the epidermis at a given point of time) for the polyurethane-acrylate formulation DYN 
with three different ethinylestradiol concentrations (1%, 2% and 5% (w/w) in the solution). In 
spite of the different drug loadings all formulations showed similar permeation curves. All 
preparations delivered the same percentage of ethinylestradiol through the epidermis during the 
course of the experiment indicating that the permeation increased proportionately to the drug 
content in the formulation. 
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Fig. 19: Relative EE permeation from DynamX® film forming solutions (DYN) with different drug concentrations; 
mean values ± standard deviation, n = 4 
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4.2.2. Solvent 
Fig. 20 shows the permeated drug amounts of the polyurethane-acrylate formulation DYN with 
different solvents after 24 hours in the human epidermis model. The replacement of ethanol with 
neat isopropanol or a binary mixture of isopropanol and ethanol did not improve the 
ethinylestradiol permeation but, to the contrary, reduced the ethinylestradiol amount that arrived 
in the receptor compartment. The usage of ethyl acetate instead of ethanol resulted also in a 
slight decrease of the ethinylestradiol delivery. Only the preparation with the mixture of ethanol 
and ethyl acetate (1:1) showed slightly, but not substantially higher permeation values than the 
formulation with neat ethanol.  
The differences between the ethinylestradiol permeation from the formulation with neat ethanol 
in the two sets of experiments resulted from the fact that skin samples of two different donors 
were used due to capacity reasons.  
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Fig. 20: EE permeation from DynamX® film forming solutions (DYN) with ethanol, isopropanol, ethyl acetate or 
binary mixtures of isopropanol or ethyl acetate with ethanol as solvents; ethinylestradiol: 5% (w/w) in the 
solution; mean values ± standard deviation, n = 4; skin samples from two different donors 
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5. Discussion 
5.1. Drug release and permeation from different film forming solutions 
In a first evaluation the four different film forming polymeric solutions were compared in terms 
of their release and permeation behaviour. The studies were carried out with two drugs of 
different polarity, caffeine and ethinylestradiol.  
The release experiments through the artificial membrane with both drugs revealed noticeable 
differences in the release rates of the polymeric formulations and the polymer-free reference 
solution (Fig. 15 and Fig. 17). However, the ranking of the formulations was similar for both 
drugs in spite of their different physico-chemical properties.  
 
In the caffeine experiment (Fig. 15) all formulations showed a decreasing drug flux over time 
while a similar effect occurred only with the SIL formulation in the ethinylestradiol study 
(Fig. 17). The reason for this was probably the depletion of the formed films during the course of 
the experiments that resulted in a lower concentration gradient between formulation and receptor 
compartment. A lower concentration gradient leads to a reduced drug flux according to Fick’s 
first law of diffusion 
 
J = 
Adt
dm
× = D ×  K × h
dc   ⎥⎦
⎤⎢⎣
⎡
×hcm
g
2
μ
   (Eq. 6)  
 
where J represents the drug flux, m is the permeated drug amount at a given point of time t, A is 
the permeation area, D is the diffusion coefficient of the drug in the membrane, K is the partition 
coefficient of the drug between formulation and membrane, c is the concentration gradient over 
the membrane and h is the membrane thickness. 
The depletion was more pronounced for the caffeine films (5.7% - 30.2%) than for the 
ethinylestradiol films (0.2% - 7.1%) because the release level for caffeine was higher than for 
ethinylestradiol, but the drug loading in the formulations was considerably lower for caffeine. 
This could be the reason why all caffeine formulations displayed a decreasing drug flux, but 
none of the ethinylestradiol preparations except SIL, which showed a substantially higher release 
than the other polymeric systems with ethinylestradiol.  
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The extraordinary high release of the SIL formulation in both experiments might be related to the 
fact that both the membrane as well as the film forming solution consisted mainly of silicone. 
Hence it can be speculated that the drug diffusion at the interface between the formulation and 
the membrane was facilitated due to this similarity of the chemical structures [15]. It is also 
possible that part of the silicone formulation penetrated into the membrane changing its 
permeability for the drugs. 
Although the results for the SIL formulation should therefore be interpreted with caution the 
silicone membrane was beneficial for the release testing of the polymeric formulations in a 
different respect. In account of the high membrane lipophilicity and the lack of pores [8, 16] the 
diffusion of water from the receptor into the donor compartment of the diffusion cell was 
limited. This limitation was sufficient to allow the forming of the polymeric film even with water 
soluble polymers. A previous experiment had shown that other frequently used membranes such 
as regenerated cellulose were not able to limit the water diffusion to this extent, not even after a 
lipophilic impregnation of the membrane with isopropyl myristate. These membranes hindered 
the film forming for example in case of the hydroxypropylcellulose formulation (KLU) and were 
therefore not suited for the release testing. 
 
Heat separated human epidermis allowed a distinction between the different polymeric 
compositions and the polymer-free reference solution as well (Fig. 16 and Fig. 18). The ranking 
of the formulations, however, was different in the permeation experiments (caffeine: release 
SIL>KLU>DYN≈REF>EUD, permeation DYN>SIL>REF>KLU>EUD, ethinylestradiol: 
release SIL>KLU>REF>DYN>EUD, permeation DYN>KLU>REF>SIL>EUD). An exception 
to this was merely the acrylate formulation with the film former Eudragit® RL as this 
formulation produced the lowest results of all formulations in the release as well as in the 
permeation experiments and for either of the tested drugs. In the literature a good correlation 
between the drug permeation through a silicone membrane and through human skin has been 
described for some compounds [16, 17]. However, this correlation does not generally occur for 
all drugs and all drug vehicles [18-20] and was apparently not observed in our experiments. This 
underlines that release experiments cannot be utilized to predict the drug permeation through the 
epidermis [21] and that their value in a formulation selection process is limited. The decision for 
one of the formulation candidates should rather be based on the permeation experiments with 
human epidermis as relevant biological barrier. 
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In the relevant permeation model the formulation with the polyurethane-acrylate DynamX® as 
film former (DYN) reached the highest permeation values after 24 hours among the four tested 
polymeric formulations. This was the case for the hydrophilic caffeine as well as for the 
lipophilic ethinylestradiol although the delivery levels varied for the two drugs. The film forming 
system DYN achieved higher results than the corresponding polymer-free reference solutions 
which indicates an enhancing effect on the permeation of both drugs. On the basis of these 
positive results the polyurethane-acrylate formulation DYN was selected as core formulation for 
the following experiments. 
5.2. Influence of drug concentration and solvent on the EE permeation 
As film forming systems are a fairly novel and not yet well investigated dosage form for 
transdermal delivery it is useful to gain further information about possibilities to control the drug 
delivery from the system and to increase its efficiency. Hence drug loading and solvent influence 
were further investigated. 
 
Fig. 19 demonstrates that the permeation from the tested formulation (DYN) increased 
proportionately to the drug loading. This was expected as the concentration gradient between 
polymeric film and skin increased with the rising drug loading of the formulation. This gradient 
is a major driving force for the drug flux according to Fick’s first law of diffusion (Eq. 6). 
However, the drug concentration can only be utilized in a calculable way to increase the drug 
flux as long as no crystallization occurs in the formed film. In the course of the film formation on 
the skin the drug concentration in the system increases continuously with the ongoing 
evaporation of the volatile solvent. During this process the concentration of the drug in the 
forming film might reach a point where the solubility in the formulation is exceeded and drug 
crystals start to form. From research with conventional transdermal patches it is known that the 
formation of drug crystals leads to a reduction in drug flux as the thermodynamic activity of the 
drug in the matrix decreases [22-24]. Due to this it can be speculated that the apparent 
proportionality between the drug loading and the drug permeation will no longer be given as 
soon as crystallization occurs in the film. In our experiments with an ethinylestradiol 
concentration up to 5% in the solution, however, no drug crystals appeared. This was confirmed 
by light microscopic observations of the films. Therefore no negative impact on the drug flux 
was observed and the proportionality between drug loading and drug permeation was given. 
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Nevertheless, the risk of crystallization should be kept in mind should the ethinylestradiol 
loading of the polymeric solution be further increased (beyond 5%) in this film forming system. 
 
Another parameter with possible influence on the drug permeation is the solvent of the 
formulation. Due to the fact that the solvent in a film forming formulation has to be highly 
volatile, compatible with the polymer and the drug and tolerable for the application on the skin, 
the choice of possible solvents is limited. Ethanol for example complies with all the requirements 
and was therefore chosen as basic solvent for the development of this dosage form. 
Apart from its function to solubilize the other excipients and the drug, however, the solvent can 
also serve as permeation enhancer. Ethanol for example is known to be a good permeant for the 
skin and has a permeation enhancing effect for many drugs. The mechanisms that are discussed 
for this effect are an alteration of the partitioning of the drug into the skin, interactions with the 
skin lipids or solvent drag [25-28]. Other solvents such as isopropanol and ethyl acetate have 
been described in the literature to have an even stronger enhancing effect on the permeation of 
steroidal hormones than ethanol [29-33]. For this reason it was investigated if an exchange of 
ethanol against isopropanol, ethyl acetate or a binary mixture of these solvents with ethanol 
could lead to an improvement in drug permeation for a further optimisation of the delivery 
system. 
As demonstrated in Fig. 20 the formulations with isopropanol or a mixture of isopropanol and 
ethanol did not achieve an increase of the ethinylestradiol permeation in comparison to the 
original formulation with neat ethanol but rather reduced the drug flux. Neat ethyl acetate did 
also fail to increase the ethinylestradiol transport through the epidermis. In consequence, these 
solvents cannot serve to improve the ethinylestradiol permeation from the film forming system. 
Only the mixture of ethyl acetate with ethanol showed a slightly higher permeation than the 
original formulation with neat ethanol.  
This result is in accordance with the findings of Catz et al. concerning the enhancing effects of 
solvent mixtures on the permeation of levonorgestrel, a highly lipophilic steroidal hormone like 
ethinylestradiol, though hairless mouse skin [30]. However, it does not agree with other findings 
of the same group for a similar experiment with human cadaver skin [31]. In those experiments 
the solution of levonorgestrel in neat ethyl acetate produced the best results followed by the 
mixture of the two solvents and neat ethanol. A reason for the different findings might be that the 
results of Catz et al. for levonorgestrel cannot be transferred to other steroidal hormones in spite 
of the similar chemical properties. Another reason could be that the contact time of the solvent to 
the skin is of importance [34] which was different in the two experiments. In our experiments the 
 70
First release and permeation experiments 
solvent evaporated quickly after the application to the epidermal membrane (open donor 
chamber). In contrast to this the contact between solvent and skin was provided throughout the 
whole experiment in the work of Catz et al. (closed donor chamber), offering more time for 
possible interactions of the solvents with the skin. The condition of a closed donor chamber, 
however, was not suitable for our experiments as the film forming solutions are not supposed to 
remain in a liquid state but to dry quickly after application to the skin. 
 
The results of the permeation experiments with different solvents indicate that a mixture of ethyl 
acetate und ethanol might have a positive impact on the ethinylestradiol permeation in 
comparison to the usage of neat ethanol. However, since the observed improvement was only 
moderate a change of the solvent does not seem to be a promising measure to substantially 
increase the delivering efficiency of the film forming solution for ethinylestradiol. 
 
The two experiments have shown that both parameters, drug concentration and solvent, can have 
an impact on the drug permeation, but that only the drug loading is a viable option to 
considerably improve the drug delivery from the film forming system. 
6. Conclusion 
The performed experiments with caffeine and ethinylestradiol revealed distinct differences 
between four film forming solutions concerning their drug release and permeation properties. 
However, the rank order observed in the release experiments with an artificial membrane was not 
in accordance with the results obtained with human epidermis as relevant biological barrier. For 
both tested drugs the formulation with the polyurethane-acrylate DynamX® showed a permeation 
enhancing effect in comparison to the polymer-free reference solution. It also displayed the 
highest permeation results among the tested formulations in the relevant human epidermis model 
and was therefore selected for further experiments. The ethinylestradiol amount delivered by the 
DYN formulation increased proportionately with rising drug loading of the film forming system 
but was not substantially improved by changes of the volatile solvent in the composition. These 
results indicate that a drug delivery from film forming solutions to the skin seems generally 
feasible and that further research is encouraged to prove the relevance of this novel approach for 
the transdermal drug delivery. 
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CHAPTER 4 
Delivery of ethinylestradiol from film forming polymeric solutions 
across human epidermis in vitro and in vivo in pigs 
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1. Abstract 
Film forming polymeric solutions may present an alternative to the common transdermal dosage 
forms such as patches or gels. To evaluate the potential of these systems for transdermal drug 
delivery the permeation of ethinylestradiol from four formulations with different polymers was 
tested across heat separated human epidermis. The formulation with the best results was then 
modified by incorporating chemical enhancers to further increase the efficiency of the delivery 
system. Finally, drug delivery from the developed film forming systems was compared to a 
commercially available transdermal patch in vitro as well as in vivo in pigs. Among the tested 
preparations the formulation with polyurethane-14-AMP-acrylates copolymer (DynamX®) 
showed the highest ethinylestradiol permeation. The drug transport was further increased with 
the incorporation of oleic acid as penetration enhancer, especially when used in combination 
with propylene glycol. The enhancing effect of oleic acid/propylene glycol was concentration 
dependant and increased disproportionately with rising enhancer content. The film forming 
solution showed a higher ethinylestradiol permeation through heat separated human epidermis 
than the commercial EVRA® patch in vitro and achieved measurable plasma concentrations of 
ethinylestradiol in vivo in pigs. These promising results encourage the further development of 
film forming polymeric solutions as novel transdermal dosage form. 
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Film forming polymeric solution; Transdermal drug delivery; Human epidermis; Pigs; Ethinylestradiol 
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2. Introduction 
Film forming polymeric solutions have been formulated as a new approach for the transdermal 
delivery of drugs. In a previously performed screening process several formulations with 
polymers from different chemical classes had been identified that formed fast-drying, flexible 
films with good adhesion to the skin (chapter 2). Four film forming solutions resulting from this 
screening process were selected for further investigations.  
 
The aim of this study was to assess the capability of the film forming polymeric solutions for the 
transdermal delivery of ethinylestradiol (EE). Ethinylestradiol is a lipophilic steroidal hormone 
mainly used in the indication contraception. The delivering efficiency of the film forming 
solutions for EE was investigated in permeation experiments through heat separated human 
epidermis. The polymers used in the tested formulations were hydroxypropylcellulose 
(Klucel® LF), ammonio methacrylate copolymer type A (Eudragit® RL PO), polyurethane-14 
and AMP-acrylates copolymer (DynamX®) and silicon gum (SGM 36). Along with the four 
formulations a polymer free ethanolic solution of the drug was tested to evaluate the influence of 
the different formulations/polymers on the EE permeation. Previous experiments with an 
ethinylestradiol concentration of 1% had already indicated a preference for one of the 
formulations. However, as the drug concentration can be used to improve the permeation 
(chapter 3) it was decided to increase the drug loading for these experiments from 1% to 5% in 
the solution. The comparison of the film forming preparations with different polymers was 
repeated with the higher drug loading to confirm the results from the first study for the 
formulation selection. 
 
Based on the results of these experiment the formulation with the best performance was selected 
and modified in its composition in order to further increase the drug permeation. For this purpose 
selected chemical penetration enhancers (laurocapram, N-methyl-pyrrolidone, propylene glycol, 
propylene carbonate, oleic acid or R-(+)-limonene) were incorporated into the film forming 
preparations. Subsequently, binary enhancer combinations were tested for a further improvement 
of the film forming system. Propylene glycol has been described in the literature to act 
synergistically with many enhancers such as oleic acid, R-(+)-limonene or isopropyl myristate 
[1-3]. Hence it was chosen as co-enhancer for oleic acid and R-(+)-limonene in this study. 
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Having determined the most efficient enhancer or enhancer combination for the film forming 
system the influence of the enhancer concentration was investigated. 
 
In the last step, the film forming solution was compared to a commercial transdermal product 
that evidentially delivers a therapeutically sufficient amount of EE to the systemic circulation in 
humans (EVRA® patch). The comparison with the transdermal patch was performed in vitro in 
the heat separated human epidermis model as well as in vivo in pigs. The pig has been widely 
recognized as relevant model for dermal or transdermal investigations due to the similar structure 
of pig skin in comparison to human skin [4, 5]. The in vivo experiment was a single dose 
application study over a time period of seven days during which the EE plasma levels in the 
animals were determined at predetermined intervals. In addition to the plasma levels, a first 
impression of the local tolerance and the persistence of the developed film forming solution on 
living skin was gained from the in vivo experiment that could be valuable for the further 
development of this novel dosage form. 
3. Materials and Methods 
3.1. Materials 
Ethinylestradiol was supplied by Schering AG, Berlin, Germany. The polymers were kindly 
provided by Roehm Pharma Polymers, Darmstadt, Germany (ammonio methacrylate copolymer 
type A, Eudragit® RL PO), National Starch and Chemical Company, Bridgewater, USA 
(polyurethane-14 and AMP-acrylates copolymer, DynamX®), Hercules Inc., Wilmington, USA 
(hydroxypropylcellulose, Klucel® LF) and Dow Corning S.A., Seneffe, Belgium (silicon gum, 
SGM 36). Ethanol (96%), triethyl citrate, propylene carbonate, propylene glycol and  
R-(+)-limonene were purchased from Merck, Darmstadt, Germany. Oleic acid (super refined) 
was a gift from Croda GmbH, Nettetal, Germany. Laurocapram (Azone®) was purchased from 
Yick-Vic Chemicals, Hong Kong, China. N-methyl-pyrrolidone (Pharmasolve®) was a gift from 
ISP, Cologne, Germany. Dow Corning® Q7-9180 (hexamethyldisiloxane/octamethyltrisiloxane) 
and Dow Corning® 193 Fluid (PEG-12 Dimethicone) were gifts from Dow Corning S.A., 
Seneffe, Belgium. EVRA® (Janssen-Cilag GmbH, Neuss, Germany) patches were purchased 
from a local pharmacy. EVRA® is a matrix type patch (A = 20 cm2) containing 0.6 mg 
ethinylestradiol and 6 mg norelgestromin. All chemicals used for the phosphate buffered saline 
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were of analytical grade and purchased from Merck, Darmstadt, Germany. γ-Cyclodextrins were 
kindly provided by Wacker, Eddyville, USA. 
3.2. Preparation of the tested formulations 
For the preparation of the solutions all ingredients (drug substance (EE), polymer, plasticizer and 
enhancer) were dissolved in ethanol (96%) and stirred overnight on a magnetic stirrer. For the 
silicone formulation an emulsion was formulated with the polymer, the volatile silicone (Dow 
Corning® Q7-9180), a silicone emulsifier (Dow Corning® 193 Fluid) and the smallest amount of 
ethanol (96%) required to dissolve the drug. This was necessary as EE did not dissolve in the 
volatile silicone used for the dissolution of the silicone gum. The EE concentration in all 
formulations was 5% (w/w) in the polymeric solution. In this concentration the drug was 
completely dissolvable in all preparations. The formulations (Table 11) were stored in glass vials 
sealed tightly with a siliconized rubber plug and an aluminium vial cap. 
 
Table 11: Composition of the tested film forming solutions and the reference with ethinylestradiol 
 
Formulation EUD DYN KLU SIL REF 
Polymer Eudragit® RL PO DynamX® Klucel® LF SGM 36 - 
Polymer content [%] 20.0 10.0 5.0 10.0 - 
Triethyl citrate [%] 6.0 1.0 1.0 - - 
Ethanol [%] 69.0 67.2 89.0 25.0 95.0 
Water [%] - 16.8 - - - 
Q7-9180 [%] - - - 51.5 - 
193 Fluid [%] - - - 8.5 - 
Ethinylestradiol [%] 5.0 5.0 5.0 5.0 5.0 
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3.3. In vitro permeation experiments through human epidermis 
The skin used for the preparation of the epidermal membrane was obtained from caucasian 
patients who had undergone abdominal plastic surgery. The patients were in good health and had 
no medical history of any dermatological disease. The approval from the ethics committee of the 
‘Caritas-Traegergesellschaft Trier e.V.’ was available.  
The preparation of the epidermal sheets and the experimental setup (all glass `Franz` type 
diffusion cells, 1.76 cm2, 12 ml, phosphate buffered saline with 0.5% γ-cyclodextrin as receptor 
fluid) has been described earlier (see chapter 3, sections 3.3, 3.4 for details). 
The experiments were started after the application of 100 mg of the formulation to the epidermis 
(2.84 mg EE/cm2). This amount was necessary to ensure complete and even coverage of the 
epidermis without the need of an additional distribution device such as a brush to avoid 
mechanical stress for the epidermal membrane. 
For the comparison with the commercial transdermal patch, however, only 20 mg of the 
preparations (0.57 mg EE/cm2) were applied because this amount is small enough to be 
applicable to a patient under realistic conditions without flowing away from the application site 
and complies with the OECD Guideline No. 28 for the conduct of skin absorption studies [6]. 
Due to the small quantity of the sample a soft brush was required for the application in these 
experiments. 
From the commercial transdermal matrix patches circular discs with a diameter of 1.5 cm 
(containing 0.03 mg EE/cm2) were prepared with a scalpel and pressed carefully to the epidermis 
before mounting the membranes in the diffusion cells.  
The donor compartment was kept open throughout the whole experiment. The permeation 
experiments (four replicates per formulation) were conducted over a 24 hours period. During this 
period samples (200 µl) were drawn at predetermined intervals and replaced by aliquots of the 
receptor fluid. The saturation concentration cs of EE in the receptor solution was 
cs ethinylestradiol = 557 µg/ml, sink conditions were maintained at any time.  
The samples from the permeation experiments were analysed for ethinylestradiol by HPLC 
(autosampler model 717plus, pump model 600, all Waters, Milford, USA). No sample pre-
treatment was required. The solid phase used was a reversed phase column (Lichrospher 100 
RP 18, 125 x 4mm, 5 µm) at ambient temperature. The mobile phase was acetonitril/water (1:1) 
at a flow rate of 1.5 ml/min. Ethinylestradiol was detected with a fluorescence detector (SFM25, 
Kontron, Zurich, Switzerland) using a wavelength of 280 nm for excitation and 310 nm for 
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emission [7]. The retention time for ethinylestradiol was approximately 2.7 minutes. The method 
provided good precision and linearity in the required concentration range  
(0.1 – 25 µg/ml, R2 = 0.9999). The chromatography software used was Millennium® (Waters, 
Milford, USA).  
The results of the permeation experiments are shown as cumulated drug amount [µg] permeated 
per unit surface area [cm2] plotted as a function of time. 
For the experiments with chemical enhancers an enhancement factor was calculated by dividing 
the absolute drug amount permeated from the formulation with enhancer after 24 hours by the 
absolute drug amount permeated from the enhancer free formulation after 24 hours 
[ ]
[ ]µgenhancerwithoutamountdrugpermeated
µgenhancerwithamountdrugpermeatedfactortEnhancemen =   (Eq. 7) 
Direct comparisons between different formulations within one set of experiments were always 
performed with skin samples from the same donor. 
3.4. In vivo permeation study in pigs 
The in vivo study was performed with 8 female pigs (German Landrace, age 3-4 months, Charles 
River Laboratories, Sulzfeld, Germany) in accordance with the German animals act [8] and 
under approval from the responsible authority (Niedersächsiches Landesamt für 
Verbraucherschutz und Lebensmittelsicherheit, Oldenburg, Germany). 
The pig race selected for this study was the German Landrace pig. In this race the bristle-growth 
is less dense than in the commonly used Goettingen minipig [9]. 
 
The animals were divided into two groups of four animals, the patch group and the film forming 
solution group. The allocation to the groups was performed by body weight randomization to 
yield groups with approximately equal mean body weight (approximately 23.5 ± 0.5 kg). On the 
day before the start of the experiment the test areas on the back of the animals were shaved 
without damaging the skin. Prior to the application of the test medication the skin was cleaned 
carefully with ethanol to avoid adhesion problems caused by fatty residues on the skin. The 
animals of the patch group were treated with the commercially available EVRA® patch (one 
patch per animal, A = 20cm2, 0.03 mg EE/cm2). In case of a partly detachment of the patch 
during the course of the experiment (less than 90% skin contact) the patch was removed and a 
fresh patch was applied to a different location on the back of the animal. In the other group 
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300 µl of the prepared film forming polymeric solution (DYN, 5% (w/w) ethinylestradiol in the 
solution) were applied to the test area (A = 20cm2, corresponding to the size of the commercial 
patch) with the help of a syringe. The applied dose per surface area (0.57 mg EE/cm2) 
corresponded to the dose applied in the in vitro study with human epidermis. Following the 
administration the animals were restrained for at least one hour in slings. The slings allowed the 
free movement of the head but prevented access to the application site by the animals. The liquid 
formulation dried on the skin within five minutes. Both test items, the patch as well as the film 
forming solution, were applied once at the beginning of the experiment and were supposed to 
remain in contact with the skin for the recommended wearing period of the commercial patch 
(seven days). On a daily basis the appearance of the test items, any occurring skin reactions and 
necessary patch replacements were recorded. 
 
For the determination of the ethinylestradiol plasma levels 5 ml blood samples were drawn 
before the application and after 6 h, 12 h, 24 h, 48 h, 72 h, 144 h and 168 h from the vena 
jugularis of each animal, processed for lithium-heparin plasma by centrifugation and kept frozen 
until sample analysis. 
The ethinylestradiol plasma concentration in the samples was determined by GC-MS. For the 
analysis ethinylestradiol was extracted from the plasma samples, derivatized and spiked with D4-
EE as internal standard. The capillary column used for the analysis was a 50%-phenyl-50%-
dimethyl-polysiloxane phase (Zebron™ ZB50, 30m x 0.32mm, 0.25 µm film, Phenomenex Ltd., 
Aschaffenburg, Germany). The retention time for EE and D4-EE was approximately 
7.6 minutes. For the detection a mass spectrometer (R10-10C, Nermag, Rueil-Malmaison, 
France) was used with negative ions chemical ionization (NICI) using ammonia as reagent gas. 
Ethinylestradiol was detected with the mass/charge ratio (m/z) of 490, D4-EE (internal standard) 
with m/z 494. The method assured good linearity and precision in the defined range  
(10 – 500 pg/ml, R2 = 0.998). 
The determined ethinylestradiol plasma concentrations are given in pg/ml and are plotted as a 
function of time. The area under the plasma concentration versus time curve over seven days 
(AUC0 –168 h) was calculated by the trapezoidal rule. 
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4. Results 
4.1. EE delivery from film forming solutions with different polymers 
Of the four tested formulations the preparation with polyurethane-14 and AMP-acrylates 
copolymer DynamX® (DYN) as film forming polymer transported the highest amount of EE 
through heat separated human epidermis (Fig. 21), followed by the hydroxypropylcellulose 
Klucel® LF formulation (KLU). The fact that these preparations delivered a higher amount of 
drug substance than the ethanolic reference solution indicates that the presence of these polymers 
and/or the plasticizer had an enhancing effect on the drug flux. Contrary to this, the formulation 
with the methacrylate copolymer Eudragit® RL PO (EUD) seemed to retain the drug substance 
rather than promote its permeation through the epidermis. The silicone formulation 
with SGM 36 (SIL), finally, had neither a retarding nor an enhancing effect on the drug flux in 
comparison to the ethanolic reference solution. Due to the fact that the DYN formulation showed 
not only the highest but also the fastest drug delivery (in accordance with the earlier results with 
the lower drug concentration, chapter 3) it was considered the formulation with the highest 
potential and was therefore selected for all further investigations. 
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Fig. 21: Ethinylestradiol permeation from different polymeric solutions/films and an ethanolic reference solution  
through human epidermis; 5% (w/w) EE in the solution; mean values ± standard deviation, n = 4 
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4.2. Incorporation of chemical enhancers 
4.2.1. Influence of different enhancers on the EE permeation 
For the selection of a suitable enhancer for ethinylestradiol several DYN formulations were 
tested that contained one of the pre-selected enhancers in a concentration of 5% (w/w). Of the six 
selected substances only oleic acid (OA) and R-(+)-limonene (LIM) showed a moderately 
enhancing effect for ethinylestradiol in the DYN formulation (enhancement factor 1.9 and 1.4 
based on the permeated drug amounts after 24 hours; Fig. 22). Propylene carbonate (PC), 
propylene glycol (PG) and N-methyl-pyrrolidone (NMP) achieved no increase in drug 
permeation. Laurocapram (Azone®, AZO) even reduced the permeated amount of drug substance 
(factor 0.5) compared to the enhancer free formulation. 
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Fig. 22: Enhancement factors for the ethinylestradiol permeation from DynamX® film forming solutions (DYN) 
with the enhancers laurocapram (Azone®, AZO), N-methyl-pyrrolidone (NMP), propylene carbonate (PC), 
propylene glycol (PG), R-(+)-limonene (LIM), oleic acid (OA) and from an enhancer free film forming 
solution (-) based on the permeated drug amounts after 24 hours; enhancer content: 5% (w/w) in the 
solution; ethinylestradiol content: 5% (w/w) in the solution; mean values ± standard deviation, n = 4 
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4.2.2. Synergistic effects of binary enhancer combinations 
To make use of possible synergistic effects DYN formulations with binary enhancer 
combinations were tested containing propylene glycol and one of the enhancers that had 
previously proved to be efficient for ethinylestradiol (oleic acid or R-(+)-limonene). Propylene 
glycol and the co-enhancer were each incorporated in a concentration of 2.5% (w/w) adding up 
to a total enhancer concentration of 5% (w/w) in the preparations. Fig. 23 shows the 
enhancement factors resulting from these enhancer combinations in comparison to the factors 
achieved by the formulations containing only one single enhancer in a concentration of 5% 
(w/w). Both enhancer combinations increased the ethinylestradiol permeation much more 
efficiently than the single enhancer compounds. Similar to the results seen with the single 
compounds the propylene glycol combination with oleic acid achieved a higher permeation than 
the combination with R-(+)-limonene (enhancement factor 4.6 for oleic acid/propylene glycol 
versus 3.3 for R-(+)-limonene/propylene glycol). 
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Fig. 23: Enhancement factors for the ethinylestradiol permeation from DynamX® film forming solutions (DYN) 
with the enhancers propylene glycol (PG), R-(+)-limonene (LIM), oleic acid (OA) and binary mixtures 
(1:1) of propylene glycol with R-(+)-limonene (LIM/PG) or propylene glycol with oleic acid (OA/PG) 
based on the permeated drug amounts after 24 hours; total enhancer content: 5% (w/w) in the solution; 
ethinylestradiol content: 5% (w/w) in the solution; mean values ± standard deviation, n = 4 
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4.2.3. Impact of the enhancer concentration on the EE permeation 
In the previous experiments the chemical enhancers were incorporated into the DYN formulation 
in a concentration of 5% (w/w). However, permeation enhancers such as oleic acid are a possible 
source for skin irritation [10] and are therefore to be used with caution. For a better evaluation of 
the benefits of the enhancer content on the ethinylestradiol permeation DYN preparations with 
different enhancer concentrations (1%, 3% or 5% w/w) and an enhancer free formulation were 
compared. For these experiments the binary enhancer combination oleic acid/propylene 
glycol (1:1) was chosen as this combination had displayed the highest enhancing efficiency for 
EE in the previous experiment. Fig. 24 shows the permeated drug amounts after 24 hours for the 
formulations with different enhancer contents. As expected the preparation with the highest 
enhancer content achieved also the highest EE permeation. However, the ethinylestradiol 
permeation did not rise linearly but showed a disproportionately high increase with rising 
enhancer concentrations. 
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Fig. 24: Ethinylestradiol permeation from DynamX® film forming solutions (DYN) with different enhancer 
concentrations through heat separated human epidermis based on the permeated drug amounts after 
24 hours; enhancer: oleic acid/propylene glycol (1:1); ethinylestradiol content: 5% (w/w) in the solution; 
mean values ± standard deviation, n = 4 
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4.3. Comparison of the film forming solution to a transdermal patch 
 4.3.1. In vitro permeation 
Fig. 25 shows the ethinylestradiol permeation from the developed DYN film forming solution 
with enhancer (propylene glycol/oleic acid (1:1), 5% w/w) or without enhancer in comparison to 
the permeation from the commercially available patch (EVRA®) through human epidermis in 
vitro. Both film forming formulations showed a higher permeation than the commercial patch 
over 24 hours. While the enhancer free formulation transported more than double the 
ethinylestradiol amount of the marketed patch, the formulation with oleic acid and propylene 
glycol as permeation enhancer delivered about seven times as much ethinylestradiol than the 
EVRA® patch through heat separated human epidermis. 
 
 
 
0
5
10
15
20
0 5 10 15 20 25
time [h]
pe
rm
ea
te
d 
am
ou
nt
 o
f 
et
hi
ny
le
st
ra
di
ol
  [
µg
/c
m
2 ] with
enhancer
without
enhancer
EVRA®
 
 
 
 
 
 
 
 
 
 
Fig. 25: Ethinylestradiol permeation from DynamX® film forming solutions (DYN) and from the EVRA® patch  
through human epidermis; enhancer: 5% (w/w) oleic acid/propylene glycol (1:1); ethinylestradiol dose: 
0.57 mg/cm2 in the solution, 0.03 mg/cm2 in the patch; mean values ± standard deviation, n = 4 
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4.3.2. In vivo study in pigs 
In the animal study both tested dosage forms, the commercial patch and the developed film 
forming solution showed sufficient contact to the skin. In the patch group only one patch had to 
be replaced on day four due to loss of contact. The developed film forming system DYN also 
showed good adhesion. After application the liquid formed a clear, glossy film on the skin, 
which started to display cracks after one day. The films ceased to be visibly detectable after three 
to six days. After seven days no residues were visible on the skin of the animals in this group. In 
the patch group brown residues were observed after removal of the patches. 
 
Both dosage forms, the patch and the developed film forming system, were well tolerated. No 
erythema or other skin reactions were observed. The reddening noted in one animal of the patch 
group after removal of the patch was most probably related to the mechanical stress of the 
removal procedure. Both dosage forms showed also a good systemic tolerance as none of the 
animals died or displayed any item-related changes of behaviour, body weight, food 
consumption or external appearance. 
 
The plasma levels of ethinylestradiol in the animals of the two test groups during the course of 
the experiment are shown in Fig. 26, 27 and 28. Due to the fact that the detected ethinylestradiol 
concentrations in the plasma were lower than expected some of the data points were below the 
validation range and had to be calculated by extrapolation. Therefore the given data is only
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Fig. 26: Ethinylestradiol plasma concentration in pigs after single application of the DynamX® film forming 
solution (DYN), (0.57 mg EE/cm2, 20 cm2; total EE dose: 11.4 mg) 
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Fig. 27: Ethinylestradiol plasma concentration in pigs after single application of the DynamX® film forming  
solution (DYN), (0.57 mg EE/cm2, 20 cm2; total EE dose: 11.4 mg) 
 
semi-quantitative and has to be interpreted with due caution. The determined plasma 
concentration levels showed considerable variations in both groups. While maximum plasma 
concentrations were reached after 48 hours (tmax) in three of the four animals in the patch group 
the animals in the film forming group displayed varying tmax values: 6 hours (animal no. 7), 
24 hours (animal no. 6) and 72 hours (animal no. 5). In one animal of each group (animals no. 3 
and 8) extremely low plasma concentrations of ethinylestradiol were detected without 
identifiable maximum. Although the determined ethinylestradiol plasma levels showed 
considerable variations in both groups the calculated area under the plasma concentration versus 
time curve (AUC 0 – 168 h) was on a higher level for the animals with the film forming solution 
than for the animals with the patches (Table 12). 
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Fig. 28: Ethinylestradiol plasma concentration in pigs after single application of the EVRA® patch 
(0.03 mg EE/cm2, 20 cm2; total EE dose: 0.6 mg) 
 90
Delivery of ethinylestradiol 
Table 12: tmax and AUC 0 – 168h values based on the ethinylestradiol plasma concentration versus time curves 
after single application of the EVRA® patch or the DYN film forming solution to pigs 
 
EVRA® patch Film forming solution 
Animal No. 
tmax  
[h] 
AUC 0-168h 
[pg*ml-1*h] 
Animal No. 
tmax  
[h] 
AUC 0-168h 
[pg*ml-1*h] 
1 48 146 5 72 1353 
2 48 111 6 24 10572 
3 - - 7 6 555 
4 48 659 8 - 279 
 
5. Discussion 
5.1. Effects of the film forming polymer 
For the development of film forming polymeric solutions as drug delivery systems the choice of 
a suitable polymer for the formulation is very important. The film former does not only influence 
the mechanical properties of the formed film such as flexibility or abrasion resistance, the 
adhesion to the skin (in cooperation with the plasticizer) or the appearance of the film 
(transparency, smoothness, gloss) (chapter 2) but affects also the drug permeation from the film 
into the skin as demonstrated in Fig. 21. Depending on their chemical properties, polymers and 
drugs can interact in different ways, for example by ionic forces, hydrogen bonding or through 
the degree of solubilization of the drug in the polymer [11, 12]. An important factor with impact 
on the drug permeation can be the ability of the polymer to influence the physical state of the 
drug in the matrix by acting as crystallization inhibitor. When the formulation is applied to the 
skin the drug is completely dissolved. With the evaporation of the solvent the drug concentration 
within the formulation rises which increases the thermodynamic activity of the drug in the 
formulation and with it the drug flux [13, 14]. However, when the saturation level of the 
formulation is exceeded crystallization might occur, which has a negative impact on the drug 
flux. Antinucleating polymers such as DynamX® can accordingly contribute to an increased drug 
delivery as they can prevent crystallization [15-17] in the formed films. In films of polymers that 
lack this antinucleating ability such as the silicon gum SGM 36 crystallization was observed 
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after the evaporation of the solvent which might contribute to the comparatively low permeation 
results of this formulation. However, to what extent the suggested effects contribute to the 
different performance of the formulations cannot be clarified without further investigations due 
to the diversity in the chemical structures of the utilized polymers. 
5.2. Incorporation of chemical enhancers 
On the basis of the positive results with the DYN formulation further measures were taken to 
increase the delivering efficiency of the selected formulation. 
 
One commonly applied approach to overcome the skin as efficient absorption barrier is the 
incorporation of a chemical penetration enhancer. Chemical enhancers may improve the drug 
absorption by various mechanisms such as improving the solubility of the drug in the vehicle, 
promoting the partitioning of the drug into the skin or disrupting the lipid bilayer structures in 
the skin [18]. The enhancing efficiency of a chemical enhancer is drug specific and dependant on 
the chemical properties of the drug substance such as the lipophilicity [19]. Many substances 
have been described in the literature as penetration enhancers for estradiol [20-26], which is very 
similar to ethinylestradiol concerning the chemical structure. Six of these enhancers were tested 
in the human epidermis model to identify the most efficient enhancer for ethinylestradiol in the 
developed polymeric system. Of the six enhancers only oleic acid (OA) and R-(+)-limonene 
(LIM) achieved positive results while propylene carbonate (PC), propylene glycol (PG), N-
methyl-pyrrolidone (NMP) and laurocapram (Azone®, AZO) did not increase the delivery of 
ethinylestradiol (Fig. 22). R-(+)-limonene and oleic acid act mainly by causing a disorder in the 
intercellular lipid structures of the horny layer [27, 28] which facilitates the permeation of 
lipophilic drugs such as ethinylestradiol through the skin. A similar mechanism of action is also 
described for laurocapram [29, 30] and examples can be found in the literature for its enhancing 
effect on the permeation of highly lipophilic steroids such as estradiol [31, 32]. Our experiments, 
however, a permeation enhancement for the highly lipophilic ethinylestradiol (log Poct  ≈ 3.7) by 
laurocapram was not observed. The results rather support the findings of Diez-Sales et al. who 
described that although the enhancing efficiency of laurocapram for lipophilic drugs increased 
with rising enhancer concentrations it showed no effect for compounds of very high lipophilicity 
(log Poct > 3) [33]. 
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In contrast to oleic acid, R-(+)-limonene and laurocapram the three other enhancers follow a 
different mechanism of action. They serve mainly as co-solvents that increase the solubility of 
the drug in the formulation as well as in the skin [25, 34]. As ethinylestradiol was already 
completely dissolved in the liquid formulation as well as in the formed film (no drug crystals 
were observed in the film), the solubility of the drug in the vehicle could not be further 
improved. It is possible that the co-solvents improve the partitioning of lipophilic drugs into the 
skin by solubilizing them in the aqueous regions in the intercellular structures of the horny layer 
as suggested by Barry et al. [35]. However, this effect did either not apply to ethinylestradiol as 
drug molecule or was too weak to result in a measurably increased drug permeation in our 
experiments. Especially the efficiency of propylene glycol as sole penetration enhancer is 
discussed controversially in the literature. While some authors describe a permeation promoting 
effect of propylene glycol for lipophilic drugs [18, 23, 36] others have not seen similar effects 
[20, 37, 38]. The results of our experiments support the latter as the permeation of the lipophilic 
ethinylestradiol from the film forming system was not increased by the presence of propylene 
glycol alone. However, when the enhancer was used in combination with co-enhancers such as 
oleic acid or R-(+)-limonene a synergistic enhancing effect on the ethinylestradiol permeation 
was observed (Fig. 23). This is in accordance with findings in the literature where a similar 
effect has been reported for other, hydrophilic and lipophilic drugs [1, 23, 39-41]. The 
observation that the ethinylestradiol permeation did not rise linearly with the enhancer 
concentration but showed a disproportionately high increase (Fig. 24) might also be related to the 
synergistic action of the two enhancers. It can be speculated that this synergy results from an 
improved partitioning of the oleic acid into the stratum corneum due to the presence of the 
propylene glycol. 
5.3. EE delivery from film forming solutions versus transdermal patch 
The permeation experiments through heat separated human epidermis have shown that both 
developed film forming formulations, the DYN formulation with propylene glycol/oleic acid 
(1:1) as enhancer and even the formulation without enhancer, delivered a higher drug amount 
through the epidermis in 24 hours than the commercial transdermal patch (Fig. 25). At least in 
this in vitro model the incorporation of a chemical enhancer such as propylene glycol/oleic acid 
(1:1) was not required to reach the same delivery level as the commercial patch. However, the 
delivering efficiency of the film forming solution was lower than that of the commercial patch. 
Only 0.8% of the applied drug was transported through the epidermis by the film forming 
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formulation without chemical enhancer while the patch delivered 6.2% of the administered drug 
amount in 24 hours. Therefore the incorporation of enhancers might be useful to increase the 
delivering efficiency of the system. With this measure the required drug concentration in the 
system can be reduced in order to save drug substance and lower the environmental 
contamination caused by the amount of drug remaining in the system after usage. A prerequisite 
for this measure would be, however, that the enhancer containing formulation demonstrates a 
good local tolerance on the skin.  
 
The positive findings from the in vitro experiment concerning the potential of film forming 
polymeric solutions as transdermal delivery system for ethinylestradiol were supported by the in 
vivo results. Although the variations were high and the delivery kinetic remained unclear it can 
be stated that it was possible to induce detectable plasma levels of ethinylestradiol in vivo in a 
relevant animal model with the film forming solutions. A trend was observed that the delivered 
ethinylestradiol amounts were higher than those delivered by the commercial transdermal patch 
(Table 12). However, additional experiments are required to profoundly investigate the delivery 
kinetic of the drug from the developed system. 
6. Conclusion 
Film forming polymeric solutions with and even without chemical permeation enhancers have 
demonstrated potential as transdermal drug delivery systems for ethinylestradiol in vitro and in 
vivo. Further research is necessary to prove the relevance of film forming solutions as 
transdermal dosage form but the obtained results are encouraging for the further development of 
this novel drug delivering technology for the skin. 
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CHAPTER 5 
Permeation of levonorgestrel from film forming polymeric solutions 
across human epidermis in vitro 
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1. Abstract 
The aim of this study was to investigate film forming polymeric solutions for the delivery of 
steroidal hormones for hormone replacement therapy or contraception. In previous in vitro 
experiments a film forming solution had successfully delivered a similar amount of 
ethinylestradiol through human epidermis than a commercially available contraceptive patch 
(EVRA®). Estrogens are usually administered in combination with progestins to reduce their side 
effects on various hormone sensitive tissues. Therefore the aim of the current study was to test 
the developed film forming system concerning a possible co-administration of the progestin 
levonorgestrel with the estrogenic compound ethinylestradiol. The performed permeation 
experiments with heat separated human epidermis indicated that the film forming system was 
capable of simultaneously delivering ethinylestradiol and levonorgestrel. No mutual influences 
on the drug permeation occurred between the two drugs in the tested concentrations. The 
polymeric formulation as such and oleic acid/propylene glycol as additional chemical enhancers 
had a positive impact on the levonorgestrel permeation, similar to the effects observed for 
ethinylestradiol. With an enhancer content of 5% of oleic acid and 5% propylene glycol the film 
forming system delivered a similar amount of levonorgestrel through the epidermis than the 
Fem7® Combi patch, which is marketed for the indication hormone replacement therapy. These 
results demonstrate the potential of film forming polymeric solutions as novel dosage form for 
the skin and encourage their further development as transdermal delivery system for steroidal 
hormones such as ethinylestradiol or levonorgestrel. 
 
Keywords:  
Film forming polymeric solution, Transdermal delivery system, Drug permeation, Levonorgestrel 
 101
Permeation of levonorgestrel 
2. Introduction 
Transdermal delivery devices, mainly in the form of matrix or reservoir patches, are currently 
used for a number of indications, among them hormone replacement therapy (HRT) and 
contraception. In comparison to the widely used oral dosage forms the transdermal hormone 
delivery can provide several advantages: Transdermally applied ethinylestradiol for example, a 
frequently used synthetic estrogen for contraception, does not underlie the hepatic first pass 
effect. This effect is responsible for the low bioavailability of the drug after oral administration 
(bioavailability approximately 40-50% [1]) and various changes in the hepatic serum parameters 
[2]. In contrast to the oral application route plasma peaks are minimized with the transdermal 
application, reducing the occurrence of side effects. Moreover, the efficacy of the medication is 
not affected by disorders of the gastrointestinal tract like vomiting or diarrhoea. 
Several polymeric patches are available for HRT with estrogens like estradiol and progestins 
such as levonorgestrel (Fem7® Combi, Solvay, Germany) or norethindrone acetate (Climara 
ProTM, Berlex, USA, CombiPatch®, Novartis, USA). For contraception the only currently 
marketed product is the EVRA® (EU) or Ortho-EVRATM (US) patch. It contains ethinylestradiol 
as estrogenic compound and norelgestromin as progestin. The EVRA® patch is continuously 
worn by the patient for a period of seven days after which it is replaced by a fresh patch. After 
three weeks of application a patch-free week completes the menstrual cycle. This dosing scheme 
especially addresses women who are opposed to oral medication or who do not want to be 
obliged to remember taking an oral contraceptive on a daily basis [3, 4]. 
 
To benefit from the advantages of the transdermal application route without the disadvantages 
often associated with transdermal patches (skin irritation, high visibility) film forming polymeric 
solutions have been suggested for the transdermal delivery of the steroidal hormones. The basic 
principle of these delivery systems and their development has been described earlier (chapter 2).  
 
The aim of this study was to investigate if film forming solutions can serve as drug delivery 
systems for the indications contraception or HRT. A film forming solution that had displayed 
encouraging results in earlier experiments was selected as core formulation for these 
experiments. The selected preparation contained polyurethane-14 and AMP-acrylates copolymer 
(DynamX®) as film former, triethyl citrate as plasticizer, water and the volatile solvent ethanol. 
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In a previous permeation experiment this preparation loaded with 5% (w/w) ethinylestradiol 
(EE) had delivered a higher amount of the estrogen through heat separated human epidermis than 
the contraceptive EVRA® patch (chapter 4). This result indicated that the delivery of a sufficient 
amount of a suitable estrogenic compound from the developed film forming system was feasible 
in vitro. For contraceptive purposes (and often also for HRT), however, estrogens are not 
administered as mono therapy as they are supposed to increase the severe risk of endometrial 
hyperplasia and breast cancer [5-7]. To reduce these side effects the estrogen is combined with a 
progestin because of the anti-estrogenic activity of these progesterone or testosterone derivatives 
(down regulation of the estrogen receptors, decrease of the endometrium thickness) [8]. Hence a 
novel film forming solution for contraception or HRT is required to supply not only a sufficient 
amount of ethinylestradiol but also the necessary amount of a suitable progestin to the systemic 
circulation. 
 
Based on this requirement the selected core formulation was tested concerning the simultaneous 
delivery of ethinylestradiol and levonorgestrel as progestin. Levonorgestrel (LN), a testosterone 
derivative (Mr = 312.45, log Poct  ≈ 3.5, Fig. 29), was chosen from the group of progestins due to 
its high potency [8] and the consequently low required dose. Furthermore it was one of the three 
progestins (levonorgestrel, norelgestromin and norethindrone acetate) that were already used in 
commercial transdermal patches. For the first experiments the core film forming solution was 
loaded with 5% of EE (corresponding to the drug loading in previous experiments) and 0.3% of 
LN (w/w in the solution). 0.3% was the highest LN concentration that could be reached in the 
formulation without the additional incorporation of a solubilizer. The drug permeation from this 
formulation was then investigated in the biologically relevant heat separated human epidermis 
model. 
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Fig. 29: Chemical structure of levonorgestrel 
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In a first step the film forming solution with EE and LN was compared to the corresponding 
mono formulations containing either EE or LN to measure possible interactions between the two 
drugs with effect on the drug permeation. In the next step the impact of the polymeric 
formulation was investigated. In previous experiments the polymeric formulation as such had 
acted as moderate permeation enhancer for EE (chapter 4). Moreover, the effect of additional 
chemical penetration enhancers on the permeation of the two drugs was studied. A binary 
mixture of propylene glycol and oleic acid (1:1) was chosen as chemical enhancer. This 
combination had considerably improved the EE permeation in earlier experiments (chapter 4) 
and was expected to have a positive effect on the LN permeation as well. The efficiency of a 
permeation enhancer is closely connected to the chemical properties of the drug substance [9] 
and both drugs, LN as well as EE, are hormones with a steroidal structure and similar 
lipophilicity (log Poct: EE ≈ 3.7, LN ≈ 3.5). Finally, the LN formulation with and without 
enhancer was compared to a marketed transdermal patch containing LN to evaluate if a 
corresponding delivery level for LN could be reached with the developed formulation. Since no 
contraceptive patch with LN was available, the Fem7® Combi patch (“Phase 2”) for hormone 
replacement therapy was selected as reference. The film forming composition was further 
optimised to match the drug delivery of this commercial patch in vitro.  
3. Materials and Methods 
3.1. Materials 
Ethinylestradiol (EE) and levonorgestrel (LN) were supplied by Schering AG, Berlin, Germany. 
polyurethane-14 and AMP-acrylates copolymer (DynamX®) was kindly provided by National 
Starch and Chemical Company, Bridgewater, USA. Ethanol (96%), triethyl citrate and propylene 
glycol were purchased from Merck, Darmstadt, Germany. Oleic acid (super refined) was a gift 
from Croda GmbH, Nettetal, Germany. Propylene carbonate was kindly provided by Huntsman 
Corp., Zaventem, Belgium. Fem7® Combi patches “Phase 2” (Solvay Arzneimittel GmbH, 
Hannover, Germany) were purchased from a local pharmacy. Fem7® Combi “Phase 2” is a 
matrix patch (A = 15 cm2) containing 1.5 mg estradiol hemihydrate and 1.5 mg levonorgestrel. 
All chemicals used for the phosphate buffered saline were of analytical grade and purchased 
from Merck, Darmstadt, Germany. γ-Cyclodextrins were kindly provided by Wacker, Eddyville, 
USA. 
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3.2. Preparation of the tested formulations 
For the preparation of the film forming solutions the drug substances (5% EE, 0.3% LN, w/w) 
were dissolved in ethanol (96%). Having obtained a clear solution the polyurethane-14 and 
AMP-acrylates copolymer (10% w/w), dissolved in a mixture of water and ethanol, was added 
and the preparation was stirred overnight for complete dissolution of the polymer. Finally, the 
remaining ingredients such as plasticizer (triethyl citrate) or enhancer (oleic acid/propylene 
glycol) were added and the solution was stirred for another 24 hours before use. The 
formulations were stored in glass vials sealed tightly with a siliconized rubber plug and an 
aluminium vial cap. For the ethanolic reference solution 5% EE and 0.3% LN (w/w) were 
dissolved in ethanol (96%). 
3.3. Permeation experiments 
The skin used for these experiments was obtained from Caucasian patients who had undergone 
abdominal plastic surgery. The patients were in good health and had no medical history of any 
dermatological disease. The approval from the ethics committee of the ‘Caritas-
Traegergesellschaft Trier e.V.’ was available.  
The preparation of the epidermal sheets and the experimental setup for these experiments has 
been previously described (chapter 3, sections 3.3, 3.4). 
The experiment was started after the application of a defined amount of the formulation to the 
epidermis. For the experiments where the simultaneous application of EE and LN was tested 
100 mg of the preparations (56.8 mg/cm2) were applied to the membrane with a pipette in order 
to avoid any mechanical pressure on the epidermis. For the comparisons with the marketed 
patch, however, only 20 mg of the preparations (11.4 mg/cm2) were applied due to the fact that 
larger amounts tend to run-off from the application site under actual exposure conditions [10]. In 
these experiments a soft brush was carefully used for the application to ensure complete 
coverage of the membrane with this comparatively small amount of preparation. The donor 
compartment was kept open throughout the whole experiment. For the comparison with the 
commercially available transdermal patch circular discs with a diameter of 1.5 cm were prepared 
from the patches with a scalpel and pressed carefully to the epidermis before mounting the 
membranes between the upper and the lower part of the diffusion cells. The permeation 
experiments (four replicates per formulation) were conducted over a 24 hours period. During this 
period samples (200 µl) were drawn at predetermined intervals and replaced by aliquots of the 
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receptor fluid. The saturation concentrations cs of ethinylestradiol and levonorgestrel in the 
receptor solution were cs ethinylestradiol = 557 µg/ml and cs levonorgestrel = 123 µg/ml, sink conditions 
were maintained at any time.  
Direct comparisons between different formulations within one set of experiments were always 
performed with skin samples from the same donor. 
3.4. Chromatographic analysis 
The samples from the permeation experiments were analysed for ethinylestradiol or 
levonorgestrel by HPLC (autosampler model 717plus, pump model 600, all Waters, Milford, 
USA). No sample pre-treatment was required. The solid phase used was a reversed phase column 
(Lichrospher 100 RP 18, 125 x 4mm, 5 µm) at ambient temperature. The mobile phase was 
acetonitril/water (1:1) at a flow rate of 2.0 ml/min. Ethinylestradiol was detected with a 
fluorescence detector (SFM25, Kontron, Zurich, Switzerland) using a wavelength of 280 nm for 
excitation and 310 nm for emission [11] after approximately 2.0 minutes. LN was detected with 
an UV-VIS detector model 468 (Waters, Milford, USA) at 243 nm after approximately 
3.1 minutes. The method provided good precision and linearity in the required concentration 
range (EE: 0.1 – 25 µg/ml, R2 = 0.9999; LN: 0.05 – 10 µg/ml, R2 = 0.9999). The 
chromatography software used was Millennium® (Waters, Milford, USA). 
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4. Results 
4.1. Simultaneous delivery of EE and LN from a film forming solution 
Fig. 30 compares the simultaneous delivery of EE and LN from a film forming solution to the 
delivery of both hormones from film forming preparations containing only one of the drugs. The 
permeation curves from the formulation with the drug combination corresponded closely to the 
curves shown by the mono preparations with EE or LN. No mutual influences on the permeation 
behaviour of the two drugs was observed at the tested concentrations. 
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Fig. 30: Drug permeation through human epidermis from a film forming solution with two drugs (= comb.) in  
comparison film forming solutions with only one drug (= mono); drug content: 5.0% EE, 0.3% LN (w/w) in 
the solution; mean values ± standard deviation, n = 4 
 
4.2. Permeation of EE and LN from film forming solutions with and without 
chemical enhancer 
Fig. 31 and Fig. 32 show the delivery of EE and LN from the developed film forming solutions 
with and without enhancers and from a polymer-free reference solution of the drugs in ethanol. 
The delivery of LN was apparently increased by the presence of the polymer and/or the 
plasticizer as the polymeric formulation displayed higher permeation values than the polymer-
free reference solution. This was similar to the effect seen for EE. The factor by which the 
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permeation from the polymeric solution exceeded the permeation from the polymer-free 
preparation was lower for LN than for EE (2.9 for LN versus 4.2 for EE). The incorporation of 
5% (w/w) of oleic acid and propylene glycol in a binary mixture (1:1) increased the permeation 
of LN further, similarly to EE. Again the enhancement was more pronounced for EE than for LN 
(factor 8.9 for EE versus 5.0 for LN in comparison to the polymer-free ethanolic reference 
solution with the two drugs). 
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Fig. 31: EE permeation through human epidermis from film forming solutions with EE and LN with and without  
enhancer (oleic acid/propylene glycol 1:1, 5% w/w) and from an ethanolic reference solution; drug content: 
5.0% EE, 0.3% LN (w/w) in the solution; mean values ± standard deviation, n = 4 
 
0
2
4
6
8
10
0 5 10 15 20 25
time [h]
pe
rm
ea
te
d 
am
ou
nt
 o
f 
le
vo
no
rg
es
tre
l [
µg
/c
m
2 ] with
enhancer
without
enhancer
reference
solution
 
 
 
 
 
 
 
 
 
 
Fig. 32: LN permeation through human epidermis from film forming solutions with EE and LN with and without  
enhancer (oleic acid/propylene glycol 1:1, 5% w/w) and from an ethanolic reference solution; drug content: 
5.0% EE, 0.3% LN (w/w) in the solution; mean values ± standard deviation, n = 4 
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4.3. Comparison of the film forming solution to a transdermal patch 
Fig. 33 displays the LN permeation from the film forming solutions with or without 5% (w/w) of 
propylene glycol and oleic acid (1:1) as enhancer in comparison to the permeation from the 
commercially available Fem7® Combi patch. Neither the enhancer-free formulation nor the 
preparation with the chemical enhancer mixture was able to reach the delivery level of the 
commercial patch after 24 hours. Therefore an optimisation of the formulation was required. In 
order to increase the LN permeation from the film forming system three different approaches 
were selected: Firstly, the drug loading was increased from 0.3% to 0.4% LN by incorporating 
5% (w/w) of propylene carbonate as solubilizer for LN. Secondly, the oleic acid content in the 
binary enhancer mixture was increased from 2.5% to 3.75% (w/w) while the propylene glycol 
content was reduced from 2.5% to 1.25% (w/w) to keep a total enhancer content of 5% (w/w). 
And thirdly, the total enhancer content was raised from 5% to 10% (w/w) of the binary oleic 
acid/propylene glycol (1:1) mixture. All three approaches had a positive effect on the LN 
permeation as demonstrated in Fig. 34. However, of the three variations the increase of the total 
enhancer content showed the highest improvement. By raising the total enhancer content from 
5% to 10% a drug delivery level similar to that of the Fem7® Combi patch could be reached in 
vitro as displayed in Fig. 35. 
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Fig. 33: LN permeation from film forming solutions with and without enhancer (oleic acid/propylene glycol 1:1,  
5% w/w) and from the Fem7® Combi patch through human epidermis; LN dose: 0.034 mg/cm2 in the 
solution, 0.100 mg/cm2 in the patch; mean values ± standard deviation, n = 4 
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Fig. 34: LN permeation through human epidermis from film forming solutions with different contents of 
levonorgestrel (LN), oleic acid (OA) or propylene glycol (PG); concentrations (w/w) in the solution;  
mean values ± standard deviation, n = 4 
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Fig. 35: LN permeation from the optimised film forming solution with enhancer (oleic acid/propylene glycol 1:1,  
10% w/w) and from the Fem7® Combi patch through human epidermis; LN dose: 0.034 mg/cm2 in the 
solution, 0.100 mg/cm2 in the patch; mean values ± standard deviation, n = 4 
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5. Discussion 
5.1. Delivery of LN from film forming solutions through human epidermis 
Based on the previous positive results with EE the aim of this study was to continue the 
investigation on the film forming solution as delivery system for steroidal hormones for 
contraception or HRT. The results of the permeation experiments with the estrogen EE and the 
progestin LN indicate that the simultaneous delivery of both drugs from the developed film 
forming polymeric solution seems generally feasible. Up to 0.3% of LN could be dissolved in the 
polymeric formulation with EE without causing any solubility problems during manufacturing. 
Also no crystallization with a negative impact on the drug flux occurred in the formed film 
(microscopic observation) in spite of the higher total drug content. No mutual influences on the 
permeation of the two drugs, neither positive nor negative, were observed as demonstrated in 
Fig. 30. 
 
The polymeric formulation itself and the chemical enhancers propylene glycol and oleic acid in a 
total concentration of 5% had a positive effect on the permeation of both drugs (Fig. 31 and 
Fig. 32). However, the delivering efficiency of the polymeric system was fairly low for both 
drugs as less than 3% of the applied drug amounts permeated through the epidermis in 24 hours. 
In spite of the positive impact of the enhancer mixture on the LN permeation it was not possible 
to reach a similar delivery level as the commercial HRT patch that was used as ‘positive control’ 
(Fig. 33). One reason for this was certainly the solubility related low drug loading of the film 
forming system that resulted in a lower LN dose compared to the patch (0.034 mg/cm2 in the 
film forming solution versus 0.100 mg/cm2 in the patch). Therefore a further optimization of the 
formulation was required. 
 
The first attempt to improve the LN delivery through the epidermis was to increase the drug 
loading of the preparation with the help of a solubilizer. A higher drug loading leads to a higher 
concentration gradient at the membrane and consequently a higher drug flux. The concentration 
of the solubilizer was confined to 5% to limit the expected changes of the film properties (drying 
time, adhesion) due to the additional presence of the non-volatile solubilizer. In a preliminary 
experiment several co-solvents such as propylene glycol, polyethylene glycol and propylene 
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carbonate in the aforementioned concentration of 5% were tested as solubilizers for LN. Only 
propylene carbonate achieved an increase in the LN loading from 0.3% to 0.4%. Apart from 
these solubilizing qualities propylene carbonate possesses additional positive properties. It is 
miscible with ethanol, non-toxic for the administration on the skin and non-irritant [12] and was 
therefore considered a suitable solubilizer for LN in the film forming composition. The increase 
in drug loading from 0.3% to 0.4% LN (factor 1.3) achieved by propylene carbonate resulted in a 
similar increase in permeation (factor 1.4). This was in accordance with our earlier findings for 
EE where the permeation rose linearly with the drug content of the tested formulation 
(chapter 3). An additional enhancing effect of propylene carbonate itself, as described for other 
co-solvents in the literature [13, 14], was not observed. Although the LN permeation increased 
with this measure the improvement was not sufficient to reach the delivery rate of the 
commercial patch Fem7® Combi. 
 
Another attempt to improve the LN delivery was to increase the oleic acid concentration in the 
formulation. Oleic acid is assumed to be the main enhancing principle in the utilized binary 
enhancer mixture as it also showed a permeation promoting effect when administered without a 
co-enhancer (chapter 4). In contrast to this, propylene glycol had a rather negligible enhancing 
effect when used as sole enhancer (chapter 4). It serves rather as co-solvent in the mixture to 
promote the partitioning of its co-enhancer into the skin which subsequently increases the 
enhancing efficiency of oleic acid [15]. One approach to increase the oleic acid content in the 
formulation was to simply double the concentration of the binary enhancer mixture. An increase 
of the total enhancer content, however, could have a non-desirable side effect. The non-volatile 
enhancer compounds might have a plasticizer-like effect in the formed film with a negative 
impact on the film properties such as drying time or adhesion/stickiness (chapter 2). Therefore 
another approach was to keep the total enhancer content at 5% but to shift the balance between 
the two enhancers in favour of the oleic acid portion in the mixture (from 50% to 75%, 
corresponding to a total oleic acid content of 3.75% instead of 2.5%). However, the 
improvement of the LN permeation that was achieved with this measure was not sufficient to 
reach the targeted delivery level. Only the doubling of the total enhancer content in the 1:1 
mixture from 5% to 10% (5% oleic acid, 5% propylene glycol) produced a LN permeation 
similar to that of the marketed product after 24 hours (Fig. 35).  
Although a similar drug concentration in the receptor compartment was achieved by the 
optimized film forming solution the permeation profiles of the two dosage forms differed. While 
the patch showed a steady permeation during the experiment the film forming solution displayed 
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a high permeation in the early stages followed by a decrease in flux (Fig. 35). However, such a 
permeation profile cannot be considered typical for the film forming system at this point as it 
was not observed in experiments with the skin of another donor. 
The results of the enhancer variations supported our assumption that the oleic acid content is the 
dominating factor for the permeation enhancing effect. With rising oleic acid content the LN 
permeation rose, although not linearly probably due to the synergy of oleic acid with propylene 
glycol. This effect was similar to the observation made with EE in earlier studies (chapter 4). 
Surprisingly, the formulation with 3.75% oleic acid fit well into this picture in spite of the lower 
propylene glycol content in comparison to the tested formulations where both enhancers had 
been present in equal parts (Fig. 36). Although the presence of propylene glycol is required for a 
synergistic effect [15-17] it is apparently not necessary to supply the propylene glycol in the 
same quantity as the oleic acid. This observation might be useful in the future for a further 
optimization of the enhancer mixture in the film forming formulation. Possibly the propylene 
glycol portion and with it the total enhancer content could be reduced in order to minimize 
possible changes of the film properties without losing the synergistic permeation enhancing 
effect of the binary enhancer mixture. 
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Fig. 36: LN permeation from film forming solutions with different oleic acid concentrations and varying oleic acid 
(OA) / propylene glycol (PG) ratios through human epidermis; LN content: 0.3% LN (w/w) in the solution; 
mean values ± standard deviation, n = 4 
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5.2. Further optimization steps for a film forming contraceptive system 
The in vitro comparison of the improved film forming solution with the marketed transdermal 
patch (Fig. 35) indicates that the developed film forming system has a certain potential as 
transdermal delivery system for steroidal hormones. This is at least the case for HRT as this is 
the indication of the Fem7® Combi patch. It remains subject to further research, however, if the 
film forming system with EE and LN can also be utilized for contraceptive purposes as the 
required LN doses for contraception might be higher than for HRT. 
 
Due to the lack of a contraceptive patch with LN a direct comparison of the film forming system 
with a registered product, that evidentially delivers a sufficient amount of LN for contraception, 
was not feasible in the in vitro model. In the literature LN delivery rates of 35 µg/day [18] for 
mono products or 5 – 50 µg/day [19] for combination products with 25 – 50 µg estradiol per day 
are suggested for contraception. Provided that the results of the in vitro experiments are 
reproducible in vivo and that the developed film forming system can indeed deliver the same LN 
amount as the Fem7® combi patch (10 µg/day [20]), the LN delivery would be in the lower range 
or even below the required daily dose of LN for a contraceptive application. It is therefore highly 
probable that further optimization steps are needed to further improve the progestin delivery 
from the film forming system. 
 
For the above mentioned delivery rate of 10 µg/day the previously tested film forming 
formulation with 0.3% LN and 10% of the enhancer combination oleic acid/propylene glycol 
(1:1) would have to be applied with a formulation dose (DForm) of approximately 11.4 mg film 
forming solution/cm2 (corresponding to the dose in the in vitro study) on an area (A) of 15 cm2 
(corresponding to the size of the Fem7® combi patch). This would provide a drug dose (DLN) of 
34.2 µg/cm2 and a total dose (DLN Total) of 513 µg LN. A first measure to improve the LN 
delivery without changing the actual composition of the formulation could of course be to simply 
increase the total applied LN dose (DLN Total). This could be achieved in two ways, either by 
enlarging the application area (A) without changing the formulation dose (DForm = 11.4 mg/cm2) 
or by increasing the formulation dose (DForm) while keeping the size of the application site 
constant (A = 15 cm2). However, both measures have their limitations. Application sites 
exceeding 20 – 30 cm2, for example, are unlikely to be accepted by most patients. Applying a 
higher formulation dose per surface area, on the other hand, holds the risk that part of the 
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formulation flows away from the application site before drying [10] due to the low viscosity of 
the formulation. This would lead to an uncontrolled enlargement of the application site (A) and 
variations in the film thickness and thus the LN dose / surface area (DLN). In addition to this, a 
higher formulation dose / surface area (DForm) might result in thicker films with a stronger skin 
fixation and a more pronounced wrinkling of the skin (chapter 2), which is aesthetically 
unattractive and might have a negative impact on the patient compliance. 
 
Apart from these merely physical measures another option to improve the LN delivery from the 
system might be a quantitative or qualitative change of the film forming composition. 
Quantitative changes in the composition with a positive effect on the LN delivery might include 
a raise of the LN loading with the help of a solubilizing agent or a further increase of the oleic 
acid enhancer content. However, such changes also have their limitations as they might 
negatively affect the film properties (as described earlier) or might be problematic concerning 
the tolerability of the formulation (oleic acid is known to be moderately irritant [21, 22]). 
Qualitative changes in the film forming composition with a possible positive effect on the 
delivered LN amount could for example be the exchange of the solvent ethanol against a mixture 
of ethanol with ethyl acetate [23], the incorporation of a different permeation enhancer for LN 
(the tested enhancer mixture was very efficient for EE, but might not be ideal for LN) or the 
usage of a pro-drug instead of LN. Friend for example reported an increase of the LN delivery by 
factor 32 with Levonorgestrel-Glycidol [24]. The improvement was explained with a more 
favorable hydrophilic lipophilic balance of the drug that led to a higher solubility in the different 
domains of the skin and to higher permeation values in spite of the increased size of the 
molecule. 
 
Should all the discussed measures fail to increase the LN delivery to the required level, however, 
it might also be an option to replace LN by another progestin to develop an efficient 
contraceptive film forming solution. Suitable alternatives for LN might be progestins with either 
a higher potency than LN (resulting in a lower daily dose), a higher skin permeability (which 
would facilitate reaching the required daily dose) or simply a higher solubility in the volatile 
solvent of the formulation (to achieve a higher drug loading of the system). One example for an 
alternative progestin is 16-methylene-17α-acetoxy-19-norprogesterone (Nestorone®), a 
progesterone derivative that is soluble in ethanol, has a higher progestational activity than LN 
[8, 25] and is currently in clinical trial for the transdermal application in a metered dose topical 
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aerosol [26]. However, as the substance is still protected by intellectual property [27] it was not 
available for purchase at the time of our study. 
 
In summary it can be stated that several possibilities are available for a further optimization of 
the progestin delivery from the film forming system should the LN delivery from the tested 
system be insufficient for contraceptive purposes. However, further research and especially in 
vivo studies are required to clarify if this is actually the case. 
6. Conclusion 
The developed film forming system with polyurethane-14 and AMP-acrylates copolymer 
(DynamX®) as film former was able to simultaneously deliver an estrogen and a progestin, 
ethinylestradiol and levonorgestrel, through heat separated epidermis in vitro. The polymeric 
formulation itself and the presence of oleic acid/propylene glycol as chemical enhancers had a 
positive effect on the permeation of both drugs. The developed formulation was capable of 
transporting a similar amount of LN through the epidermis than the commercial Fem7® Combi 
patch for HRT although a total enhancer content of 10% (oleic acid/propylene glycol, 1:1) was 
required to achieve this result. Even though a further optimization of the system should be 
considered for the LN delivery these results underline the potential of the film forming 
polymeric solutions and encourage the further development of the tested film forming 
formulation as transdermal delivery system for steroidal hormones such as EE or LN. 
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CHAPTER 6 
Final discussion: Film forming polymeric solutions –  
novel drug delivery systems for the skin? 
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1. Introduction 
The aim of this work was to investigate film forming polymeric solutions as alternative dosage 
form for the skin. The results of the performed formulation and permeation experiments were 
encouraging for a further development of film forming systems for transdermal drug delivery. 
However, the investigations also revealed certain limitations of the novel dosage form with 
regard to the selection of excipients or the drug delivery. For a future use of this type of delivery 
system it is therefore important to discuss opportunities and limitations concerning the 
formulation compounds, to evaluate the drug delivering capacity of the formulations and to 
reflect on further aspects concerning the practical application that have not been addressed yet. 
Finally, the advantages and disadvantages of the film forming systems in comparison to the 
conventional dosage forms will be discussed.  
2. Considerations for the composition of film forming polymeric  
  solutions 
2.1. Suitable drugs 
The preferred application for film forming polymeric solutions is clearly the transdermal drug 
delivery. The usage of the developed formulations for dermatological indications is theoretically 
possible as well but cannot be recommended due to the nature of the solvent in the compositions. 
Dermatological diseases are often associated with inflamed skin where the administration of 
ethanolic solutions might be painful for the patient and thus not acceptable. 
 
For a transdermal application suitable drugs have to fulfil certain requirements that are 
independent of the dosage form [1]: Due to the fact that the skin is a very efficient protective 
barrier for the body, not merely against physical or microbiological noxes but also against drugs, 
only potent drugs are eligible for this application route with a daily dose of less than 10 mg. The 
size of the molecule is required to be small in order to provide a sufficient mobility in the skin 
structures (molecular weight below 500 Da). As the drug has to pass lipophilic as well as 
hydrophilic areas in the skin on its way into the systemic circulation it is advantageous if the 
drug is neither very hydrophilic nor extremely lipophilic (log Poct between 1 and 3). Uncharged 
molecules show a better permeation than charged molecules as they do not interfere with 
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charged moieties of the skin such as the negatively charged keratins. Therefore molecules with a 
pH value between 5 and 9 in aqueous solution are preferred for the transdermal application. 
Further parameters that are beneficial for the transdermal delivery of a drug are a small number 
of hydrogen bonding groups (< 2) and a low melting point [2]. 
 
Besides these general requirements for transdermal drugs some other points have to be 
considered for the film forming solutions in particular. 
The reservoir size of the dosage form is comparatively small due to the extreme thinness of the 
films (approximately 5 – 25 µm). With a formulation dose of 10 mg/cm2 and an application area 
with an acceptable size of for instance 30 cm2 the total applied formulation dose would be 
300 mg. Assuming a drug loading of 10% (which is higher than the drug loading that was used in 
this work) the applied drug dose would be approximately 30 mg. In order to reach the limit daily 
dose that is assumed for transdermal patches (10 mg/day) more than 30% of the applied dose 
would have to be absorbed. Such a high absorption was not achieved with the steroidal hormones 
that were investigated in this work. With these drugs the absorption was clearly below 10% of 
the applied dose. Taking this into account it seems obvious that the film forming solutions will 
be mainly attractive for drugs that have 
 
1.  a high potency    (example: the progestin Nestorone®) 
2.  a high skin permeability   (example: nicotin) 
3.  a high solubility in the solvent  (example: ethinylestradiol). 
 
A high potency is beneficial as it results in low required daily doses for the drug. A high skin 
permeability promotes a high exploitation of the thin reservoir provided a suitable polymeric 
matrix is given. A high solubility in the formulation, finally, allows high drug loadings and the 
establishment of a high gradient between formulation and skin. Ethinylestradiol for example, one 
of the therapeutically relevant drugs used in this work, fulfils the requirements in terms of high 
potency and sufficient solubility in the solvent. Levonorgestrel on the other hand, is also highly 
potent, but dissolved to a much lesser extent in the solvent than ethinylestradiol (0.3% versus 
5%). However, drugs with less favourable properties such as levonorgestrel are not generally 
excluded from an application with this dosage form as additional measures can be taken to 
improve the performance of the delivery systems (usage of pro-drugs, enhancers etc, see 
chapter 5). 
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An efficient delivery system, meaning a high exploitation of the drug reservoir throughout the 
wearing time, is generally desirable for all drugs. If this cannot be achieved the film forming 
system might not be attractive for expensive drugs due to the considerable portion of drug that is 
wasted. 
 
It remains subject to further research if the film forming solutions are suitable for drugs with a 
narrow therapeutic window as the kinetics of the delivery system are not yet known. With 
respect to the novelty of the film forming systems a thorough and individual evaluation for each 
new drug candidate is still inevitable until a clearer picture of the capabilities of the film forming 
solutions in general has been gained. 
2.2. Appropriate excipients 
2.2.1. Polymer 
The excipient that predominantly determines the properties of the film forming system is the 
polymer (chapter 2). The polymer influences the viscosity of the formulation and is responsible 
for the visual appearance of the formed film. In co-operation with the plasticizer it determines 
the flexibility of the film and its adhesion to the skin. Furthermore, the polymer has an impact on 
the solubility and the physical stability of the drug in the film for example by acting as 
crystallization inhibitor (chapter 4). 
 
The prerequisites for the polymer selection for this type of dosage form have been discussed in 
chapter 2. In short the polymer is required to be able to form films at the skin surface 
temperature (28°C-32°C) and should have a certain inherent flexibility and affinity to the skin to 
avoid the usage of excessive amounts of plasticizer. It has to be soluble in a highly volatile, skin-
friendly solvent. Moreover, strong gelling agents should be avoided as film former as they 
prevent an application of the formulation by spraying (which is the preferred option, see below). 
 
In spite of the many requirements the polymer screening experiments have demonstrated that the 
majority of the tested polymers could be formulated into a film forming composition with 
suitable macroscopic properties. Only four of the 14 tested polymers (chitosan, polyisobutylene, 
polyvinyl alcohol, polyvinylpyrrolidone, chapter 2) lacked some of the required properties and 
were therefore abandoned. The fact that the successfully utilized polymers differed widely in 
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their chemical structure (chapter 2, appendix 1) indicates that the formulation of this dosage form 
is not limited to certain polymer groups. It is highly probable that many more candidates for film 
forming solutions can be identified among the numerous polymers that are available on the 
market. 
Although various polymers yielded films with suitable macroscopic properties, however, the 
permeation studies have shown that some polymers are superior to others with respect to the 
drug delivery (chapters 3 and 4). The results indicated that the polymers do not only immobilize 
the drugs in a matrix on the skin, but that they may also have an enhancing (in case of the 
DynamX® formulation) or a retarding (in case of the Eudragit® RL formulation) effect on the 
drug permeation. These effects can result on the one hand from complex interactions of the 
polymeric formulation with the skin, on the other hand also from interactions of the polymer 
with the drug (chapter 4). The extent of the latter is specific for each drug – polymer 
combination, depending on the physico-chemical properties of the two compounds such as 
charge or lipophilicity. This should be kept in mind for the selection of a film forming 
formulation for a new drug candidate. The formulation with DynamX® as film former achieved 
good results with two drugs of different polarity (chapter 3) in this study. The investigated drug 
molecules were either weakly acidic (ethinylestradiol, no charge or negative charge due to 
deprotonation of the phenolic ring) or a weak acid/weak base combination (caffeine, positive and 
negative charge at the same time at neutral pH values). However, in the enhancer free film 
forming solutions (pH 6 – 8) the drugs were practically non-charged. Therefore the question 
remains open if the formulation with the anionic film former DynamX® is also favorable for 
charged molecules, especially if the drugs are positively charged. 
2.2.2. Solvent 
The solvent is also a very important compound in the film forming solution although it is not part 
of the actual film on the skin due to its quick evaporation. The solvent must have a sufficient 
solubility for the polymer as well as for the drug. Only a high solubilizing power of the solvent 
for the drug allows substantial variations of the drug loading to modulate the drug delivery to the 
skin (chapters 3 and 5). Apart from this indirect impact on the permeation the solvent can also 
exert a direct influence on the drug flux. Depending on the nature of the solvent and its 
permeation enhancing properties it can promote the drug transport to different extents in spite of 
its short contact time with the skin (chapter 3). This should be kept in mind for a further 
formulation development.  
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In addition to its solubilizing properties for the polymer and the drug a suitable solvent for a film 
forming solution is required to be highly volatile to provide short drying times and thus a good 
patient compliance. Together with the polymer it is supposed to spread well on the skin after 
application to produce a smooth film with a uniform thickness on the application site. Both 
requirements are not met for example by the solvent water. During the formulation experiments 
an aqueous chitosan formulation displayed unacceptably long drying times (chapter 2) and an 
uneven spreading on the skin due to the high surface tension of the aqueous polymeric 
formulation. Consequently, water cannot be considered a suitable solvent for the formulation of a 
film forming polymeric composition. Solvents such as ethanol, isopropanol or ethyl acetate with 
a higher volatility and a better spreading are to be preferred. 
2.2.3. Plasticizer 
In polymeric applications the main purpose of a plasticizer is to facilitate the film forming and to 
increase the flexibility of the resulting film. Additionally, the formulation experiments have 
shown that the skin adhesion of the films can be modulated with the help of plasticizers 
(chapter 2). 
 
The plasticizer has to be thoroughly selected with regard to the film former. It has to miscible 
with the polymer to produce clear films with low visibility on the skin. Since the efficiency of a 
plasticizer is polymer dependant no general rule can be applied as to which plasticizer content is 
required to produce films with the desired properties. The individual determination of the 
adequate plasticizer content is inevitable. An insufficient amount of the excipient leads to brittle 
films with low skin adhesion. An excessive amount of plasticizer on the other hand results in 
smooth, but sticky films (chapter 2). Both results are unacceptable for a reliable drug delivery by 
the film forming system and a good patient compliance. 
 
The plasticizer should preferably have a low skin permeability to prevent leaking from the 
formed film. A substantial leaking would not only raise safety concerns but would also lead to a 
deterioration of the film properties. In case of a loss of plasticizer the film becomes brittle and 
loses part of its adhesive properties. Such an effect was for example observed in a pre-
experiment for the animal study with rats (chapter 4). Contrary to the behaviour of the DynamX® 
film forming solution on human skin or pig skin (chapters 2 and 4) the films on the rat skin 
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became brittle after less than two hours and started to flake off. It was speculated that the higher 
permeability of the rat skin in comparison to human or pig skin was responsible for this different 
behaviour. It might have facilitated the diffusion of the plasticizer from the film into the skin, 
leaving the brittle, plasticizer depleted film behind. Such an effect should be avoided to ensure a 
reliable skin contact of the film forming system throughout the full wearing time. 
 
It is noteworthy that not all film formers required a plasticizer in the formulation experiments 
(chapter 2). The acrylate polymers Eudragit® NE 40D and Avalure® AC 118 as well as the 
silicone gum formed adequate films without the help of a plasticizing agent. 
2.2.4. Further excipients 
Apart from the basic compounds of a film forming polymeric solution (polymer, solvent and 
plasticizer) it can be appropriate to incorporate further excipients into the preparation. 
For some polymers such as the acrylate Eudragit® E 100 it is beneficial to add a crosslinker 
(succinic acid) to the composition to improve the film stability. For some drugs a solubilizer or 
co-solvent can be required (chapter 5) in order to increase the drug loading of the formulation 
and the with it the drug flux. For the same purpose chemical enhancers can be included 
(chapters 4 and 5). Further examples for supplementary excipients are antioxidants to stabilize 
oxidation sensitive drugs in the preparation during storage, sun screens for the protection of 
photosensitive drugs or dyes to facilitate the localisation of the formed film for the patient. 
 
A precondition for the incorporation of further excipients is the compatibility of the materials 
with all other compounds. Furthermore it has to be kept in mind that every change in the film 
composition might negatively affect the macroscopic properties of the formed film such as 
stability, adhesion to the skin or stickiness of the outer surface of the film. Therefore it is 
advisable to re-evaluate the macroscopic properties of the formed film after any adjustment of 
the composition. 
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3. Evaluation of the drug delivering capacity of film forming  
  solutions 
3.1. Efficiency 
The results of the permeation experiments through heat separated human epidermis have 
demonstrated that the delivery of caffeine, ethinylestradiol and levonorgestrel was basically 
feasible with the developed film forming systems (chapters 3, 4, 5). For the therapeutically 
relevant drugs ethinylestradiol and levonorgestrel it was also possible to achieve similar delivery 
levels than commercially available transdermal patches (chapters 4 and 5). In spite of this 
positive result, however, it became also clear during the experiments that the delivering 
efficiency for the two steroidal hormones was limited. Less than 5% of the drug loading 
permeated through the epidermis in 24 hours even in the presence of chemical enhancers. The 
overall efficiency of the film forming system is closely connected to the length of the wearing 
period (see section 3.3). If a film with a drug release of less than 5% per day is worn only for one 
or two days (which is highly probable with respect to the observations in the pig study, 
chapter 4) a high percentage of the drug substance is wasted. This can be an economic issue. In 
case of water soluble polymers it can additionally be an environmental concern if the film with 
the residual drug is showered off and deposited with the sewage water. 
 
For film forming solutions with drugs of low skin permeability such as most steroidal hormones 
[3, 4] it is therefore recommended to search for further options to improve the delivering 
efficiency of the polymeric system. Some options for this have been discussed in chapter 5 for 
the example levonorgestrel. Among these are the identification of the most efficient chemical 
enhancer or enhancer combination for the individual drug or the usage of pro-drugs such as 
esters that are activated by esterases in the skin. The usage of occlusive conditions is no option to 
improve the drug flux from the current film forming solutions as the developed systems were all 
non-occlusive (chapter 2). In order to use this effect further research would be required to 
identify polymers that fulfil the requirements listed in section 2.2.1 and that are additionally able 
to induce occlusive conditions under similarly thin films (5 – 25 µm). 
 
If the need for a further optimization of the film forming system is actually required, however, is 
mainly dependant on the drug itself and its skin permeability. The delivering efficiency of the 
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film forming system for caffeine for example was considerably higher than for the steroidal 
hormones in spite of the low drug loading of the films. In the caffeine experiments between 10% 
and 15% of the applied dose permeated through the epidermis even without chemical enhancer. 
This underlines that a careful choice of drug is very important for the development of an efficient 
film forming system. 
3.2. Delivery kinetics 
Apart from the delivering efficiency in terms of absolute amounts or exploitation of the reservoir 
the delivering kinetics are an important feature of a dosage form. The steady plasma levels that 
are achieved by transdermal patches are one of the major advantages in comparison to oral 
dosage forms. However, from the performed in vivo study with pigs no clear information about 
the delivery kinetics from the tested film forming solution (with ethinylestradiol and DynamX® 
as film former) could be derived. Further research is necessary to gain more information in this 
respect and to investigate if the film forming solutions can provide a similarly steady drug supply 
as the transdermal patches. 
3.3. Wearing time and removability 
Most indications where transdermal dosage forms are administered require a permanent 
medication. While transdermal semisolid dosage forms have to be applied at least on a daily 
basis the conventional transdermal patches aim at longer dosing intervals (twice weekly or 
weekly application). It is supposed that most patients prefer a less frequent dosing and that a 
weekly application serves to improve the patient compliance. 
 
With respect to the low depletion of the drug reservoir that was observed in the permeation 
experiments with ethinylestradiol and levonorgestrel (chapters 4 and 5) an application frequency 
for the DynamX® film forming solution of once weekly seems theoretically feasible. However, 
the observations during the in vivo study with pigs (chapter 4) suggested rather a shorter dosing 
interval. After one or two days the films on the animal skin began to display cracks and started to 
flake off. The observation led to the assumption that a wearing period of one or maximally two 
days can be achieved with the tested DynamX® formulation. This estimate is supported by the 
fact that the polymer is basically water-soluble, being originally designed for hair care 
applications. In spite of a certain water resistance the film is completely removed during the 
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showering and drying process (observation during the formulation experiments). Although the 
lack of water permanence reduces the possible dosing intervals for this particular formulation it 
is not purely a disadvantage. A positive aspect is that it also facilitates the handling of the 
medication. The patient can simply shower the remaining film off without residue and apply a 
new dose after the shower as part of his or her daily routine. 
 
In contrast to the water-soluble film forming preparations, non water-soluble polymeric 
formulations (for example with the acrylate Eudragit® RL PO) might provide longer dosing 
intervals. However, in the course of time these films will suffer from abrasion by the patients 
clothing or will begin to flake off. At that point a replacement of the film is required to ensure a 
reliable drug delivery. Due to their extreme thinness and low cohesion the films cannot be peeled 
away. The non-water-soluble films have to be removed with the help of organic solvents such as 
ethanol or isopropanol. This is clearly a disadvantage compared to the water-soluble films as the 
frequent usage of organic solvents can be harmful for the skin. However, in case of emergencies 
such as life threatening adverse effects or allergic reactions the organic solvents allow the instant 
removal of the formed films. 
 
Based on the observations in this study with the DynamX® formulation it can be assumed that 
the film forming systems are suited for a daily or possibly a twice weekly application. Even for 
the non water-soluble formulations a weekly application does not seem to be an option due to the 
thinness of the formed films. It is unlikely that they will be able withstand the mechanical strain 
exerted by the constant movement of the skin and the contact to clothing for as long as seven 
days. However, further studies on human skin are required to verify this estimate. 
 
For the practical application the resistance of the formed films to perspiration will also have to 
be addressed in the further development of the film forming systems. With regard to transdermal 
patches heavy sweating can lead to adhesion failure and loss of the patch [5]. Therefore the 
influence of sweating on the films formed by the polymeric solutions has to be determined to 
investigate the reliability of the drug delivery under different climatic conditions and bodily 
exercise. This is especially important for the formulations with water-solube polymers as sweat 
is an aqueous medium [6]. 
 129
Final discussion 
4. Further aspects for the future development process 
4.1. Tolerability 
The tolerability of the formulation is a very important issue and should already be considered 
during the selection of the formulation compounds. A safety testing of the film forming solutions 
was not part of this investigation but has to be addressed during the further development of the 
film forming solutions. For a first orientation however, it can be noted that during the polymer 
screening process (chapter 2) and in the preliminary in vivo study in pigs (chapter 4) no signs for 
skin irritation were observed with the tested DynamX® formulation. Additionally, the tested film 
forming systems were found to be non-occlusive (chapter 2) which also reduces the risk of skin 
irritation. The incorporation of chemical penetration enhancers into the film forming 
formulations can be problematic in this respect as many enhancers are potential skin irritants. 
However, it should be taken into consideration that the tolerability of a formulation always has to 
be seen in relation to the benefits of the medication for the patient.  
 
For future testing of the film forming solutions on human subjects it has to be kept in mind that 
sufficient safety data is not only required for the film forming composition but also for the single 
excipients in the formulation. This might generate considerable effort for excipients that are not 
monographed in a pharmacopoeia. For materials that are originally cosmetic ingredients (such as 
the acrylate polymer Avalure® AC 118 and the polyurethane-acrylate DynamX®) a basic 
toxicological characterization is often provided by the manufacturer, but the data is mostly not 
sufficient to allow the usage of the excipient in clinical trials. 
4.2. Application device 
One open question for the further development of film forming solutions as dosage form for the 
skin is the application device. Principally, a simple application with the help of a pipette or a 
brush is feasible. However, the most reliable way to administer the film forming liquid would be 
an application by spraying. This would ensure a controlled application, that is the administration 
of a precise volume on a defined skin area, with only minimal involvement of the patient. The 
use of a spraying device would also be very convenient for the patient [7], which is a prerequisite 
for a good patient compliance. 
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Suggestions for appropriate spraying devices are found in the literature. Morgan et al. for 
example developed a metered dose topical aerosol for the application of ethanolic solutions of 
steroidal hormones [8]. The device consisted of a pressurized aerosol container with a metered 
valve, a nozzle with a defined spray angle and a nozzle shroud to ensure a perpendicular position 
of the nozzle to the skin. A cross-sectional drawing of the device is shown in Fig. 37. Leichtnam 
et al. have suggested similar devices, pressurized and mechanical, for the application of an 
ethanolic testosterone spray [9]. Mechanical spraying devices are primarily used for liquids with 
low viscosities and have the advantage that the filling can be performed without special 
equipment. Pressurized devices on the other hand are more expensive to manufacture but can 
also deliver liquids with higher viscosities. They usually provide a finer droplet size and thus a 
more uniform distribution of the formulation on the sprayed surface than the mechanical devices 
[9]. 
In the formulation experiments one of the evaluation criteria was the viscosity of the polymeric 
solution and the target was to formulate solutions with low to moderate viscosity in order to 
provide the opportunity of an application by spraying. The DynamX® formulation fulfilled this 
criterion by displaying a low, water-like viscosity (chapter 2). A preliminary experiment with a 
mechanical pump spray device (100 µl per spray valve) indicated that a distribution of this 
formulation with a mechanical device was principally feasible. Therefore both options, 
pressurized or non-pressurized aerosols, can be considered for the application of this film 
forming system. 
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Fig. 37: Cross-sectional drawing of a metered dose spraying device according to Morgan [8] (modified) 
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The technical details of the application device such as valve volume, nozzle shroud length and 
diameter have to be adjusted to the individual formulation. In the formulation experiments 
(chapter 2) the evaluation of the film properties was based on an application volume of 10 mg of 
the polymeric formulation per cm2. This dose was small enough not to flow away from the 
application site and can therefore be considered a target formulation dose for the spraying 
device. The size of the application area that is to be covered with the formulation depends on the 
delivering efficiency of the film forming system and the target daily dose of the delivered drug. 
It should not exceed 20 – 30 cm2, on the one hand for reasons of patient compliance, on the other 
hand because a larger area would limit the locations on the body where the application device 
could be placed (the area should be even for a uniform distribution of the liquid). The application 
area together with the formulation dose then defines the valve volume, the targeted spray angle 
of the valve and the dimensions of the nozzle shroud. 
 
Metered dose spraying devices have been used before with sufficient precision for the 
application of steroidal hormones [9, 10]. It is expected that a similar precision can be reached 
for the application of the film forming system. However, the dose uniformity and the even 
distribution of the drug loaded film on the skin will have to be confirmed once an appropriate 
application device has been developed. 
 
An individualization of the dose is also imaginable. This could either be achieved by varying the 
number of sprays or by adjusting the valve volume (‘dial-a-dose’ principle) although the latter 
would require a more sophisticated valve technology. 
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5. Advantages and disadvantages of film forming systems in  
  comparison to conventional transdermal delivery systems 
5.1. Wearing comfort  
The film formed on the skin by the polymeric solution is colourless, transparent and therefore 
almost invisible (chapter 2, Fig. 8). This is clearly an advantage in comparison to some 
commercial patches that are highly visible on the skin as illustrated in chapter 1, Fig. 7. The low 
visibility of the formed film could have a positive impact on the patient compliance especially in 
female patients who prefer a discreet medication [11]. 
Due to their thinness and flexibility the formed films are more comfortable to wear than the 
considerably thicker and more rigid transdermal patches, especially when these are of a large 
size. 
 
Transdermal semisolids such as gels or creams are usually rubbed into the skin after application. 
They do not persist visually on the skin and are therefore as discreet as the film forming 
compositions. Semisolid formulations are usually comfortable to wear but may leave a sticky or 
greasy feel directly after application. This is avoided with the non-sticky and non-greasy film 
forming compositions (chapter 2). 
5.2. Application  
In contrast to the application of semisolid formulations the envisaged administration of the film 
forming solutions by spraying is convenient and non-messy for the patient, similar to the 
administration of conventional patches. However, for the application of the film forming system 
a spraying device is required that is not necessary for the other dosage forms. 
 
With an appropriate spraying device the dosing of the film forming solution can be performed 
with a higher accuracy than in case of the semisolid formulations due to the precisely defined 
size of the application area. It remains an open question, though, if the high dosing accuracy of 
the transdermal patches can be matched. 
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Due to their liquid character the dosing flexibility of the film forming systems is higher 
compared to the conventional patches. For manufacturing reasons these are mostly offered in a 
limited number of doses only. A convenient flexibility can especially be provided for the 
sprayable formulations if a ‘dial-a-dose’ device can be realized as suggested by Thomas et al. for 
the Metered Dose Topical Spray [2]. 
5.3. Drug delivery 
Concerning the application frequency the film forming solutions can presumably compete with 
daily patches or possibly twice weekly patches, but they are unlikely to reach the weekly applied 
transdermal systems in this respect. However, the pitfalls associated with weekly patches such as 
skin irritation, patch loss or persistent residues on the skin are also avoided. 
 
In comparison to the semisolid formulations the application frequency of the film forming 
solutions is similar (daily) or possibly lower (every other day or twice weekly). Contrary to the 
semisolids, however, the film forming compositions can provide a sustained drug release during 
the full wearing period as the film represents an external drug reservoir on the skin. The 
polymeric matrix serves as fixation for the drug which is also an advantage because the drug 
cannot be wiped off contrary to the situation with semisolids. Drug loss or environmental 
contamination, which is especially problematic with highly potent drugs such as hormones, is 
therefore prevented. 
 
Another point that can be both an advantage and a disadvantage is the non-occlusive property of 
the film forming system. Compared to many patches this can be an advantage as occlusion is 
often a source for skin irritation. On the other hand it can also be a disadvantage because 
occlusive conditions can have a penetration enhancing effect for some drugs and on certain areas 
of the body. 
 
In the permeation studies with steroidal hormones only a low percentage of the drug loading had 
permeated from the film forming solutions through the epidermis in 24 hours (2.8% with 
ethinylestradiol, 4.4% with levonorgestrel). In the same time period 6.2% of the ethinylestradiol 
loading had permeated from the EVRA® patch and 1.4% of the levonorgestrel loading from the 
Fem7® Combi patch. Therefore the drug delivering efficiency in terms of exploitation of the 
reservoir was comparatively low in all tested systems. However, the transdermal patches are 
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designed for a wearing period of seven days. Such a wearing time will presumably not be 
achieved with the film forming systems. Therefore the weekly patches might have an advantage 
in this respect as the overall exploitation of their drug reservoir is higher.  
However, the amount of comparative data gathered so far is not sufficient to draw any general 
conclusion concerning the delivering efficiency of one dosage form or the other. A direct 
comparison of the film forming solutions with semisolid formulations in this respect remains 
also subject to further research. Furthermore it has to be kept in mind that the efficiency of the 
drug permeation is predominantly dependent on the permeation properties of the drug and on the 
individual formulation (excipients, enhancers etc.) and less on the type of dosage form. 
5.4. Costs 
With regard to the manufacturing costs the film forming solutions have the advantage that the 
manufacturing process is fairly simple. Contrary to the production of transdermal patches 
expensive manufacturing equipment is not required. 
 
In contrast to the patches or semisolids a special device is needed for the precise and patient 
convenient application of the film forming systems. The design and the manufacturing costs for 
such an application device would generate additional costs in comparison to the other dosage 
forms. 
 
The costs for the formulation as such depend on the singular excipients and cannot be compared 
in general. 
6. Conclusion 
The investigations within this work have demonstrated that film forming solutions as drug 
delivery systems for the skin can be formulated with a variety of excipients, but that the selection 
of the excipients has to be performed with care. Film forming solutions take an intermediate 
position between the transdermal patches and semisolids and combine properties of both dosage 
forms. As a result the novel dosage form features a different combination of advantages and 
disadvantages (Table 13) distinguishes it from the existing dosage forms. Further research 
concerning the delivery kinetics and the suitability of this dosage form for a broader range of 
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drugs is necessary for a better evaluation of the opportunities and the limitations of these 
delivery systems. Once this knowledge has been gained the film forming polymeric solutions 
might indeed present a viable alternative to the conventional dosage forms for the skin in the 
future. 
 
 
Table 13: Advantages (highlighted in grey) and disadvantages or the film forming system in comparison   
       to the conventional transdermal dosage forms 
 
 Patch Film forming system Semisolid 
Wearing comfort    
Appearance Highly visible Almost invisible Invisible 
Flexibility Low High High 
Skin feel Non-sticky, non-greasy Non-sticky, non-greasy Sometimes sticky, greasy 
    
Application    
Application process Convenient Convenient1 Sometimes messy 
Dosing accuracy High High1 Low 
Dosing flexibility Low High1 High 
    
Drug delivery    
Dosing interval 1 – 7 days 1 – 2 days 1 day or less 
Sustained release Yes Yes No 
Occlusive properties Yes No No 
Contamination of clothing 
/ people No No Possible 
Persistent residues after 
removal Possible No No 
    
Costs    
Manufacturing equipment High Low Low 
Application device No Yes No 
 
1 Application of the film forming system with a metered dose spray system provided. 
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Summary 
The aim of this thesis was to develop and investigate a novel delivery system for the skin in the 
form of film forming polymeric solutions. For this purpose various excipients were studied and 
formulation experiments were performed to provide the technological basis for the new delivery 
system. Methods for the evaluation and characterization of the novel dosage form were 
developed and assessed. Finally, the drug delivery from the film forming systems was 
investigated. Comparative in vitro and in vivo studies with registered transdermal patches were 
carried out to assess the drug delivering potential of the new dosage form. 
 
In a first step of the study 14 film forming polymers from different chemical groups were 
screened to identify suitable excipients for the new dosage form. Formulations with varying 
polymer content, plasticizer type and plasticizer concentration were manufactured and evaluated. 
For this purpose a score system on living skin was established. The score system based on five 
macroscopic key properties for the film forming system, which were viscosity, drying time, 
outward stickiness, cosmetic attractiveness and permanence on the skin. The experiments 
revealed that a careful choice of the excipients as well as the determination of their suitable 
concentrations in the composition is a crucial factor. Only 10 of the over 150 different 
compositions produced films with the desired properties on the skin. 
To gather more information about the properties of the film forming systems four of the 10 
formulations containing the film formers Eudragit® RL PO (an acrylate), DynamX® (a 
polyurethane-acrylate), Klucel® LF (a cellulose derivative) and SGM 36 (silicon gum) were 
further characterized. All four films were assessed to be non-occlusive in vitro as well as in vivo, 
although the exact results of the two methods differed. The mechanical properties of the 
formulations were also determined in vitro but did not match the observations made in the in 
vivo evaluation concerning flexibility or strength of the films on skin. Therefore the in vitro 
method cannot replace the in vivo evaluation at this point. 
 
In the next step drug loaded film forming solutions were investigated with regard to their drug 
delivery characteristics. For this purpose two different drugs, the hydrophilic model drug 
caffeine and the lipophilic, therapeutically relevant ethinylestradiol, were incorporated into four 
selected film forming solutions. Release tests through an artificial silicone membrane as well as 
permeation experiments through heat separated human epidermis were performed. All 
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experiments showed differences among the selected film forming solutions and a polymer-free 
reference solution. In case of the permeation studies with human epidermis either penetration 
enhancing or retarding effects of the different polymeric systems were indicated. However, the 
results of the release and the permeation methods were not in accordance in terms of the ranking 
of the formulations. This underlines the importance of using a biologically relevant membrane 
for formulation selection processes. Based on the results of the permeation experiment with 
human skin the formulation with the polyurethane-acrylate film former DynamX® was selected 
for further studies as it had shown the best results for both tested drugs at this point. 
Further permeation experiments with ethinylestradiol revealed that the solvent of the formulation 
can influence the drug permeation by acting as penetration enhancer. This could be measured in 
spite of the short presence of the solvent on the skin. Moreover, it was shown that the permeation 
improved linearly with an increasing drug loading within the tested range of 1% - 5% in the 
solution. A further improvement of the ethinylestradiol permeation was achieved by adding 
chemical penetration enhancers to the film forming composition. Oleic acid and  
R-(+)-limonene were successful in this respect, especially in combination with propylene glycol. 
The enhancing effect of the oleic acid/propylene glycol (1:1) combination, which was the most 
efficient enhancer for ethinylestradiol in these experiments, increased disproportionately with the 
enhancer concentration due to the synergy of the two compounds. 
 
The comparison of the DynamX® film forming system with the commercial EVRA® patch 
revealed that the film forming formulations were able to deliver a higher amount of 
ethinylestradiol through human epidermis in vitro in 24 hours than the patch. Unexpectedly this 
was even measured without chemical enhancers. An in vivo study with pigs supported these 
positive findings. A single application of the film forming system without enhancer induced 
measurable plasma levels of ethinylestradiol. The plasma levels tended to be higher than those of 
the parallel group with the EVRA® patch. However, considerable variations were observed and 
the kinetics of the drug delivery from the film forming systems remained unclear. 
 
Based on the positive results with ethinylestradiol the thought of developing a film forming 
delivery system for hormone replacement therapy or contraception was pursued further. For this 
purpose the simultaneous delivery of a progestin, levonorgestrel, together with ethinylestradiol 
was investigated. Permeation experiments revealed that a simultaneous delivery of both 
hormones was feasible without detectable mutual influences on the permeation of the two drugs. 
The penetration enhancing effects of the polymeric formulation and the enhancer combination 
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oleic acid/propylene glycol on levonorgestrel were similar to those observed for ethinylestradiol. 
The comparison to a commercial transdermal patch with levonorgestrel, Fem7® Combi, revealed 
that the delivery level of the transdermal patch through human epidermis in vitro could be 
reached with the film forming system, but only with an enhancer content of 10% (5% oleic acid, 
5% propylene glycol). 
 
The present work has demonstrated that film forming solutions for the application on the skin 
can be formulated with a variety of excipients, but that the selection of the excipients has to be 
performed with care. The potential of the film forming solutions as drug delivery systems has 
been shown in comparative permeation experiments with registered transdermal patches. 
However, further research concerning the delivery kinetics and the suitability of this dosage form 
for a broader range of drugs is necessary for a better evaluation of the opportunities and the 
limitations of these delivery systems. Due to the fact that the properties of the film forming 
solutions show similarities to the patches in some respects (for example convenient application, 
sustained release, no environmental contamination) and to the semisolids in other respects (such 
as comfortable wearing, dosing flexibility, low visibility) they feature a combination of 
advantages and disadvantages that distinguishes them clearly from the conventional dosage 
forms. In summary these results are encouraging for the further development of film forming 
polymeric solutions as alternative drug delivery systems for the skin. 
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Zusammenfassung 
Das Ziel der vorliegenden Arbeit war es, eine neue Arzneiformen für die Haut in Form von 
filmbildenden Polymerlösungen zu entwickeln und zu untersuchen. Zu diesem Zweck wurden 
verschiedene Hilfsstoffe getestet und Formulierungsversuche durchgeführt, um eine 
technologische Basis für die neue Darreichungsform zu schaffen. Methoden zur Bewertung und 
Charakterisierung der Formulierungen wurden entwickelt und bewertet. Abschließend wurde die 
Wirkstoffverabreichung aus den filmbildenden Systemen untersucht. Es wurden vergleichende 
Untersuchungen mit zugelassenen transdermalen Pflastern durchgeführt, um das Potential der 
neuen Arzneiform hinsichtlich der Wirkstoffverabreichung einschätzen zu können.  
 
In einem ersten Schritt der Arbeit wurden 14 filmbildende Polymere untersucht, die 
unterschiedlichen chemischen Gruppen angehörten, um geeignete Hilfsstoffe für die Arzneiform 
zu identifizieren. Durch Variation des Polymergehalts, sowie des Weichmacher-Typs und  
–Gehalts wurden unterschiedliche Rezepturen erzeugt und bewertet. Für die Bewertung wurde 
ein Punkte-Systems auf lebender Haut entwickelt. Das Punkte-System basierte auf fünf 
makroskopischen Bewertungskriterien, die als wichtig für die spätere Anwendung erachtet 
wurden: Viskosität, Trocknungszeit, äußere Klebrigkeit, kosmetische Attraktivität und 
Nachhaltigkeit auf der Haut. Die Formulierungsversuche machten deutlich, dass der sorgfältigen 
Auswahl der Hilfsstoffe (Polymer, Weichmacher und Lösungsmittel), sowie der genauen 
Festlegung des Gehalts der einzelnen Komponenten eine große Bedeutung zukommt. Lediglich 
10 der über 150 Formulierungen waren in der Lage waren, Filme mit den gewünschten 
Eigenschaften auf der Haut zu erzeugen. 
Um zusätzliche Information über die Eigenschaften der filmbildenden Systeme zu sammeln, 
wurden vier dieser 10 Formulierungen mit den Filmbildnern Eudragit® RL PO (ein Acrylat), 
DynamX® (ein Polyurethane-Acrylat), Klucel® LF (ein Cellulose-Derivat) und SGM 36 
(Silikongummi) weitergehend charakterisiert. Alle Filme waren nicht-okklusiv, weder im in 
vitro-, noch im in vivo-Versuch, wobei die genauen Ergebnisse beider Methoden nicht 
übereinstimmten. Die mechanischen Eigenschaften der Polymerfilme wurden ebenfalls in vitro 
bestimmt, entsprachen jedoch ebenfalls nicht den in den Evaluierungsversuchen gemachten 
Beobachtungen hinsichtlich Flexibilität und Festigkeit der Filme auf der Haut. Die in vitro 
Methode kann daher zu diesem Zeitpunkt die in vivo Bewertung nicht ersetzen.  
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Im nächsten Schritt wurden wirkstoffhaltige filmbildende Lösungen im Hinblick auf ihr 
Freisetzungs- und Permeationsverhalten untersucht. Dazu wurden zwei verschiedene 
Arzneistoffe, die hydrophile Modellsubstanz Coffein sowie der therapeutisch relevante 
Arzneistoff Ethinylestradiol, in vier verschiedene filmbildende Formulierungen eingearbeitet. 
Mit den wirkstoffhaltigen Formulierungen wurden Freisetzungsversuche durch eine synthetische 
Silikonmembran sowie Permeationsversuche durch Humanepidermis durchgeführt. Alle 
Experimente zeigten Unterschiede zwischen den vier Polymerformulierungen und einer 
polymerfreien Referenzlösung. Im Falle der Permeationsuntersuchungen an Humanepidermis 
deutete dies auf permeationsfördernde oder –hindernde Effekte der Polymerformulierungen hin. 
Beide Ergebnisse der Freisetzungs- und Permeationsmethoden wiesen jedoch keine 
Übereinstimmung hinsichtlich der Rangfolge der Formulierungen auf. Dies unterstreicht, dass 
eine Formulierungsauswahl nur anhand von Versuchen mit einer biologisch relevanten Membran 
getroffen werden sollte. Auf Basis der Permeationsexperimente mit Humanepidermis wurde die 
Formulierung mit dem Polyurethane-Acrylat Filmbildner DynamX® für alle weiteren Versuche 
ausgewählt, da sie die besten Ergebnisse für beide Arzneistoffe, das hydrophile Coffein und das 
lipophile Ethinylestradiol, erzielt hatte. 
Weitere Versuche mit Ethinylestradiol zeigten, dass das Lösungsmittel der Formulierung die 
Wirkstoffpermeation beeinflussen kann, indem es als Penetrationsbeschleuniger wirkt. Dies war 
trotz der nur kurzen Kontaktzeit des Lösungsmittels mit der Haut erkennbar. Weiterhin konnte 
gezeigt werden, dass sich die Wirkstoffpermeation durch Erhöhung der Arzneistoffbeladung des 
Systems innerhalb der getesteten Grenzen (1% - 5% in der Lösung) verbessern ließ. Eine weitere 
Verbesserung der Ethinylestradiol-Permeation ließ sich durch Zusatz eines chemischen 
Penetrationsverbesserers erzielen. Ölsäure und R-(+)-Limonen waren in dieser Hinsicht 
erfolgreich, vor allem in Kombination mit Propylenglykol. Der permeationsverbessernde Effekt 
der Kombination Ölsäure / Propylenglykol (1:1), die für Ethinylestradiol die besten Ergebnisse 
erzielte, stieg überproportional mit der Enhancerkonzentration durch die Synergie der beiden 
Komponenten. 
 
Der Vergleich des filmbildenden DynamX® Systems mit dem kommerziell erhältlichen EVRA® 
Pflaster zeigte, dass die filmbildende Lösung in der Lage war, in 24 Stunden eine größere Menge 
an Ethinylestradiol durch die Humanepidermis diffundieren zu lassen als das Pflaster. Dies war 
überraschenderweise sogar ohne Penetrationsverbesserer möglich. Eine in vivo-Studie mit 
Schweinen unterstützte diese positiven Ergebnisse. Nach einmaliger Applikation des 
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filmbildenden Systems ohne Enhancer wurden messbare Ethinylestradiol-Plasmaspiegel erreicht, 
die tendenziell sogar höher waren als in der Vergleichsgruppe mit dem EVRA® Pflaster. Jedoch 
wurden bei dem Versuch erhebliche Schwankungen beobachtet und die Kinetik der 
Arzneistoffabsorption blieb unklar. 
 
Auf Basis der positiven Ergebnisse mit Ethinylestradiol wurde der Gedanke, ein filmbildendes 
System zur Hormonersatztherapie oder Kontrazeption zu entwickeln, weitergeführt. Dazu wurde 
die gleichzeitige Verabreichung eines Gestagens, Levonorgestrel, zusammen mit 
Ethinylestradiol untersucht. In Permeationsuntersuchungen wurde gezeigt, dass beide Hormone 
ohne gegenseitige Beeinflussung des Wirkstofftransports verabreicht werden konnten. Die 
permeationsfördernden Effekte der Polymerformulierung und der Penetrationsverbesserer 
Ölsäure / Propylenglykol auf Levonorgestrel waren denen auf Ethinylestradiol vergleichbar. Der 
Vergleich mit dem kommerziell erhältlichen transdermalen Levonorgestrel-Pflaster 
Fem7® Combi zeigte, dass eine vergleichbare Arzneistoffpermeation durch Humanepidermis in 
vitro erreicht werden konnte, jedoch nur mit einer Enhancer-Konzentration von 10% 
(5% Ölsäure, 5% Propylenglykol). 
 
Die vorliegende Arbeit hat gezeigt, dass die Entwicklung einer filmbildenden Polymerlösung zur 
transdermalen Arzneistoffverabreichung mit einer Reihe von Hilfsstoffe möglich ist. Bei der 
Auswahl der Hilfsstoffe ist jedoch sorgfältig vorzugehen. Das Potential der entwickelten 
Systeme hinsichtlich der Wirkstoffapplikation konnte anhand vergleichender 
Permeationsuntersuchungen mit zugelassenen transdermalen Pflastern gezeigt werden. Weitere 
Untersuchungen mit Kinetik-Studien und einer breiteren Arzneistoffauswahl sind jedoch 
erforderlich, um die Möglichkeiten und Einschränkungen dieser Arzneiform besser bewerten zu 
können. Aufgrund der Tatsache, dass die filmbildenden Polymerlösungen auf der einen Seite 
Gemeinsamkeiten mit den Pflastern aufweisen (z.B. bequeme Applikation, verlängerte 
Freisetzung, keine Kontamination der Umwelt), auf der anderen Seite aber auch 
Übereinstimmungen mit einigen Eigenschaften der halbfesten Arzneiformen zeigen (etwa 
hinsichtlich Tragekomfort, Dosierungsflexibilität oder geringe Sichtbarkeit), weisen sie eine 
Kombination von Vor- und Nachteilen auf, die sie deutlich von den konventionellen 
Arzneiformen unterscheidet. Zusammenfassend sind diese Ergebnisse ermutigend für die weitere 
Entwicklung der filmbildenden Polymerlösungen als alternatives Wirkstoffapplikationssystem 
für die Haut. 
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Appendix 1 
Schematic structures of polymers used in the formulations experiments 
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Appendix 2 
Results of the formulation experiments with the polymers 
 
Avalure® AC 118, Dermacryl® 79, DynamX®, Eudragit® E 100 
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Evaluation score system : see chapter 2 
Highlighted formulations: rating 1 in all five evaluation criteria 
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e® AC 118 A1 7.0 10.5 82.5 1 1 1 1 2
A2 10.0 15.0 75.0 1 1 1 1 1
A3 15.0 22.5 62.5 1 1 1 2 1
A4 15.0 3.0 22.5 59.5 1 1 2 2 1
A5 15.0 4.5 22.5 58.0 1 1 2 2 1
acryl® 79 B1 3.0 0.9 92.3 3.0 2 1 1 2 1
B2 7.0 93.0 1 1 1 2 1
B3 10.0 2.0 88.0 2 1 1 2 3
B4 15.0 3.0 82.0 2 1 1 2 3
B5 15.0 4.5 80.5 2 1 1 2 3
B6 20.0 6.0 74.0 2 1 1 1 3
B7 7.0 2.1 90.9 1 1 1 1 1
B8 7.0 2.1 87.9 3.0 1 1 1 1 3
B9 10.0 3.0 87.0 1 1 1 2 1
B10 10.0 4.0 86.0 1 1 1 1 3
B11 15.0 4.5 80.5 2 1 1 2 1
B12 15.0 6.0 79.0 2 1 1 1 2
B13 20.0 8.0 72.0 2 1 1 1 3
namX® C1 4.2 0.2 33.0 62.6 1 2 1 1 1
C2 4.2 0.2 7.1 88.5 1 1 1 1 2
C3 10.0 0.5 16.8 72.7 1 1 1 1 2
C4 10.0 1.0 16.8 72.2 1 1 1 1 1
C5 10.0 3.5 16.8 69.7 2 1 2 1 1
C6 15.0 0.9 25.2 58.9 2 1 1 1 3
C7 15.0 1.5 25.2 58.3 2 1 1 1 2
C8 20.0 7.0 33.6 39.4 3 2 2 1 1
t® E 100 D1 42 18.9 3.8 11.7 2.3 21.0 3 1 3 3 2
D2 42 18.9 3.8 11.7 23.3 3 1 3 3 2
D3 42 18.9 3.8 35.0 3 1 3 3 2
D4 30 13.5 2.7 53.8 2 1 3 3 1
D5 20 9.0 1.8 67.4 1 1 2 2 1
D6 10 1.0 0.9 88.1 1 1 1 1 1
D7 20 2.0 1.8 76.2 1 1 1 1 2
D8 20 3.0 3.0 74.0 1 1 1 1 3
D9 20 4.0 0.9 75.9 1 1 2 1 1
D10 20 4.0 1.8 74.2 2 1 2 1 3
D11 20 4.0 3.6 72.4 2 1 2 1 3
D12 20 4.0 3.8 72.2 1 1 2 1 1
D13 20 4.0 76.1 1 1 1 2 1
D14 30 6.0 64.1 2 1 3 2 3
D15 10 3.0 1.4 75.6 10.5 1 1 2 1 1
D16 15 1.5 1.4 77.2 5.0 1 1 1 1 2
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Results of the formulation experiments with the polymers 
 
Eudragit® NE 40D, Eudragit® RL PO, Eudragit® S 100 
 
 
 
 
 
 
 
 
 
 
Po
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation score system : see chapter 2 
Highlighted formulations: rating 1 in all five evaluation criteria 
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udragit® NE 40D E1 5.0 7.5 87.5 1 1 1 1 2
E2 7.0 10.5 82.5 1 1 1 1 1
E3 7.0 10.5 80.4 2.1 1 1 2 1 1
E4 10.0 15.0 75.0 2 1 1 1 1
E5 15.0 22.5 62.5 3 1 1 2 1
udragit® RL PO F1 10.0 2.0 88.0 1 1 1 1 2
F2 20.0 4.0 76.0 1 1 1 1 3
F3 30.0 6.0 64.0 2 1 1 2 2
F4 40.0 8.0 52.0 3 1 1 2 3
F5 10.0 3.0 87.0 1 1 1 1 2
F6 20.0 6.0 74.0 1 1 1 1 1
F7 30.0 9.0 61.0 2 1 1 2 1
F8 40.0 12.0 48.0 3 1 1 3 1
F9 40.0 18.0 42.0 3 1 2 3 1
F10 10.0 2.0 68.0 1 1 1 2 3
F11 15.0 0.9 69.1 20.0 2 1 1 2 2
F12 15.0 70.0 15.0 2 1 1 2 3
F13 20.0 4.0 66.0 15.0 2 1 2 2 3
F14 20.0 4.0 1.8 74.2 10.0 1 1 1 1 2
F15 20.0 4.0 3.8 72.2 1 1 1 1 2
F16 20.0 6.0 74.0 1 1 1 1 3
udragit® S 100 G1 0.5 1.0 91.5 7.0
G2 5.0 1.6 93.0 1 1 1 1 1
G3 7.0 2.8 90.2 1 1 1 1 2
G4 10.0 3.0 87.0 2 1 1 1 3
G5 10.0 4.0 86.0 2 1 1 1 3
G6 10.0 5.0 85.0 2 1 1 1 3
G7 10.0 6.0 84.0 2 1 1 1 3
G8 20.0 6.0 74.0 3 1 1 2 2
G9 10.0 3.0 87.0 2 1 1 2 2
G10 10.0 2.0 86.0 2.0 2 1 1 1 2
G11 10.0 5.0 83.0 2.0 2 1 1 1 3
insoluble
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Results of the formulation experiments with the polymers 
 
Kollidon® VA 64, Klucel® LF, SGM 36, Oppanol®
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Evaluation score system : see chapter 2 
Highlighted formulations: rating 1 in all five evaluation criteria 
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ollidon® VA 64 H1 5.0 95.0 1 1 2 1 3
H2 10.0 90.0 1 1 1 2 2
H3 15.0 85.0 1 1 1 2 2
H4 20.0 80.0 2 1 1 2 2
H5 10.0 89.0 1.0 2 1 1 1 3
H6 10.0 88.0 2.0 2 1 1 1 3
H7 10.0 87.0 3.0 2 1 1 1 3
H8 10.0 86.0 4.0 1 1 1 1 3
H9 5.0 88.0 2.0 5.0 2 1 1 2 3
H10 15.0 0.75 84.3 2 1 1 1 3
H11 15.0 1.5 83.5 2 1 1 1 3
H12 15.0 3.0 82.0 2 1 1 1 3
H13 15.0 4.5 80.5 1 1 2 1 3
H14 15.0 6.0 79.0 1 1 2 1 3
H15 15.0 7.5 77.6 1 1 3 1 o
H16 10.0 1.0 89.0 1 1 1 1 3
H17 10.0 2.0 88.0 1 1 1 1 3
H18 10.0 3.0 87.0 1 1 1 1 2
H19 10.0 4.0 86.0 1 1 1 1 1
ucel® LF I1 2.0 98.0 1 1 1 1 3
I2 5.0 90.0 2 1 1 1 2
I3 10.0 90.0 3 1 1 2 2
I4 5.0 0.5 94.5 1 1 1 1 2
I5 5.0 1.0 94.0 1 1 1 1 1
I6 5.0 1.5 93.5 1 1 2 1 1
GM 36 J1 7.0 93.0 1 1 1 1 2
J2 10.0 90.0 1 1 1 1 1
J3 12.0 88.0 2 1 1 1 1
J4 15.0 85.0 3 1 1 1 1
J5 20.0 80.0 3 1 2 1 1
ppanol® 10SFN M1 10.0 90.0
ppanol® 10SFN M2 10.0 90.0
ppanol® 10SFN M3 10.0 90.0
ppanol® B100 M4 10.0 90.0
ppanol® B100 M5 10.0 90.0
ppanol® B100 M6 10.0 90.0
ppanol® 10SFN M7 5.0 95.0
ppanol® B100 M8 5.0 95.0
insoluble 90°C (24h, 500 rpm)
insoluble 90°C (24h, 500 rpm)
insoluble 20°C (24h, 500 rpm)
insoluble 50°C (24h, 500 rpm)
insoluble 90°C (24h, 500 rpm)
insoluble 20°C (24h, 500 rpm)
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Results of the formulation experiments with the polymers 
 
Hydagen® HCMF, PVA 7200, Kollidon® 12 PF 
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 Hy
 
 
 
 
 
 
 
 
 
 PV
 
 
 
 
 
 
 
 
 
 
 Ko
dagen® HCMF K1 1.0 39.8 60.0 0.6
K2 1.0 45.0 50.0 0.6
K3 1.0 50.0 48.4 0.6 3 3 1 2 3
K4 1.0 50.0 48.0 0.25 0.75 3 3 1 2 3
K5 1.5 75.0 22.5 0.1 0.9 3 3 1 2 3
K6 1.75 87.5 9.5 0.15 1.1 3 3 1 2 3
K7 1.0 50.0 48.2 0.2 0.6 3 3 1 2 3
K8 1.0 50.0 48.1 0.3 0.6 3 3 2 2 3
K9 1.0 50.0 48.0 0.25 0.75 3 3 2 2 3
K10 2.0 96.9 1.2 3 3 1 2 3
K11 3.0 95.3 1.8 3 3 1 2 3
K12 4.0 93.7 2.4 3 3 1 2 3
K13 5.0 92.0 3.0 3 3 1 2 3
K14 6.0 90.0 3.6 3 3 1 2 3
A 7200 L1 10.0 90.0
L2 10.0 90.0
L3 10.0 73.0 4.0 13.0
L4 10.0 62.0 8.0 20.0
L5 10.0 40.0 50.0
L6 5.0 60.0 25.0 10.0
L7 5.0 65.0 20.0 10.0 2 1 1 1 3
L8 5.0 60.0 23.0 10.0 2.0 2 1 1 1 3
L9 5.0 60.0 28.0 5.0 2.0 2 1 1 1 3
L10 5.0 60.0 20.0 10.0 5.0 2 1 1 1 3
L11 5.0 59.0 28.0 5.0 2.0 1.0 2 1 1 1 3
L12 5.0 58.0 28.0 5.0 2.0 2.0 2 1 1 1 3
L13 5.0 55.0 28.0 5.0 2.0 5.0 2 1 1 1 2
L14 5.0 50.0 28.0 5.0 2.0 10.0 3 1 1 1 2
L15 5.0 53.0 28.0 5.0 2.0 7.0 2 1 1 1 2
L16 5.0 50.0 30.0 5.0 10.0 2 1 1 1 2
llidon® 12 PF N1 15.0 80.5 4.5 2 1 2 1 3
N2 15.0 82.0 3.0 2 1 2 1 3
N3 15.0 83.5 1.5 2 1 2 1 3
N4 15.0 85.0 2 1 2 1 3
N5 10.0 90.0 1 1 2 1 3
N6 5.0 95.0 1 1 2 1 3
N7 5.0 1.0 94.0 1 1 3 1 3
N8 5.0 1.0 94.0 1 1 3 1 3
N9 5.0 1.0 94.0 1 1 3 1 3
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Abstract (English) 
Abstract (English) 
The aim of this thesis was to develop and investigate film forming polymeric solutions as a novel 
delivery system for the skin. These solutions form very thin, flexible and almost invisible films 
on the skin which can serve as a reservoir for the transdermal delivery of drugs. In a first step 
various excipients were studied and formulation experiments were performed to provide the 
technological basis for the new delivery system. Compositions with different polymers were 
identified that provided suitable properties for the intended application (short drying time, low 
viscosity, permanence on the skin). Methods for the evaluation and characterization of the novel 
dosage form were developed and assessed. The drug delivery from the film forming systems 
through human epidermis was investigated with caffeine as model drug and steroidal hormones 
as therapeutically relevant compounds. The impact of different parameters on the drug 
permeation from the polymeric system was tested. Among these parameters were the nature of 
the solvent, the drug concentration or the incorporation of chemical enhancers. Finally, 
comparative in vitro and in vivo studies with registered transdermal patches were carried out to 
assess the drug delivering potential of the new dosage form for steroidal hormones. The obtained 
results have demonstrated that film forming polymeric solutions are a promising approach for 
transdermal drug delivery that should be pursued further in the future. 
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Abstract (Deutsch) 
Abstract (Deutsch) 
Das Ziel der vorliegenden Arbeit war es, filmbildenden Polymerlösungen als neue Arzneiform 
für die Haut zu entwickeln und zu untersuchen. Diese Lösungen bilden auf der Haut sehr dünne, 
flexible und nahezu unsichtbare Filme, die als Reservoir für die transdermale 
Wirkstoffapplikation dienen können. In einem ersten Schritt wurden verschiedene Hilfsstoffe 
getestet und Formulierungsversuche durchgeführt, um eine technologische Basis für die neue 
Darreichungsform zu schaffen. Zubereitungen mit verschiedenen Polymeren wurden 
identifiziert, die geeignete Eigenschaften für die beabsichtigte Anwendung aufwiesen (kurze 
Trocknungsdauer, geringe Viskosität, Nachhaltigkeit auf der Haut). Methoden zur Evaluierung 
und Charakterisierung der Formulierungen wurden entwickelt und bewertet. Die 
Wirkstoffverabreichung aus den filmbildenden Systemen durch Humanepidermis wurde mit der 
Modellsubstanz Koffein sowie mit therapeutisch relevanten steroidalen Hormonen untersucht. 
Der Einfluss verschiedener Parameter auf die Wirkstoffpenetration aus den Polymersystemen 
wurde getestet. Zu diesen Parametern gehörten die Art des Lösungsmittels, die 
Wirkstoffbeladung und die Gegenwart von chemischen Penetrationsverbesserern. Schließlich 
wurden vergleichende Untersuchungen mit zugelassenen transdermalen Pflastern durchgeführt, 
um das Potential der neuen Arzneiform hinsichtlich der Wirkstoffverabreichung einschätzen zu 
können. Die erzielten Ergebnisse haben gezeigt, dass filmbildende Polymerlösungen ein 
vielversprechender Ansatz für die transdermale Wirkstoffgabe sind, der in Zukunft 
weiterverfolgt werden sollte. 
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